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2Preface and outline
Nucleic acids are versatile molecules, but that might not seem obvious at first 
glance. DNA is primarily known for its double helical appearance, and as carrier of 
the blueprint of life; RNA is mainly known as essential intermediate in translating the 
genetic code to proteins. Both DNA and RNA, however, serve other purposes that can 
even be unrelated to their genetic content. In 1990, researchers selected specific RNA 
molecules that were capable of binding molecules that normally do not interact with 
RNA. These molecules were selected from a large pool of RNA molecules, by a process 
that was named systematic evolution of ligands by exponential enrichment, or SELEX. 
The resulting RNA molecules were named ‘aptamers’ which roughly means ‘fitting 
part’. Two years later, a single stranded DNA molecule was identified that specifically 
binds thrombin, a protein that normally does not interact with DNA. This served as 
the first example of a DNA aptamer. In the following years, numerous DNA and RNA 
aptamers, capable of binding a wide variety of targets, became available, leading to a 
plethora of potential applications. The capability of binding a specified target results 
from an intricate interplay between the nucleotide composition of the DNA or RNA 
molecule, the three-dimensional shape that this composition enables, and specific 
features of the target itself. Unfortunately, no accurate predictions can be made 
on which nucleotide composition will allow an aptamer to bind a specified target, 
therefore aptamer selection remains largely a trial and error approach. Selection of 
DNA aptamers and subsequent characterization of the aptamer-target interaction is 
the main focus of this thesis.
Besides aptamers, various other groups of molecules are capable of binding 
specified target molecules. Each group has its own advantages and disadvantages, 
when compared to the others. In Chapter 1 four of such groups are described in 
general terms and their specific features are compared. 
One advanced technique to study aptamer-target interactions is Surface Plasmon 
Resonance (SPR). With this technique, binding interactions can be monitored in 
real-time, allowing for gaining valuable insights in the speed of complex formation 
and dissociation. Chapter 2 provides an overview on how to initiate SPR experiments 
and how to correctly process and analyze kinetic data. 
In Chapter 3 the selection and subsequent characterization of streptavidin-
binding aptamers is described. In this work five aptamers were identified and their 
binding kinetics were determined using SPR. Furthermore, the aptamers and the 
aptamer-streptavidin complex were studied by native mass spectrometry and small 
angle X-ray scattering. 
In order to gain additional information on the aptamer-streptavidin complex, 
crystallization trials were performed in an attempt to co-crystallize the complex. 
These trials, and other methods for the characterization of the molecular basis of 
aptamer-protein interactions, are described in Chapter 4. 
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SpaC, a subunit of pili present on the probiotic Gram-positive bacterium 
Lactobacillus rhamnosus GG, was also used as target for aptamer selection. Cloning 
of the gene and recombinant production of SpaC protein are described in Chapter 5, 
as well as the characterization of enriched DNA oligonucleotides. 
Experimental conditions for aptamer selection are often based on practical 
considerations and convenience, partly because the dynamics of aptamer selection 
are not fully understood. To gain a more fundamental insight in the dynamics of 
selection, samples of multiple selection rounds, obtained during distinct experiments, 
were barcoded, pooled and subjected to a multiplexed high throughput sequencing 
approach. Results and practical details of this approach are described in Chapter 6. 
A new application of SPR is presented in Chapter 7: a method for capturing 
supercoiled plasmid DNA. The method makes use of a triple helix forming 
oligonucleotide and facilitates studying protein-DNA interactions on DNA with a 
physiologically relevant topology. 
Finally, Chapter 8 summarizes the research described in this thesis and discusses 
new developments that are beneficial for aptamer selection. Future opportunities for 
aptamer applications are discussed as well. 
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Alternative affinity tools: more attractive 
than antibodies?
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Abstract
Antibodies are the most successful affinity tools used today, in both fundamental and 
applied research (diagnostics, purification and therapeutics). Nonetheless, antibodies 
do have their limitations, including high production costs and low stability. Alternative 
affinity tools based on nucleic acids (aptamers), polypeptides (engineered binding 
proteins) and inorganic matrices (molecular imprinted polymers) have received 
considerable attention. A major advantage of these alternatives concerns the 
efficient (microbial) production and in vitro selection procedures. The latter approach 
allows for the high-throughput optimization of aptamers and engineered binding 
proteins, e.g. aiming at enhanced chemical and physical stability. This has resulted 
in a rapid development of the fields of nucleic acid- and protein-based affinity tools 
and, although they are certainly not as widely used as antibodies, the number of 
their applications has steadily increased in recent years. In this chapter, we compare 
the properties of the more conventional antibodies with these innovative affinity 
tools. Recent advances of affinity tool developments are described, both in a medical 
setting (e.g. diagnostics, therapeutics and drug delivery) and in several niche areas 
for which antibodies appear to be less attractive. Furthermore, an outlook is provided 
on anticipated future developments.
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Introduction
Many of the current applications in life sciences and biotechnology require the use of 
highly selective binders for the detection, purification or removal of specific molecules. 
The tools that allow these processes to proceed are generally referred to as affinity 
tools. At present, antibodies of mammals are the best characterized and most widely 
used affinity tools. Natural antibody targets (antigens) are surface molecules of 
invading entities (bacteria and viruses), including (poly)peptides and carbohydrates. 
However, owing to their unlimited variability, an infinite number of organic molecules 
are potential antigens that can be captured with very high affinity and specificity. 
Nowadays, antibodies can easily be produced using a range of techniques by either 
the immune system or synthetic libraries 101. Nevertheless, antibodies do have their 
limitations 16. They are reasonably sensitive to harsh conditions and are rapidly 
inactivated under acidic conditions, in the presence of proteases or at elevated 
temperatures. In addition, antibodies are large multi domain protein complexes with 
specific disulfide bonds and glycosylations. This implies that producing antibodies 
is generally difficult and expensive. Moreover, the extensive use of antibodies and 
their applications (e.g. as therapeutic agents) has resulted in a complicated patent 
situation 143. Therefore, in recent years, other affinity tools, such as engineered binding 
proteins, aptamers and molecular imprinted polymers (MIPs), have gained a lot of 
interest as potential alternatives for antibodies in many applications. An overview 
of selected companies that are currently developing new affinity tools as alternative 
to antibodies is provided in Supplementary Table S1.1 (at page 28 and http://www.
BiochemJ.org/bj/436/bj4360001add.htm).
The new affinity tools have several advantages compared with antibodies. 
Attractive features include a reduced molecular mass, an enhanced stability, a more 
efficient selection and screening procedure, and cost-effective production methods. 
In this chapter, we aim to provide an overview of the current state of antibodies, 
engineered binding proteins, aptamers and MIPs, as affinity tools for different 
applications. We compare the properties and production methods of each tool and 
provide information on screening and binder-selection procedures. Furthermore, we 
elaborate on the potential of each affinity tool and relate this to various applications 
in a medical setting (diagnostics, therapeutics and drug delivery) and several niche 
applications for which antibodies appear to be less suitable.
Antibodies
Antibodies recognize their target with high specificity, and they generally bind it 
with a very high affinity, typically in the nano/pico-molar range. Depending on 
their origin, antibodies are polyclonal or monoclonal. A polyclonal antibody (pAb) 
is purified from blood serum of immunized mammals; it is a set of antibody variants 
that bind different epitopes of a target antigen, and are therefore not very specific. 
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A monoclonal antibody (mAb) is a single antibody variant that is derived from a single 
cell line (hybridoma) 139; mAbs bind only one epitope on a single antigen, making 
them more specific than pAbs 37.
Because of their high specificity and affinity, antibodies are useful for a wide variety 
of applications. Antibodies, especially mAbs, are nowadays the most widely used 
tool for diagnostic applications in fundamental and applied research. Furthermore, 
because of their potential to specifically interact with (neutralize) a target molecule, 
several U.S. Food and Drug Administration (FDA)-approved mAbs are used in the 
clinic as therapeutics in the treatment of diseases ranging from inflammation to 
cancer 195, 224.
Hybridoma: an endless antibody supply
Once an antibody-producing hybridoma cell line is established, it provides an endless 
supply of mAbs, because hybridomas are fusions of antibody-producing spleen cells 
and immortal myeloma cells 139 (Figure 1.1). Immunization of mice with antigen is the 
first step to establish a hybridoma. An appropriate immunization protocol is critical for 
provoking an adequate immune response. Several strategies have been developed to 
increase throughput and success rate of immunization and to decrease the number 
of animals needed, including single-step immunization 319, genetic immunization 32 
and multiplex immunization 198. Only when an immune response is confirmed, can 
mouse spleen cells be harvested and fused with myeloma cells to continue hybridoma 
selection. After cell fusion, the mixture 
of hybridomas is generally diluted in 
such a way that each resulting micro 
culture is derived from a single cell. 
This limiting dilution cloning (LDC) 
procedure is simple, but it is time-
consuming and has a low throughput. 
Several other selection methods with 
higher throughput, based on flow 
cytometry and cell sorting, have 
been established 23. The next step is 
screening of supernatants, to identify 
hybridomas that produce antibodies 
with the desired properties. To this 
end, the antigen microarray assay, 
basically a miniaturized ELISA, reduces 
the amount of time and reagents 
required compared with conventional 
ELISA screening 50. Once appropriate 
Figure 1.1: Hybridoma selection. When a mouse 
is injected with a certain antigen and detection of an 
immune response is confirmed, spleen cells are harvested 
and fused with myeloma cells. Fusion products are grown 
in selective media to select for fused cells. After LDC of 
fused cells, cell supernatants are screened for mAbs with 
the desired antigen specificity.
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hybridomas are selected, they can 
be preserved and used for antibody 
production.
Regardless of whether 
antibodies are polyclonal or 
monoclonal, the most commonly 
used antibodies are of the IgG type. 
IgGs are Y-shaped and consist of 
two longer ‘heavy’ chains and 
two shorter ‘light’ chains bound 
together by disulfide bonds 
(Figure 1.2A). The Fab region 
consists of constant and variable 
domains of the heavy and light 
chain. Antigen binding takes place 
at the complementarity-determining regions (CDRs), which are located in the variable 
domains (VH and VL) in the Fab region. The Fc region consists of the constant heavy 
chain domains; it maintains stability and is involved in other interactions of the 
immune system.
Medical applications
Antibodies are often used in biochemical laboratories for numerous routine 
diagnostic tests such as ELISA and Western blotting. In a medical setting, these 
tests are generally used for the detection of infectious and parasitic diseases. In 
addition, ELISA is also often used for routine screening of food and environmental 
samples for microbial and chemical contamination. It is difficult to multiplex ELISAs 
because of cross-reactivity of secondary antibodies, which are required for enhanced 
sensitivity 322. The pregnancy test is a well-known example of a cheap and easy to 
use diagnostic test that relies on antibodies [detection of the pregnancy-associated 
hormone hCG (human chorionic gonadotropin)]. Although this pregnancy test has 
been on the market for over 35 years 26, development of similar tests for other targets 
has been slow. However, increased interest in point-of-care diagnostics has rapidly 
increased the number of diagnostic tests available within the last 10 years 293, e.g. in 
2004, the FDA approved the first rapid test for HIV in oral fluids 20. The number of 
point-of-care applications is expected to increase steadily in the near future.
One of the most advanced applications of antibodies to date, however, is their use 
as therapeutic agents. Muromonab-CD3 (Orthoclone OKT3), an anti-CD3 antibody, 
became the first murine mAb to be approved by the FDA in 1986 as a therapeutic 
agent to prevent organ rejection after transplantation 79. Administration of these 
murine antibodies, however, carried the risk of an undesired immune response 
Figure 1.2: Schematic structures of a human IgG and 
heavy chain antibody. A) Human IgG. Two heavy and 
light chains are linked together by disulfide bonds. The Fab 
region consists of constant (C) and variable (V) domains of 
the heavy (H) and light (L) chain. CDRs are located in the 
variable domains (VH and VL ) in the Fab region. The Fc 
region consists of the constant heavy chain domains. B) 
Heavy chain antibody. Two heavy chains, consisting of two 
constant regions C) and one variable region (V), are linked 
together by disulfide bonds.
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CH1
CL
CH2
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(immunogenicity) and other side effects 296. It took until 1994 before the second mAb 
[Abciximab (ReoPro), a chimaeric anti-GPIIb/IIIa antibody] received FDA approval, 
partly because the side effects of these murine mAbs had to be reduced; to date, 
over 30 mAbs are FDA-approved 9. Technological advances have enabled production 
of chimeric and later humanized antibodies (a human IgG scaffold with only the CDRs 
of murine origin), which have fewer side effects than their murine counterparts; the 
current state-of-the-art is a fully human antibody, produced by transgenic mice 157.
Therapeutic mAbs can operate through different mechanisms. Some mAbs act 
independently of the Fc domain of the antibody by blocking the interaction between a 
receptor and the receptor molecule (by binding to either one of them), or by inducing 
a signal transduction cascade upon receptor binding. Other mechanisms do require 
the Fc domain to recruit components of the immune system to lyse target cells by 
either antibody-dependent cell-mediated cytotoxicity or complement-dependent 
cytotoxicity 161.
Antibodies are also used for targeted drug delivery. For this purpose, mAbs 
are labelled with radioisotopes or toxic drugs, combining antibody specificity with 
enhanced toxicity because of their label. Two radioimmunoconjugates [Ibritumomab 
tiuxetan (Zevalin), anti-CD20, and Tositumomab-131I (Bexxar), anti-CD20] are FDA-
approved 310, whereas the only FDA-approved conjugate with a toxin [Gemtuzumab 
ozogamicin (Mylotarg), anti-CD33] has recently been withdrawn from the market 
because of concerns about the product’s safety and clinical benefits to patients 61. 
Radioimmunoconjugates can also be used for in vivo imaging of tumors, to evaluate 
targeting or success of therapy. Specific binding of antibodies to their target allows 
for a very good signal-to-noise ratio. This imaging is Fc-independent, therefore 
conjugates of antibody fragments could be used for imaging as well.
Drawbacks of antibodies
High selectivity and affinity make antibodies especially suitable for diagnostic and 
therapeutic applications. Antibodies have a large and complex structure, which 
allows them to bind antigens and simultaneously recruit components of the immune 
system and, as we have seen before, this is an essential property in some forms 
of immunotherapy. However, owing to their complex structure, antibodies are 
susceptible to degradation, aggregation, modification (e.g. oxidation or deamidation) 
and denaturation. Moreover, the bulky nature of antibodies also limits their potential 
for some other applications; in affinity chromatography, smaller binders are preferred 
because of enhanced efficiency, whereas smaller binders exhibit an improved signal-
to-noise ratio when applied to molecular imaging.
Antibodies have not yet been successfully produced in simple microbial hosts, 
because of their large complex structure and the required specific post-translational 
glycosylation. Hence they have to be produced in mammalian cell lines instead 
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[e.g. NS0, Per.C6®, Chinese-hamster ovary (CHO) and human embryonic kidney 
(HEK)-293 cells], the cultivation of which is complex and costly (expensive media, long 
fermentation lead times, scaling issues, use of gases). Although nowadays mAbs are 
well produced and purified under mild conditions, they nonetheless remain sensitive 
to aggregation, deamination and oxidation. The use of antibodies is therefore often 
restricted to conditions resembling their physiological environment. In the presence of 
organic solvents or in other non-physiological conditions (e.g. elevated temperature, 
high pH and high salt concentration), they generally lose their function.
When administered intravenously, antibodies can have half-lives of several weeks 29. 
A long half-life is desirable for some applications, because it increases efficacy and 
reduces the required dose. On the other hand, for certain applications, short half-
lives are preferred, for instance when rapid clearance of toxic immunoconjugates is 
required to reduce whole-body exposure.
Size-related limitations of antibodies can be alleviated by using specific parts 
of antibodies that can be produced in microbial hosts (e.g. Fab regions or variable 
domains). These parts are smaller and, as such, they can reach deeper into tumors; 
in addition, half-lives can be tailored 29. Removing fragments of the antibody that 
are not directly involved in target binding, however, can negatively affect affinity. In 
addition, antibody fragments tend to aggregate, making it difficult to purify them 95.
An alternative for antibody fragments are heavy chain antibodies (Figure 1.2B). 
Heavy chain antibodies are natural variants that lack a light chain; they are isolated 
from camelid species 86 and cartilaginous fish 266. Heavy chain antibodies from camelid 
species are much smaller than classic antibodies, and, like artificially truncated 
antibody fragments, they can be produced in microbial hosts. As such, they are being 
optimized for certain specificities 87, 299, 318, by using high-throughput analyses such as 
phage display (see below).
Engineered binding proteins
In parallel to the development of antibody-based binding proteins, such as the antibody 
fragments and single-domain antibodies, independent studies have focused on 
modifying non-antibody proteins into binding proteins, with the goal of developing 
binding proteins with improved features 9. The concept of engineering new binding 
functions is based on the molecular composition of antibodies (Figure 1.2). The typical 
structural element of an antibody is a well-conserved rigid scaffold on which highly 
variable loops (CDRs) are positioned. Similarly, binding proteins can be isolated from 
large libraries of protein variants with a constant framework and randomized variable 
regions that can, in principle, interact with any target molecule. These new binding 
proteins have great potential as affinity tools in various biotechnological applications 
and as therapeutic agents.
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The generation of novel binding proteins
An important aspect of successful design and engineering of a binding protein 
scaffold is the ability to generate and analyze a large number of mutated derivatives. A 
powerful high-throughput technology for evolution-driven engineering is molecular 
display: the generation of large (poly)peptide libraries and subsequent selection for 
variants with desired biological and physicochemical properties. Display technologies 
are based on a physical link between a protein and its encoding gene, hence coupling 
phenotype and genotype. The most commonly used display technology is phage 
display 259. However, other methods such as bacterial and yeast cell-surface display 46 67, 
ribosome display 156, 320 and mRNA display 156 have also been successfully applied. In 
this chapter, we will restrict ourselves to describing phage display for the selection of 
engineered binding proteins.
In phage display technology, nucleotide sequences encoding variants of peptides, 
antibodies or proteins are fused to a gene that encodes a phage coat protein. After 
correct assembly, phage particles display the encoded (poly)peptide on their surface 217. 
The most widely used vectors for library construction are based on the filamentous 
phages fd, M13 and related phagemids 133, 213, 258. However, display systems based on 
other phages and viruses have also been developed, including the lytic phages λ and 
T7 21. A current shortcoming of phage display is that only a limited number of vectors, 
libraries and complete systems are commercially available.
In general, when a phage display procedure with an M13 phagemid vector is 
used, a library of variant DNA sequences encoding a protein of interest is created 
using in vitro evolution techniques 181. These variants are subsequently cloned into 
the phagemid vector as fusion to a coat protein gene (frequently the pIII-gene) 
(Figure 1.3). Escherichia coli cells are transformed with the phagemids and then 
infected with a helper-phage, generating a library of phages displaying the variant 
proteins. The phage library is exposed to an immobilized target molecule, and the 
phages with appropriate specificity and affinity are captured. The non-binding 
phages are washed off, although some non-specific binding can occur. Bound phages 
are eluted by conditions that disrupt the interaction between the displayed protein 
and the target. Eluted phages are then used to re-infect E. coli cells. The resulting 
amplified phage population is a secondary library that is highly enriched in phages 
displaying proteins that bind to the target. In an iterative process, these steps are 
repeated using washing steps with increasing stringency (bio-panning), resulting in 
a phage population enriched in a limited number of variants with the desired binding 
affinity and specificity. After several rounds of bio-panning (generally three to five), 
monoclonal phages may be selected and analyzed individually. Target-binding (poly)
peptides are identified by DNA sequence analysis of the phage and may subsequently 
be used as input material for another series of in vitro evolution in order to obtain a 
(poly)peptide with even higher binding affinity.
13
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The diversity of protein scaffolds
In the last two decades, over 50 new alternative non-Ig protein scaffolds have been 
reported as potential affinity tools. These protein scaffolds comprise an extremely 
diverse group of binding molecules, which differ in many aspects such as origin, 
size, structural topology, engineering strategies, mode of interaction and applicability. 
The classification of these protein scaffolds is most often based on their structures 
and the strategies applied for engineering the binding affinity. Two examples of 
protein scaffolds that have been used successfully are discussed in some more detail 
below; these and other protein scaffolds have been the focus of several excellent 
reviews 16, 74, 83, 90, 105, 203, 204, 216, 260.
Figure 1.3: M13 phage display cycle. A library of DNA fragments encoding random variants of the protein 
of interest (POI) is created (fused to gene encoding M13 coat protein pIII) and cloned into a phagemid vector. 
Escherichia coli cells are transformed with the obtained constructs and subsequently infected with helper-phage 
to create a library of phages, each displaying a variant of the protein of interest. The library is exposed to 
an immobilized target molecule. Non-binding phages are washed away. Bound phages are eluted and then 
amplified by infecting bacterial cells. This selection and amplification process can be repeated as necessary 
using more stringent washing conditions in order to obtain phages with the displayed protein of interest variants 
with the highest target-binding affinity. Finally, the DNA of high-affinity binding phages can be sequenced or 
subjected to another round of evolution.
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Fibronectin type III domain (FN3) 
belongs to the immunoglobulin-like 
β-sandwich class of scaffold proteins. FN3 
is a small 10 kDa domain occurring in many 
animal proteins involved in ligand binding 
(e.g. cell-surface receptors), and is one of 
the most widely used scaffolds today 17, 140. 
The β-sandwich structure consists of seven 
β-strands with three connecting loops on 
one end of the sheet, closely resembling 
the structure of an Ig variable domain 
(Figure 1.4A). Initially, two of the surface 
loops were randomized, and binders were 
selected using phage display 140. In a more 
recent study, all three surface loops were randomly varied, after which the best 
binders were successfully selected using mRNA display 312. At AdNexus Therapeutics, 
FN3-based scaffold proteins (AdNectins) are being used to develop novel cancer 
therapeutics (see Table S1.1). The first AdNectin product concerns a protein designed 
to block the VEGFR2 [vascular endothelial growth factor (VEGF) receptor 2] signal 
transduction pathway, inhibiting the growth of new blood vessels in tumors.
Designed ankyrin repeat proteins (DARPins) belong to the repeat protein class of 
scaffold proteins. DARPins are small (14–21 kDa) modular proteins derived from natural 
ankyrin repeat proteins, which are versatile binding proteins, the corresponding genes 
of which are highly abundant in the human genome 271, 272. DARPins have a modular 
architecture consisting of a single structural motif that occurs several times, and, after 
stacking, they form an elongated repetitive domain that is shielded by two capping 
repeats (Figure 1.4B). Libraries have been constructed in which residues residing in a 
loop and on a helix were randomized in each repeat; subsequently multiple repeats 
were randomly assembled 15. The selection method most frequently used with DARPin 
libraries is ribosome display. High-affinity binders have been selected against targets 
such as maltose-binding protein 15 and an anti-IgE antibody 292.
Considerations for choosing the right scaffold
The wide variety of potential applications, such as therapeutics, diagnostics, affinity 
purification and molecular imaging, has led to the exploration of many different 
protein scaffolds. However, depending on the intended application, potential selection 
criteria include origin, size and structure of the protein to be used as a scaffold. For 
eventual commercial application of a selected scaffold protein, desirable features 
are their efficient production, high solubility, stability, specificity and a favorable 
intellectual property (IP) situation.
Figure 1.4:  Three-dimensional structures 
of engineered binding proteins. The overall 
structures of A) an FN3 monobody (PDB code: 
3K2M 309) and B) a DARPin (PDB code: 1SVX 15) are 
shown. 
A                                       B
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It is very important that the selected protein has a compact and structurally 
rigid core framework that has a relatively high intrinsic stability. This is an obvious 
requirement to generate a library by randomization of solvent-exposed amino acid 
residues, without affecting the scaffold’s fold and half-life. The interface topography 
is a major determinant of protein-protein interactions. Therefore, if protein binding 
is intended, the shape of the selected protein’s binding site (convex, flat or concave) 
could influence epitope selection and the binding mode 216.
In case the binding proteins are intended for therapeutic use, a potential problem 
of novel scaffolds may be their immunogenicity. Therefore, considerations should be 
made about the origin of the protein used as a scaffold; compared with a protein 
from a distinct origin, a human protein is less likely to cause an undesired immune 
response. Another disadvantage of using therapeutic proteins of non-human origin 
is the fact that they may face additional problems from regulatory authorities with 
respect to immunogenicity issues. However, it should be mentioned that human 
scaffold proteins may become immunogenic when multiple surface-exposed amino 
acids are randomized or when their binding site is altered.
Small size is often a desired feature of the selected protein used as a scaffold. For 
instance, in molecular imaging of tumor cells, the binding protein should rapidly 
find its target molecule in the patient, whereas unbound binding proteins should be 
quickly excreted; this will result in high-contrast tumor imaging and a reduced time 
between injection and imaging. Because small binding proteins tend to require less 
time for target recognition or for excretion, bigger scaffold proteins (e.g. antibodies) 
are less attractive for this particular application.
Stability of the selected protein scaffold is of great importance when used for 
affinity-purification applications. The protein should be sufficiently resistant to 
elevated temperatures, organic solvents, detergents and pH changes; in addition, 
the column material should preferably be cleanable and reusable. Most of the above-
described conditions are detrimental to proteins, especially antibodies, and it might 
therefore be interesting to investigate proteins from thermophilic micro-organisms 
as candidate scaffolds. Proteins from these thermophiles generally display a high 
intrinsic thermal and chemical stability 80, 289.
The above considerations indicate that non-antibody protein scaffolds do not 
constitute a homogeneous group with similar properties. It is difficult to predict 
which of these diverse proteins are most suitable for a certain application. Although 
several of these binding proteins may have a lot of potential for biotechnological 
applications, the development of these alternatives to antibodies is still in an early 
phase of proof-of-principle evaluation. With respect to medical applications, only a 
few have progressed to clinical trials. Furthermore, expertise is often limited to single 
laboratories, and only a few libraries of protein variants are commercially available 282.
16
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Aptamers
Aptamers are oligonucleotide ligands that are selected for high affinity binding to 
molecular targets. Both RNA- and single-stranded DNA (ssDNA)-based aptamers 
have been described, generally with a size of 15–60 nt. Reported aptamer targets 
range from small organic molecules such as ethanolamine and acetylcholine 24, 165 to 
large protein complexes 18, 285 and even cells 27, 281. The term ‘aptamer’ is derived from 
the Latin word ‘aptus’ (to fit) and the Greek word ‘meros’ (part or piece). Aptamers 
can have affinities in the nanomolar range, which is comparable with that of mAbs 118. 
Target-binding aptamers are generally selected using a so-called systematic evolution 
of ligands by exponential enrichment (SELEX) procedure, reported independently by 
two groups in 1990 58, 285.
The choice for either DNA or RNA as a basis for aptamer development depends 
on practical considerations and partly on the final application. RNA has a relatively 
flexible backbone compared with DNA, and as such it has a broader range of potential 
target molecules. However, an obvious practical drawback of RNA is the fact that it 
is more prone to chemical and enzymatic degradation. In addition, selection of RNA 
aptamers is more laborious as its processing requires more enzymatic steps. Although 
RNA stability issues can partly be overcome by using modified nucleotides (e.g. 
spiegelmers, see below), it might be desirable for some applications (e.g. biosensors 
or affinity chromatography) to use the naturally more robust DNA aptamers. To date, 
however, the only FDA-approved therapeutic aptamer (Pegaptanib, see below), is an 
RNA aptamer.
Aptamers are selected in vitro
In contrast with the classical production of antibodies in animals, all steps of a 
SELEX procedure take place in a test tube. The in vitro SELEX procedure consists of 
multiple selection rounds, enriching proper binders in each subsequent round. The 
principle of iterative enrichment of binding oligonucleotides resembles the selection 
of binding proteins by phage display. A large pool of synthetic oligonucleotides 
(1014–1015 molecules) is used for selection. The pool typically has a random region of 
30–80 nucleotides and is flanked by two fixed primer sequences. After selection, the 
resulting aptamers can be shortened in additional work to find the minimal sequence 
required for target binding, which is usually 15–60 nt (Figure 1.5).
During each selection round, target-binding oligonucleotides are separated from 
those that bind the target with lower affinity or not at all. Efficient enrichment of the 
best binding sequences is essential, and several SELEX strategies have been developed 
to achieve this, including affinity chromatography 305, capillary electrophoresis 177 and 
target-coated magnetic beads 268 (for a more complete overview of SELEX strategies, 
see 269). Selection strategies depend on the desired affinity and specificity of the 
aptamer, the properties of the nucleic acid (RNA or DNA) used during selection, and 
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also the properties of the target (e.g. 
size, charge or presence of functional 
groups). In addition, aptamers with 
different features can be selected: 
e.g. aptamers that are very specific 
for a given target and do not bind 
any similar molecules 118, aptamers 
that self-report target binding 120, 206, 
or aptamers that catalyze a chemical 
reaction (ribozymes) 305. However, 
incorporation of such features requires 
a well-designed selection strategy.
Sequences are mixed with target 
and those bound to the target 
are recovered and subsequently 
PCR-amplified. For selection of DNA 
aptamers, the two strands of the PCR 
products are separated and one strand 
is recovered. For selection of RNA 
aptamers, transcription of the DNA is 
required before selection, and reverse 
transcription of the bound fraction is 
carried out before PCR amplification. 
In both cases, the resulting enriched 
pool is the starting material for the 
next round of selection.
After eight to fifteen selection 
rounds, remaining sequences are cloned and sequenced. In some rare cases, the pool 
of potential aptamers is dominated by just one sequence 305; in most cases, however, 
a number of different sequences that all fold in similar ways are present 14, 127. After 
sequencing, further characterization of several individual sequences is needed to 
determine the binding kinetics and specificity of binding, to select the aptamer that 
is most suitable for a predefined application.
The versatility of aptamers
Like antibodies and engineered binding proteins, aptamers can specifically bind 
targets of interest. Unique features of aptamers, however, are their small size 
(15–60 nt equals 5–20 kDa; antibodies are 150–160 kDa) and the relative ease of 
chemical modification (e.g. biotinylation or addition of fluorescent labels). These 
properties make them useful for a wide variety of applications. Aptamers can, for 
Figure 1.5: Selection of DNA aptamers. A library of 
random DNA fragments, with a random and two fixed 
regions, is exposed to an immobilized target molecule. 
Non-binding DNA molecules are washed away. Bound 
DNA molecules are eluted, PCR-amplified and made 
single-stranded. For selection of RNA aptamers, the 
DNA pool is transcribed to RNA before target binding, 
and the bound RNA sequences are reverse-transcribed 
before PCR. The selection and amplification process can 
be repeated as necessary using more stringent washing 
conditions in order to obtain higher-affinity molecules. 
Finally, the DNA molecules can be sequenced and 
characterized further.
Binding
selection
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Start with ~1015 variants
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instance, substitute for antibodies in the frequently used ELISA assays 55, and they 
have potential for generating different types of biosensors (see below).
One feature of aptamers is of particular interest for the development of new types of 
biosensors: upon target binding, the structure of an aptamer changes to some extent. 
In contrast with antibodies, this structural change can be used to design aptamer 
sensors that are similar to molecular beacons 288, using a fluorophore-quencher pair 
at the ends of the molecule, or by incorporation of fluorescent base pair analogues 
in the sequence 120, 166. As a result of the structural changes induced by target binding, 
the fluorophore moves away from the quencher. Consequently, fluorescence is no 
longer absorbed by the quencher and this can be measured. Following the same 
principle, electrochemical detection of target binding is possible 3. Measuring target 
binding as a result of structural changes is impossible for antibodies, because any 
structural changes are very small and it is difficult to incorporate a fluorophore-
quencher pair within an antibody 155.
Unlike antibodies, aptamers are easily regenerated, at high temperatures or with 
high salt concentrations, and because of their small size, they can be efficiently 
immobilized on surfaces with high densities. This allows the design of small and 
reusable biosensors. Regeneration is also of interest for affinity-purification 
processes. Aptamers conjugated to resins can, for instance, be used to purify proteins, 
without a tag, from crude cell extracts 117, or they can be used for the separation 
of chiral compounds, provided that the aptamer is specific enough for one of the 
enantiomers 248.
In 2004, Pegaptanib (Macugen) 82 became the first, and currently the only, aptamer-
based therapeutic to be approved by the FDA. This RNA aptamer has an antagonistic 
function, by binding all isoforms, except the smallest (VEGF121), of human VEGF, a 
major regulator of aberrant and excessive blood vessel growth and permeability in 
the eye. The aptamer does not provoke any undesired immune response because 
of its nucleic acid origin 196. However, 2 years later, an antibody-based treatment, 
Lucentis (antibody fragment), was approved and took over the market, because it can 
bind all VEGF isoforms, including the smallest. Despite this setback for the aptamer 
field, Pegaptanib clearly demonstrated the potential of aptamers as therapeutics, 
and currently several aptamer-based therapeutics are in clinical trials 131. In addition 
to therapeutics, aptamers can also be used for targeted drug delivery by coupling 
them to liposomes 303 or micelles 311 that are loaded with drugs. A recent exciting 
development in targeted drug delivery is the usage of aptamer-siRNA (small 
interfering RNA) chimaeras 45, 172, 321. The aptamer domain of the chimaera specifically 
binds to a receptor at the surface of a target cell, after which the RNA molecule is 
imported by endocytosis, and subsequently released from the endosome to enter 
the RNAi (RNA interference) pathway, via which the siRNA domain ensures silencing 
of selected target genes.
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In the field of biomarker discovery, a new aptamer-based strategy has been 
described recently 77, 132. A protein sample is incubated with a mixture of aptamers 
that contain biotin and a photocleavable group. Aptamer-protein complexes are 
then captured on streptavidin beads. Once bound, proteins in the complexes are 
biotinylated and, after washing, the complexes are cleaved from the streptavidin 
bead. Biotinylated proteins in the complexes are again captured on streptavidin 
beads; after washing, bound aptamers are eluted and used for hybridization on a 
microarray. This is a multiplex proteomic approach allowing for high-throughput 
comparison of proteome profiles, whereas multiplexing in antibody-based methods 
is very difficult, as described above. This method can potentially be used to select new 
biomarkers that are specifically related to certain diseases, and to identify potential 
targets for treatment.
Drawbacks of aptamers
Numerous aptamer sequences for a wide variety of targets have been published, and 
aptamers have found their way into several applications 131, 163. SELEX, however, is 
currently rather labor-intensive, because optimal selection conditions (e.g. selection 
buffer, number of selection rounds) are target- and application-dependent and need 
to be optimized for each target. Efforts have been made to automate the SELEX 
procedure 41, but because optimal selection conditions can vary per target, it is still 
not straightforward to select a functional aptamer. It is, however, possible to develop 
aptamers that function under non-physiological conditions. For example, an aptamer 
against ochratoxin-A that was selected in aqueous buffer, also performed well in the 
presence of 20% methanol 42.
Potential commercial developments using aptamers are slowed down because 
only a few companies possess the IP pertaining to aptamers and SELEX technologies. 
In 1999, Gilead Science Inc. acquired many patents related to general aptamer-
selection strategies and of many individual aptamers. Archemix is now exclusively 
licensed to use the IP for therapeutic applications, and SomaLogic for diagnostic 
applications. This centralized IP position does not leave room for many competitors, 
but it should be noted that Archemix has issued commercial therapeutic licences to 
several companies. In the coming years, however, some patents will expire, allowing 
more companies to develop aptamer-based applications, possibly resulting in a boost 
of commercial applications in the near future 179, 284.
In contrast with antibodies, aptamers are small and very stable; the latter 
feature is especially true for those made of DNA. Nevertheless, aptamers made of 
the naturally occurring four bases are not fully resistant to degradation; especially 
in blood serum, unmodified aptamers are rapidly degraded or filtered out of the 
bloodstream. Modifications in the DNA or RNA backbone or modified nucleobases 
are often used to make aptamers less susceptible to degradation by nucleases 168. 
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Modifications can be incorporated either chemically after selection or enzymatically 
during selection. The most widely used modifications are those that replace the 2’-OH 
of the ribose sugar, for instance by -NH2,-F and -OCH3; these modified nucleotides 
are all compatible with the enzymatic steps in the SELEX procedure 130, 168 . Frequently 
used post-selection modifications include: (i) addition of 3’-end caps that reverse the 
polarity of the oligonucleotide (avoiding 3’ exonuclease activity), and (ii) addition 
of PEG [poly(ethylene glycol)] molecules at the 5’-end of the aptamer, to fine-tune 
their in vivo half-lives 131. A completely different approach to prevent degradation 
makes use of non-naturally occurring L-RNA aptamers, or Spiegelmers 137; owing 
to their non-natural origin, they are not recognized by RNases and hence they are 
very resistant to degradation. In addition, modified nucleotides are used to increase 
the chemical diversity of the random pool, which is otherwise limited to four bases. 
This has recently allowed for the selection of aptamers for targets against which no 
aptamers could be selected with an unmodified pool 290.
Molecular imprinted polymers
A MIP is a polymer that is made in the presence of a template molecule, which is 
extracted afterwards, thus leaving complementary cavities behind. The procedure to 
produce these cavities by molecular imprinting was originally published in 1949 52. 
Unlike the above-described affinity tools, MIPs are entirely synthetic scaffolds that 
have no biological origin. The imprinted polymer material is able to recognize a 
single target molecule, varying from small organic molecules to proteins, or a group 
of structurally related molecules based on their shape, size and chemical functionality.
The process of molecular imprinting
Molecular imprinting takes place in 
several steps (Figure 1.6). It starts 
with selection of a template molecule 
that resembles the final target, and of 
functional monomers based on their 
ability to interact with functional groups 
of the template molecule. Functional 
monomers bind to the template molecule 
during a pre-polymerization step and are, 
subsequently, cross-linked to form the 
imprinted polymer. Finally, the template 
molecule is removed from the matrix, 
leaving behind a cavity complementary 
in size and shape to the template. The 
obtained cavity can work as a selective 
Figure 1.6:  Molecular imprinting. Suitable 
monomers, and a template molecule that resembles 
the target molecule, are selected and mixed together 
for pre-polymerization. After polymerization, the 
template molecule is extracted, and the resulting 
cavity can be used for target binding.
Rebinding
Monomers
Template Target
Pre-polymerization 
Polymerization 
Extraction
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binding site for a specific molecule.
Two major imprinting approaches can be distinguished on the basis of the 
interaction between the functional monomer and the template molecule. During 
imprinting, the template and monomers are linked either by covalent or by 
non-covalent interactions, such as hydrogen-bonding and Van der Waals interactions. 
Covalent imprinting generally produces more homogeneous binding sites (analogous 
to mAbs); however, template removal is often difficult. Non-covalent imprinting 
generally produces more heterogeneous binding sites, with a rather wide affinity 
range for the target (analogous to pAbs). Non-covalent imprinting is used most often 
nowadays, mainly because the process is simple and a wide variety of monomers are 
commercially available. Design of better monomers and optimized polymerization 
conditions for the non-covalent imprinting approach has resulted in the production 
of more homogeneous binding sites 169. Selectivity and binding kinetics of MIPs need 
to be determined after imprinting, using the MIP as stationary phase in HPLC columns, 
or by performing batch rebinding studies 265.
MIPs can be made for small organic molecules as well as for proteins. Conditions 
for protein imprinting, however, are more restricted. Polymerization can only take 
place in the aqueous phase, because of limited protein stability in organic solvents. 
Protein imprinting has been studied intensively, and several imprinting strategies 
have been developed 69, 256. The different protein-imprinting strategies can be 
distinguished into three categories on the basis of the parts of the protein that are 
imprinted 69, 280: (i) bulk imprinting, in which the whole protein is imprinted; (ii) surface 
imprinting, in which only a part of the surface of the protein is imprinted; and (iii) 
epitope imprinting, where only a small, but typical, part of the protein is used for 
imprinting. MIPs produced by epitope imprinting can recognize the whole protein 
by binding a specific part of it, analogous to the way a mAb recognizes an antigen.
MIP composition and shape are important
Molecular imprinting looks deceptively easy, but, in fact, many aspects can influence the 
final properties of the MIP. Choice of template and functional monomers 125 obviously 
influence the end product, but the ratio of these molecules is also important. Porosity 
of MIPs depends on the solvent and temperature used for polymerization. Porosity 
is important, because pores that are too small limit flow through or make cavities 
inaccessible, whereas pores that are too large limit the overall binding capacity of the 
MIP. It is difficult to screen a large number of different polymerization conditions, by 
conventional techniques, to find the optimal conditions. Several routine conditions 
for molecular imprinting have therefore been developed over the years, although 
these might not be the best conditions to make a MIP for any specific target 5. A semi-
automated combinatorial imprinting strategy for preparation of MIPs under different 
conditions, and subsequent evaluation of these MIPS, has been developed and may 
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shorten the time required to determine optimal polymerization conditions 279.
Conventional methods for MIP production result in large polymer blocks; 
subsequent grinding and sieving yield similarly sized, but irregularly shaped, particles. 
Irregular particles are not a problem for certain applications [e.g. solid-phase 
extractions (SPEs)], but some other applications require size- and shape-defined 
particles (e.g. in vivo applications). Size and shape-defined MIPs can nowadays be 
produced in several different formats such as bead, membrane, monolayer, nanowire 
or dendrimer 314.
MIPs work well in non-aqueous environments
MIPs are very stable because of their synthetic nature; they can resist high temperatures 
and a wide pH range, and can be stored for several years without losing affinity 70. 
Unlike the affinity tools described before, MIPs work especially well in organic 
solvents instead of aqueous solutions. Production of MIPs is cheap and fast, once 
appropriate functional monomers and cross-linkers have been chosen. Numerous 
imprinted polymers, capable of binding toxins (e.g. Bisphenol A), pesticides (e.g. 
catechol), antibiotics (e.g. penicillin G) are now commercially available (see companies 
in Table S1.1), and some companies even offer to develop custom-made MIPs.
Imprinted polymers are most frequently used in SPE, a separation process that is 
used to concentrate target molecules or to remove contaminants during downstream 
processing. SPE is often used for sample preparation before analysis 287, for instance 
for the separation of enantiomers, or concentration of analytes from waste water 
or food samples. To ensure effectiveness of SPE, however, conditions should closely 
resemble those originally used to prepare the MIP. Even when using these conditions, 
extensive optimization of the SPE procedure is often required 287. Most MIPs are 
prepared in organic solvents, hence it is difficult to use aqueous solutions directly 33; 
conventional SPE can be used in this case to exchange aqueous solutions for those 
that more closely resemble polymerization conditions.
Application of MIPs in a molecular-imprinted sorbent assay, analogous to ELISA, 
for detection of theophylline and diazepam was reported for the first time in 1993 291. 
Binding affinity of target molecules to MIPs was deduced from a competition assay 
with non-labelled and radiolabelled target. Results and reproducibility were good 
compared with existing assays, but the procedure is more time-consuming and 
requires the synthesis of radiolabelled target compounds. Although this assay does 
not proceed well in aqueous solutions, it does work very well in organic solvents. In 
addition to these molecular-imprinted sorbent assays, MIPs are currently also used 
in chemical sensors; with different modes of detection, e.g. electrochemical, optical 
and mass-sensitive 98.
The application of MIPs in the drug discovery process was described previously 223. 
Molecular imprints of receptor-binding molecules are made and, subsequently, 
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used for screening compound libraries to identify molecules that have agonistic or 
antagonistic properties 30. Imprinted cavities can alternatively be used as template 
for synthesis of compounds that fit within the cavity, mimicking the template 
molecule 218, 317.
Few reports about in vivo applications of MIPs have been published, but efforts 
have been made to use MIPs for adsorption of cholesterol from body fluids 112. MIPs 
have only recently been successfully used for absorption of melittin, which induces 
cell lysis at high concentrations in the bloodstream of living mice 104. However, as the 
majority of MIP applications are restricted to non-aqueous environments, in vitro 
applications will be the main area of use for MIP technology.
The most attractive affinity tool
In the previous sections, the production, selection and relevant characteristics have 
been described for antibodies, engineered binding proteins, aptamers and MIPs. 
However, an important question remains unanswered: which tool has the most 
attractive features? This question is quite difficult to answer, because there is not 
a single affinity tool that fits all of the requirements for all of the applications. Each 
affinity tool has its own specific characteristics (see Table 1.1) and, depending on the 
intended application, one tool has more potential than another. In this section, we 
discuss the applicability of each affinity tool and relate this to various applications.
Table 1.1: Affinity tool characteristics.
Characteristics Antibody Binding protein Aptamers (ssDNA and RNA) MIPs
Size (kDa) ~150–160 <30 5–20 (15–60 nucleotides) n.a.
Selection In vivo In vitro In vitro In vitro
Production Animal or recombinant Recombinant Synthetic Synthetic (large scale low 
costs)
Post-selection 
modifications
Possible, but 
heterogeneous products
Possible, can be designed 
for homogeneous 
products
Wide variety of options (sugar, 
base, or phosphate; 5’, 3’, or 
internal) 
Possible, but should be 
taken into account during 
imprinting
Stability Several weeks at 4°C Variable DNA: Years at room 
temperature. RNA: several 
months at -80° C
Years at room 
temperature
Binding site Monoclonal: homogeneous 
Polyclonal: heterogeneous
Homogeneous Homogeneous Depending on imprinting 
strategy, heterogeneous 
or homogeneous
Target molecules Mainly immunogenic 
macromolecules 
Macromolecules and 
low molecular weight 
molecules
Low molecular weight 
molecules, macromolecules 
and cells
Mainly low molecular 
weight molecules (<1000)
In vivo half-lives Days to weeks n.a. Untreated: seconds - minutes. 
Treated: days
n.a.
Application 
conditions
Physiological Physiological and non-
physiological
Physiological, non-
physiological and organic 
solvents (to some extent)
Mainly organic solvents, 
aqueous solutions to 
some extent 
n.a., not applicable
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Affinity chromatography
The purification of proteins or small molecules by affinity chromatography is widely 
applied in all areas of life sciences and biotechnology. The process relies on purifying 
the target protein or molecule of interest from a complex mixture of molecules, on 
the basis of the target’s specific and high-affinity binding to an immobilized ligand, 
resulting, in the ideal case, in a pure target in a single step.
Antibodies are currently used for antigen purification, immunoprecipitation 
and pull-down assays; however, they are rarely used for downstream processing of 
proteins or other molecules on an industrial scale. In general, large quantities of the 
affinity ligand are required to construct such columns. In addition, antibodies have a 
limited stability, a large size and high production costs, and are therefore not the first 
choice for this application. Recently, however, a new development in immunoaffinity 
chromatography was reported, where an anti-caffeine camelid antibody was used for 
the separation of caffeine and related methylxanthines 62.
Aptamers are very promising in the field of affinity chromatography 39. Human 
L-selectin was purified from CHO cell-conditioned medium using a DNA-aptamer 
immobilized as an affinity chromatography matrix 241. More recently, Taq DNA 
polymerase was purified using a DNA-aptamer immobilized on magnetic beads 207. 
However, despite their promise as tools in affinity chromatography, there have been 
relatively few examples of the use of aptamers 316. This may, at least in part, be due 
to their variable stability and their sensitivity to nuclease activity. However, it can 
be expected that stabilized non-natural nucleotides will circumvent the instability 
problem of natural oligonucleotides, and that aptamers will find a wider application 
as ligands for protein or small-molecule purification in the near future.
MIPs have specifically received interest for the extraction of small molecules from 
complex food and other biological samples. There are various examples of successful 
MIPs for relatively low-molecular-mass molecules, such as antibiotics and toxins 323. 
MIPs are very well suited for SPE of small molecules; for example, a range of highly 
selective SPE phases based on MIPs have recently become commercially available 
(Biotage AB). However, MIPs, are at this moment, not suitable for protein purification 
purposes because of their typically harsh operational conditions.
Engineered binding proteins are potentially the most attractive alternative to 
antibodies in affinity chromatography. They are more likely to withstand the harsh 
column washing and regeneration conditions and are cheaper to produce due to their 
smaller size and simple scaffolds. At this moment, the most frequent use of affinity 
chromatography using an engineered binding protein is the purification of antibodies 
using recombinant Protein A or Protein G 92. Recently, a number of Affibody proteins 
coupled to affinity resins were demonstrated to specifically capture their target 
molecule from complex mixtures 83. In addition, Affibody proteins have been included 
in commercially available depletion columns from Agilent Technologies in order to 
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remove interfering high abundant proteins from human samples (e.g. plasma, serum). 
These results strongly suggest great potential for the development of engineered 
binding protein resins for the purification of specific proteins and other molecules.
Diagnostics
Antibodies are at this moment the best and most frequently applied tool for routine 
diagnostic tasks. ELISA and Western blot analyses are used for analyses in a range 
of medical applications, but also for analyzing food and environmental samples. 
In addition, despite their relatively high costs and limited stability, antibodies are 
increasingly used as point-of-care diagnostics, such as pregnancy and HIV tests 20, 293. 
Commercial availability is an important contributor to the widespread use of 
antibodies; it compensates for their relatively high price and limited stability to some 
extent. Development of cheaper or more stable alternatives is to be expected in the 
future. However, actual implementation of an alternative affinity tool for an existing 
application has often proven to be difficult. Once a procedure has been established 
and validated, the advantages of using an alternative affinity tool must be worth 
the effort of repeating all of the laborious and expensive testing to validate the 
procedure. Alternatives for antibodies, e.g. MIPs 291 and aptamers 170, have indeed 
been developed for ELISA assays; however, because of the above-mentioned reasons, 
they are not yet widely applied. Antibodies remain the most attractive tool for routine 
diagnostic tests. However, in case an assay should be performed at non-physiological 
conditions, or in organic solvents, aptamers, MIPs or engineered binding proteins are 
certainly worthy of consideration as a binding tool.
Therapeutics
When an affinity tool has to be developed from scratch, the characteristics of each tool 
and prerequisites for the intended application should be evaluated carefully in order 
to select the most appropriate tool. Requirements for human in vivo applications, 
for example, are the most demanding, in terms of legislation and complexity of the 
conditions in which the tool should operate. This is probably why antibodies have 
received most attention, because they can be selected and produced in an environment 
that closely resembles human in vivo conditions. Over the years, antibodies have come 
a long way from their initial in vivo selection and production, and have become very 
successful especially as therapeutics; many problems concerning immunogenicity 
have recently been solved 9, 296. However, as antibodies also have their limitations, 
alternative tools have certainly gained interest; one aptamer has been FDA-approved, 
and several aptamers and several engineered binding proteins are currently in clinical 
trials 9, 130. In this respect, MIPs receive less attention, despite the recent development 
of using them for detection and binding of melittin in vivo 104. Before MIPs can enter 
clinical trials, several key issues need to be addressed, such as compatibility of MIPs 
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with aqueous solutions.
Although the potential for in vivo application of aptamers and engineered binding 
proteins is clearly demonstrated, it will take many years before they can compete 
with the success of antibodies. For antibodies, however, it also took years before they 
became successful, perhaps best illustrated by the 8 years it took before a second 
antibody therapeutic was FDA-approved, in 1994, after approval of the first antibody 
therapeutic, in 1986.
Outlook
At present, antibodies are the most popular and best established affinity tools, 
especially in diagnostics. It appears very unlikely that alternative affinity tools will 
play a significant role in the field of diagnostics soon, simply because of the wealth 
of antibody-based assays that are readily available. Still, there may be exceptions. 
The alternative affinity tools are, at this moment, more attractive for applications 
in which antibodies are not well suited, for reasons that relate to size, physical and 
chemical stability, production costs and requirement for high-throughput analysis. For 
instance, affinity chromatography and SPE generally require cheap and stable affinity 
tools. Antibodies are too expensive and too unstable for most of these applications; 
hence application of engineered binding proteins, aptamers or MIPs might be more 
attractive in these cases. Moreover, aptamers and engineered binding proteins are 
both very promising for in vivo imaging, because they are much smaller than full-
length antibodies, and hence can better penetrate tissues, resulting in increased signal 
to noise ratios. It is important to note, however, that, although diverse applications 
may require different affinity tools (Table 1.2), the most attractive tool for a certain 
application may not necessarily be the one with the best biochemical and physical 
features. Obviously, economic properties, such as the commercial availability and 
ease of selecting improved variants, are also very important considerations.
Table 1.2: Suitability of affinity tools for various applications. 
Application Antibodies Engineered binding proteins Aptamers MIPs
Therapeutics/ treatment ++ + ++
Targeted drug delivery ++ + +
Molecular imaging ++ + +
Drug discovery +
Diagnostics ++ + ++ +
Affinity purification + ++ + ++
Biosensors + + ++
+, reported in literature; ++, commercially available
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As research on aptamers, engineered binding proteins and MIPs continues, it 
is anticipated that, in the cases of the aforementioned niche applications in which 
antibodies perform poorly, they will either progressively replace antibodies or enable 
completely novel applications. It is tempting to speculate that the types of affinity 
ligands discussed will eventually become readily available for routine diagnostic and 
industrial applications, as a useful complement of the currently available antibodies.
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Supplementary information
Table S1.1: Selected companies developing affinity tools based on novel scaffolds. For a more extensive 
list of therapeutic antibodies, see 195, 224.
Affinity tool Company Acronym Scaffold www address
Engineered 
affinity 
proteins
Adnexus (acquired by 
Bristol-Myers Squibb)
AdNectins Human tenth FN3 http://www.adnexustx.com 
Affibody Affibodies Protein-binding domain of 
Staphylococcus aureus protein A
http://www.affibody.com
Amgen (formerly Avidia) Avimer LDL (low-density lipoprotein) cell-
surface receptor domain A
http://wwwext.amgen.com
Arana (formerly EvoGenix 
Therapeutics)
Evibodies Human cytotoxic-associated antigen 
(CTLA-4)
http://www.arana.com
Pieris AG Anticalins Lipocalins http://www.pieris-ag.com 
BioTech Studio Telobodies Human PDZ domains http://www.biotechstudio.com
Bionexis AFIM Phospholipid interaction domain of 
annexin
http://www.bionexis.com
Borean Pharma Tetranectins Human C-type lectin domain (CTLD) http://www.boreanpharma.com
Covagen Fynomer Fyn SH3 (Src homology 3) domain http://covagen.ch
Dyax Kunitz domain of trypsin inhibitors http://www.dyax.com 
Immunocore (formerly 
Avidex) 
mTCR Monoclonal T-cell receptors http://www.immunocore.com 
Molecular Partners DARPins Ankyrin repeat protein http://www.molecularpartners.com 
NascaCell (formerly 
Selecore)
Microbodies Cysteine knots or knottins
Pacific Northwest 
National Laboratory, 
Department of Energy
Top7 http://www.pnl.gov
Scil Proteins Affilin Human ubiquitin/human γ -crystallin http://www.scilproteins.com
Emergent Biosolutions 
(formerly Trubion 
Pharmaceuticals)
SMIPs Binding domain from annexin http://www.truemergent.com
Aptamers AdAlta Peptide aptamers http://www.adalta.com.au 
Aptagen Aptabody Nucleic acid aptamers http://www.aptagen.com 
AptaRes MonoLex Nucleic acid aptamers http://www.aptares.net 
Archemix Nucleic acid aptamers http://www.archemix.com
Imaxio Peptide aptamers http://www.imaxio.com 
NascaCell (formerly 
Selecore)
Nucleic acid aptamers http://www.nascacell.de 
NOXXON Pharma AG Nucleic acid spiegelmers http://www.noxxon.com 
SomaLogic SOMAmers Nucleic acid aptamers http://www.somalogic.com
MIPs Biotage AB (formerly MIP 
Technologies)
AFFINILUTE Molecular imprinted polymers http://www.biotage.com
PolyIntell AFFINIMIP Molecular imprinted polymers http://www.polyintell.com 
Detection Inc. Molecular imprinted polymers http://www.raptordetection.com 
Semorex Molecular imprinted polymers http://www.semorex.com
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Initiating Surface Plasmon Resonance 
experiments and processing kinetic data
Vincent J.B. Ruigrok, John van der Oost, Hauke Smidt
Data presented in this paper were obtained within the framework of the 2011 Global 
Label-free Interaction Benchmark study, initiated by Rebecca L. Rich & David G. 
Myszka, Biosensor Tools, LLC; Salt Lake City, USA. 
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Abstract
Virtually all interactions of biomolecules can be studied using a Surface Plasmon 
Resonance (SPR)-based sensor. Such a sensor can monitor binding interactions in 
real-time, which makes it possible to study the actual kinetics of complex formation 
and dissociation. Obtaining high quality kinetic data, however, is usually not 
straightforward and requires optimization of experimental conditions. Despite the 
efforts that have been made to educate users of SPR-based biosensors on how 
experiments should be performed correctly, a lot of the published SPR data is still of 
poor quality at best. In this chapter, experimental considerations involved in initiating 
and properly performing SPR experiments as well as data analysis and presentation 
are discussed.
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Introduction
Interactions of biomolecules are 
widespread and very diverse in nature. 
They can, however, virtually all be 
studied using a Surface Plasmon 
Resonance (SPR)-based sensor. With 
such a sensor, binding interactions can 
be followed in real-time, which makes 
it possible to study the actual kinetics 
of complex formation and dissociation. 
In addition, SPR does not require any 
labelling of the binding partners; this 
is advantageous, because labelling 
can adversely affect the interaction. 
Besides SPR there are other label-free 
techniques that can be used to study 
binding interactions, such as Isothermal 
Titration Calorimetry (ITC) 63, 73, or 
Microscale Thermophoresis 119, 302. These 
techniques, however, can only be used 
to perform equilibrium assays rather 
than measuring kinetics. Knowledge 
about underlying kinetic parameters is 
certainly relevant, not only for better 
understanding of the molecular basis 
of complex formation, but also because 
different kinetics can result in a similar 
affinity (Figure 2.1). Such largely different 
interactions, from a kinetic point of 
view, would be considered equal when 
measured using an equilibrium assay. 
Alternative methods that are capable 
of measuring kinetics, on the other 
hand, are not label-free, such as Kinetic 
Exclusion Assays (KinExa) 44, or stopped-
flow assays 49.
Despite the diverse nature of interactions, the majority of the interactions studied 
using an SPR-based biosensor can be described by a simple bimolecular interaction 
model (equation 2.1), if the experiment and data analysis are done properly 232, even 
though other, more complex models, have been described and used as well 122, 185.
Figure 2.1: Simulated kinetic data. All three data 
sets have identical affinities (KD =10 nM), but widely 
different kinetics (ka, kd). A maximum binding capacity 
of 100 Response Units (RU) and analyte concentrations 
of 0, 1.2, 3.7, 11.1, 33.3 and 100 nM were assumed 
for each simulation. The program CLAMP was used for 
these simulations 193.
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Equation 2.1:  
    
A + B 
ka
⇄
kd
 AB 
In which the association rate constant ka (M
-1 s-1) is a measure for the rate of 
complex formation, and the dissociation rate constant kd (s
-1) is a measure for the rate 
at which the complex falls apart. The equilibrium dissociation constant, KD (M), of this 
reaction is a measure for the overall strength, or affinity, of the interaction and can be 
obtained in different ways (Equation 2.2). 
Equation 2.2:  KD = 
kd
ka
 = 
[A]×[B]
[AB]
In which ka and kd are the rate constants described above, [A] and [B] are the 
concentrations of the two individual binding partners, and [AB] the concentration of 
the complex at equilibrium conditions. 
In depth knowledge of the physical phenomenon of SPR 99, 100, 109 is not required in 
order to operate the biosensor. It is therefore not without reason that the interest in 
SPR-biosensors has been growing ever since the introduction of the first commercial 
SPR sensor in 1990. Numerous SPR-based systems are available nowadays, but 
Biacore (GE Healthcare) is still by far the main supplier 239. The increased use of SPR-
based biosensors is not merely positive, as a lot of the published SPR data is of 
poor quality at best 233. This seems surprising, because a large effort is made to 
educate users of SPR-based biosensors on how experiments should be performed 
correctly and to stimulate them to actually do so. A wealth of information on various 
aspects of SPR-based biosensing is available in the (annual) surveys of the biosensor 
literature 229, 230, 233, 235, and in various other SPR related publications 189, 231, 232, 234, 239. 
The primary aim of this chapter is therefore not to provide a complete overview, but 
rather to serve as a starting point for those who wish to train themselves in the art of 
SPR-biosensing; by providing an easy accessible overview on the basics of SPR and 
elaborating on the experimental considerations involved in initiating and properly 
performing SPR experiments. The focus will be on experiments that aim to obtain 
kinetic and affinity parameters of binding interactions. Data analysis and presentation 
are important factors that are often neglected in literature 233, and will therefore also 
be discussed here.
General principle of an SPR-biosensor
Polarized light that propagates in a medium of high refractive index (e.g. glass), can 
be fully reflected if it encounters a medium of lower refractive index (e.g. sample 
solution) at a specific angle (Figure 2.2); this phenomenon is called total internal 
reflection 239. Under conditions of total internal reflection an electromagnetic 
field ‘leaks’ into the medium with low refractive index, resulting in an evanescent 
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wave. The amplitude of the evanescent 
wave decreases exponentially with the 
distance from the surface. If the interface 
between the two media is coated with 
a thin layer of metal (usually gold), the 
reflected light will show a dip in intensity 
at a certain angle of reflection: θ (for 
more details see 99, 109, 239). The angle at 
which the dip in intensity occurs is very 
sensitive for the refractive index of the 
solution within the penetration depth of 
the evanescent wave. Analytes binding to 
ligand molecules within the evanescent 
field cause a change in refractive index and hence in the angle of the intensity dip (θ). 
In Biacore systems the angle at which the intensity dip occurs is monitored as a 
measure of binding. 
Although SPR is label-free, it requires that one of the binding partners is 
immobilized; this requirement is an often heard criticism, because as a result the 
measured values might not reflect the actual binding behavior in solution. However, 
over the years several studies have been published comparing SPR with various 
solution based methods. Their results clearly show that, when each technique is used 
properly, they produce comparable results 2, 49, 54. In part this is because molecules are 
often not directly attached to the surface, but to a matrix (dextran) that is attached 
to the surface. 
Reagents
For all types of interactions studied using SPR, high quality reagents are essential. Both 
analyte and ligand should (proven to) be highly pure and in a low polydispersity state. 
Data quality is linked to reagent quality, therefore, and despite all the experimental 
conditions that can be adjusted, low quality reagents will never yield high quality 
data. 
Chips 
Chips with a variety of surfaces, with different characteristics, are commercially 
available nowadays for Biacore systems; two suppliers are Biacore (GE Healthcare, 
Sweden) and XanTec bioanalytics GmbH (Germany). Most chips, however, have a 
dextran hydrogel deposited on a gold layer. This dextran layer provides a hydrophilic 
environment and an increased surface capacity for ligand binding. Biacore’s CM5 chip 
(XanTec equivalent: CMD500L) is a multipurpose chip and a useful choice to start 
experiments, although certain experiments may require more specialized surfaces 1.
Figure 2.2: General principle of SPR. In this figure 
the dip in reflected light intensity is indicated with θ, 
see text for details.
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Coupling vs capture
As described before, SPR analysis requires one of the interacting molecules to be 
immobilized on the chip surface, either via covalent coupling (Figure 2.3A) or via 
non-covalent capture approaches, using a covalently-bound capture molecule 
(Figure 2.3B). Covalent attachment usually provides a more stable surface compared 
to capturing. Nevertheless, despite that capturing is often less stable, it is done at 
milder conditions which decreases the risk of ligand inactivation. 
Covalent attachment
Covalent attachment of ligands can be done, 
amongst others by using primary amines, carboxylic 
acids or sulfur groups present in the ligand 1. The 
most straightforward, and most frequently used 
approach, is ligand coupling via a primary amine 
in the ligand [using N-(3-Dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC) and 
N-Hydroxysuccinimide (NHS)] 236. The negatively 
charged carboxyl groups in the dextran layer are 
essential, as they allow electrostatic attraction of 
positively charged protein ligands to the surface 
(pre-concentration). Pre-concentration allows for 
efficient coupling of protein ligands from dilute 
solutions (10–50 μg ml-1); usually pre-concentration 
of a protein ligand should be tested by diluting it in low salt buffers (10 mM sodium 
acetate) with varying pH, usually 4.0–6.0. The pH that results in the most efficient 
pre-concentration is not necessarily the best for coupling 22; especially when a low 
density surface is required (discussed below), or when the protein is expected to be 
unstable at low pH. In these cases one might choose a higher pH at which the ligand 
is not as heavily pre-concentrated at the surface. It is worthwhile to keep in mind that 
the coupling reaction with EDC and NHS is slow, especially at low pH; for this reason, 
remaining active groups are often blocked using 1 M ethanolamine at pH 8.0. In 
addition, pre-concentration is often not as efficient for small molecules. When a small 
molecule is used as ligand it is recommended to use a higher ligand concentration 
(µM–mM range, depending on solubility and surface density desired) and perform 
the coupling reaction at neutral pH.
Capture
Ligand capture can make use of the various tags that can be added to a protein; a 
protein with a His tag could be captured on a Ni/NTA surface, or on a surface coated 
with anti-His antibodies. Antibodies for a variety of purification tags are available; 
Figure 2.3: Immobilization methods. 
A) Covalent attachment of the Y-shaped 
ligand molecule to the chip surface. B) 
The ligand molecule is captured by 
another molecule (e.g. protein A/G, 
antibody, streptavidin) that is covalently 
attached to the chip surface. The analyte 
is depicted as star-shaped molecule. 
A B
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once coupled to a chip surface these antibodies could even be used to capture ligands 
from crude extracts. In addition, capture using antibodies produces a homogeneous 
surface, which could reduce complexity in the data. Alternatively, a ligand could be 
biotinylated for subsequent capture on a streptavidin surface. The strength of the 
biotin-streptavidin interaction is often exploited in capture approaches, despite that 
ligand biotinylation is a random process and therefore produces a heterogeneous 
surface. Over-biotinylation of the ligand should be prevented, as it can significantly 
decrease the surface capacity 214. Addition of an Avi-tag, that allows for site specific 
biotinylation 10, combines the site specificity of an antibody capture approach and the 
strength of the biotin-streptavidin interaction.
Deciding which binding partner to immobilize
Binding of heavier molecules to smaller ligands yields bigger –easier to measure– 
responses, however, coupling the smallest binding partner to the chip might not 
necessarily be the best approach. Several practical aspects can influence the decision 
on which binding partner should best be immobilized.
Non-specific binding
Before deciding which binding partner to immobilize it is recommended to check 
whether they interact with an untreated surface. This can easily be done by injecting 
the highest concentration of each binding partner that will be used in subsequent 
experiments. Small amounts of non-specific binding can be compensated for by using 
a reference channel (discussed below). Otherwise experimental conditions should be 
altered to minimize non-specific binding. Several additives can be included in the 
running buffer to reduce non-specific binding. Examples are the addition of more 
salt, detergent (usually 0.05% of Surfactant P20 or Tween 20), BSA (anywhere between 
0.1 mg ml-1 to 20 mg ml-1) and soluble dextran (~1 mg ml-1). Depending on the sample 
type, some approaches might be more effective than others, therefore it is advisable 
to assess effectiveness of additives in preventing non-specific binding. In addition, 
different chip surfaces might be explored. If non-specific binding cannot be reduced 
to a satisfactory level, the most sticky protein should be immobilized.
Avoiding avidity
Avidity effects are especially a concern when studying the kinetic behavior of bivalent 
(or multivalent) molecules, such as antibodies. A bivalent molecule in solution could 
potentially bind two ligands on the chip surface (Figure 2.4A). This will result in a 
higher apparent affinity, and the resulting data cannot be described with a simple 1:1 
model. A possible strategy might be to couple only a small amount of ligand to the 
surface, preventing that a second ligand is within reach, once the bivalent molecule 
has bound one ligand molecule (Figure 2.4B). The easiest solution to avoid avidity, 
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however, is to couple the bivalent molecule to the chip surface and inject the other 
binding partner (Figure 2.4C).
Collecting high quality data 
Obtaining high quality data requires more than good reagents and sensible decisions 
on which molecule should be attached to the chip surface. Experimental conditions, 
for instance the use of a reference surface, flow rate and regeneration can improve 
data quality to a large extend as well. 
Reference surface
Data quality can be greatly improved by using a reference surface, as it can be used 
to correct for bulk contribution, low levels of non-specific binding, injection noise, 
and baseline drift 183, 191. Using a reference surface is straightforward in instruments 
that either have multiple flow cells (e.g. Biacore 2000 and 3000) or an array (e.g. 
Biorad ProteOn XPR36, IBIS MX96), because the analyte passes over the reference and 
analyte surfaces simultaneously. To ensure a similar environment, a reference surface 
is best treated in the same way as the ligand surface. The best reference surface 
contains a modified version of the ligand that is known not to bind the analyte. When 
no such modification is available, a similar but non-target protein, or an unrelated 
protein will suffice. The reference channel should at least be activated and blocked in 
the same way as the ligand surface. 
Blank injections 
Blank injections are injections of the same buffer that is used as running buffer. Ideally 
there should be no detectable response, but often there is a minor change in the bulk 
refractive index. This change, however, should be consistent between the flow cells 
and subsequent injections. In the beginning, a number of injections usually deviate 
from subsequent injections (usually the first and second). Therefore, a number of 
blank injections (usually >4) preceding analyte injections help to equilibrate the 
Figure 2.4: Reducing avidity effects. A) Avidity effects can arise when a bivalent molecule is injected over a 
surface that contains a high density of ligand. B) Avidity effects can be reduced by binding less ligand on the 
surface. C) The best way to avoid avidity is to attach the bivalent molecule to the surface. Bivalent molecules are 
depicted as Y-shaped molecules, monovalent molecules are depicted as star-shaped molecules. 
A B C
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instrument, resulting in a more stable and reproducible signal. Blank injections are 
also necessary for double referencing of the data.
Assay types and sample injections
Regardless of the assay type used, it is important to use a dilution series that 
spans a wide concentration range (typically 100 fold). In addition, it is better to 
assay a small number of concentrations 
(generally 5) and replicate them, 
rather than injecting a large number 
of concentrations only once. Kinetic 
measurements can be performed in 
various assay formats on a Biacore 
3000: classical kinetics, short-‘n-long 
and titration kinetics (Figure 2.5). In the 
classical approach a dilution series of 
analyte is injected over the surface in 
subsequent cycles; each cycle takes an 
equal amount of time. It is essential to have 
curvature in the data to derive accurate 
ka and kd values, however, especially for 
interactions with a low kd it can take a 
long time to get sufficient curvature in 
the dissociation phase. The short-‘n-long 
assay is therefore used to save assay time; 
only the dissociation phase of the highest 
analyte concentration is monitored long 
enough to get sufficient curvature in the 
data. In a titration kinetics approach, 
a dilution series is injected over the 
surface during one cycle, starting with 
the most dilute concentration; there 
is a short dissociation time between 
injections. The analyte injections are 
followed by a single long dissociation 
phase (analogous to the short-‘n-long 
approach). Titration kinetics reduces 
the need for regeneration of the ligand 
surface. 
Figure 2.5: Assay formats for kinetic analysis. 
A) Classical kinetics assay, all analyte injections 
are monitored for the same amount of time. B) 
Short-‘n-long assay, to save time, only the dissociation 
phase of the highest analyte concentration is 
monitored long enough to obtain curvature in 
the data. C) Titration kinetics, increasing analyte 
concentrations are serially injected, followed by a 
single dissociation phase, this assay format reduces 
the need for regeneration.
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Reducing mass transport limitations
Liquid flow in a flow cell is laminar, 
resulting in an unstirred boundary layer 
at the chip surface. The thickness of the 
unstirred layer depends, amongst others, 
on the flow rate: the higher the flow rate, 
the smaller the unstirred boundary layer 
(Figure 2.6). Mass transport limitation 
occurs in the unstirred boundary layer 
if transportation of the analyte to the 
ligand is limited by diffusion. In addition, 
if a dissociated analyte is not timely 
removed from the unstirred boundary 
layer, rebinding events can occur. 
Mass transport limitations can be 
reduced by using a high flow rate and a 
low surface capacity. High flow rates result 
in a thinner unstirred boundary layer; a 
low surface capacity reduces potential 
rebinding events 189. For kinetic measurements a flow of 30 µl min-1 is often used 236, 
and the highest response should preferably not exceed 100 Response units (RU) 190. 
When a binding reaction is limited by mass transport, the association phase shows 
linearity and has little to none curvature; in addition the observed dissociation is less 
than the actual dissociation (analogous to avidity effects). 
Especially when the association rate (ka) of a binding reaction is high (above 
1×106 M-1 s-1 239) it is difficult to fully avoid mass transport limitations. In these cases, 
a two-compartment model is often used to fit and analyze data. In this model, the 
simple bimolecular interaction model (equation 2.1) is extended to yield equation 2.3.
Equation 2.3:  A0  
km
⇄
km
 A+B 
ka
⇄
kd
 AB 
The rate at which the analyte is transported in and out of the unstirred boundary 
layer (the transition between A0 and A) is described by the diffusion limited rate 
constant (km) (Figure 2.6) 
192. 
Regeneration
Regeneration is used to prematurely end the dissociation phase by injecting a short 
pulse of a solution that disrupts the complex. A regeneration step can reduce the 
assay time considerably, especially if the complex dissociates slowly. The regeneration 
condition, however, should be such that the analyte is efficiently removed without 
Figure 2.6: Mass transport limitation. This occurs 
in the unstirred boundary layer if transportation of 
the analyte to the ligand is limited by diffusion, or 
if a dissociated analyte is not timely removed from 
the unstirred boundary layer. The rate at which the 
analyte is transported in and out of the unstirred 
boundary layer is described by the diffusion limited 
rate constant (km) 
192. The unstirred boundary layer 
decreases with higher flow rates.
Flow
km
km
ka kd
Unstirred 
layer
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adversely affecting the ligand. Although the best regeneration condition should often 
be determined empirically, knowledge on the interaction and interaction partner 
might provide a clue on which types of regeneration (e.g. acid, base, SDS or salt) are 
worthwhile to test. In general, regeneration should be a short pulse (10–20 s) at a high 
flow rate. In addition, when screening for an appropriate condition it is recommended 
to start with a mild condition and gradually progress to harsher conditions. Once a 
suitable condition is found a series of binding and regeneration experiments should 
be performed, to assess whether or not the ligand is damaged by the regeneration. 
When running a sequence of injections, it is recommendable to add a buffer injection 
after the regeneration in order to prevent carryover of the regeneration solution to 
the subsequent analyte injection. 
Analyzing and presenting data
After data collection the raw data needs to be processed such that the binding 
responses become apparent. Figure 2.7A shows the raw data of a titration kinetics 
experiment, which was conducted in the framework of the 2011 Global Label-free 
Interaction Benchmark study (see supplemental text for details). The actual response 
of the binding event might be difficult to distinguish in the raw data, but becomes 
apparent after processing. 
Processing data
Two higher curves in Figure 2.7A correspond to the ligand coated channel, the bottom 
curves are from the reference channel. The first step in processing data is to set these 
responses for all channels to zero on the y-axis. Zeroing is done by subtracting the 
average response a few seconds before the injection start (Figure 2.7B). The next step, 
subtraction of the signal of the reference surface, eliminates most of the injection 
noise and bulk changes (Figure 2.7C). Sharp spikes can arise, because of the different 
positions of the reference and ligand surface, and should be eliminated from the 
data. Although the signal of binding (gray) becomes clearly visible the responses still 
show some bulk changes. These seemingly minor changes can adversely affect the 
fitting process and should be further corrected by double referencing of the data. 
Double referencing means that the average signal of several blank injections (black) is 
subtracted from the data (Figure 2.7D). Subsequently, replicate injections are overlaid 
and this data can now be analyzed using a titration kinetics model 126 (Figure 2.7E). 
Curvature is essential to obtain accurate values for the rate constants of association 
(ka) and dissociation (kd). It should be noted, however, that even with lack of curvature, 
it is still possible to obtain an accurate KD as it is defined by the ratio KD= kd / ka.
Presenting data
Generally it requires considerable effort to obtain high quality data and to extract the 
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binding constants. However, this is not 
yet the time to lean back and ponder on 
the biological implications of the results. 
Presentation of the data and the fits 
deserves attention as well! In fact, why 
would you not show the data, especially 
considering the efforts it took to obtain 
it? Not rarely, however, only the binding 
constants are reported without showing 
any data 233, which makes you wonder 
how the experiment was executed. 
The data can give a trained eye an 
indication on how well the experiment 
was performed and hence how reliable the 
reported binding constants are. A figure 
should preferably contain an overlay of 
all replicate measurements, together 
with the fit to a 1:1 model (by default). 
For long measurements it is useful to 
show the response of one or more blank 
injections, to assess the stability of the 
baseline during the measurements. 
Sharp spikes should be removed as 
they are not relevant; moreover, spikes 
force relevant data to a scale that is too 
small to be useful. In addition, the figure 
should focus on the binding event, and 
should preferably show only the baseline 
just before and just after the injections.
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Figure 2.7:  Data processing. A) Raw data from 
receptor surface (top) and reference surface (bottom) 
of buffer injections (black) and analyte injections 
(gray). B) data is zeroed to the y-axis prior to the 
first injection. C) Data of the reference surface is 
subtracted. D) The average of multiple blank injections 
is subtracted. E) Replicate injections are overlaid and 
fitted to a titration kinetics model (smooth black line). 
Surface density: 678 RU, flow: 30 µl min-1, analyte 
concentrations: 6.25, 12.5, 25, 50 and 100 nM. Fitting 
yielded for ka: 6.6 × 10
5 M-1 s-1, for kd: 1.5 × 10
-3 s-1, for 
KD: 2.2 nM.
41
Initiating Surface Plasmon Resonance experiments
2
Concluding remarks
Obtaining high quality kinetic data is usually not straightforward, but it is worth the 
effort because such data is often easy to analyze and generally follows a 1:1 binding 
behavior. A proper fit to the data, presented in a clear figure is more than a satisfying 
reward; it will provide the readers of your paper with confidence in the data and shows 
them that you know what you were doing. Unfortunately this understanding has not 
been fully recognized, as becomes clear from the amount of poor quality data that 
still is being published. After reading this chapter, we hope you are encouraged to 
only generate and present high-quality SPR data.
Supplement – An example
The data shown in Figure S2.1 was obtained within the framework of the 2011 Global 
Label-free Interaction Benchmark study (Rebecca L. Rich & David G. Myszka, Biosensor 
Tools, LLC; Salt Lake City, USA). Benchmark studies serve the important purpose of 
educating users but also to gain information on the reliability and variability of the 
technique as a whole 236. In this particular study, participants were provided with a 
biotinylated target molecule (27.3 kDa), an analyte (20 µM, 50.8 kDa), a streptavidin-
coated sensor chip (Xantec, SAD 200M), and the task to analyse the interaction. To 
standardize the analysis, the temperature was fixed to 25°C and the running buffer 
defined (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.01% tween 20, 0.1 mg ml-1 BSA, 
pH 7.4). 
During the experiment the flow was kept constant at 30 µl min-1, while ligand was 
captured at a flow of at 5 µl min-1. As initial test, the biotinylated target was captured 
to a density of 110 RU in fc 4. Because the analyte molecule is approximately two 
times heavier than the ligand the maximal response is expected to be around 205 RU, 
according to equation 2.4 (that assumes 1:1 binding).
Equation 2.4:  Analyte binding capacity (RU)=
MW analyte
MW ligand
× immobilized ligand (RU)
A test injection of 100 nM analyte, however, only yielded a response of 13 RU; 
probably the ligand was not fully active anymore. In any case, this was considered too 
low to perform a full kinetic analysis, and hence the analyte was captured to higher 
densities in the remaining channels: 424 RU in fc 2 and 678 RU in fc 3; fc 1 was left 
empty to serve as reference channel. Based on the test injection it was estimated 
that a regeneration step would not be necessary, provided the dissociation phase 
was long enough. Therefore the titration kinetics approach was chosen to be suitable. 
Five concentrations of either a 2 fold or 3 fold dilution series were injected for 
2 min, followed by a 1 min dissociation phase. The last and highest concentration, 
100 nM, was followed by a dissociation phase of 45 min, of which the last 20 min 
were excluded from the analysis. Each dilution series was injected in triplicate and 
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two buffer injection cycles were performed, one preceding each set of triplicates. 
With hindsight more buffer injections should have been performed to increase data 
quality, because the first of each triplicate does not overlay as nicely with the other 
two (Figure S2.1). Double referenced data was globally fitted using a titration kinetics 
model 126. Although the fits are not perfect, the results show that different surface 
densities and dilution series yield comparable kinetics (Figure S2.1). 
As it turns out, after returning the data, the biotinylated ligand molecule was 
actually a mix of two forms of the protein; both forms bind the analyte with distinct 
affinity and kinetics. By creating a heterogeneous surface, the initiators of the 
benchmark study set out to mimic complexity that may be encountered in regular 
experiments. During the analysis data should have been fitted with a model specific 
for a heterogeneous surface. Although such a model is available in the Biacore 3000 
analysis software for a classical kinetics assay, it is not available for a titration kinetics 
assay. Therefore, and despite that the fits are not optimal, the fits of the 1:1 model are 
the best approximation of the kinetics and affinity of the interaction. 
Figure S2.1: Results of the titration kinetics series. Two different surface densities and two different dilution 
series were used. Data points used for fitting are shown in dark gray, baseline responses are shown in black. Fits 
to the data are indicated by the smooth black line. The first injection series of each dilution series that was not 
included in the fitting is shown in light gray.
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Abstract
Aptamers are oligonucleotide ligands that are selected for high-affinity binding to 
molecular targets. Only limited knowledge relating to relations between structural 
and kinetic properties that define aptamer-target interactions is available. To this end, 
streptavidin-binding aptamers were isolated and characterized by distinct analytical 
techniques. Binding kinetics of five broadly similar aptamers were determined by 
surface plasmon resonance (SPR); affinities ranged from 35–375 nM with large 
differences in association and dissociation rates. Native mass spectrometry showed 
that streptavidin can accommodate up to two aptamer units. In a 3D model of one 
aptamer, conserved regions are exposed, strongly suggesting that they directly interact 
with the biotin-binding pockets of streptavidin. Mutational studies confirmed both 
conserved regions to be crucial for binding. An important result is the observation that 
the most abundant aptamer in our selections is not the tightest binder, emphasizing 
the importance of having insight into the kinetics of complex formation. To find the 
tightest binder it might be better to perform fewer selection rounds and to focus on 
post-selection characterization, through the use of complementary approaches as 
described in this study.
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Introduction
Aptamers are oligonucleotides (RNA or single-stranded DNA) that serve as high-
affinity binding ligands, selected to interact specifically with a target. Potential 
aptamer targets range from small organic molecules (e.g., ethanolamine 165 and 
acetylcholine 24) to proteins and large protein complexes 18, 285, and even to cells 27, 281. 
Research into aptamers has steadily increased after their initial development in 
1990 58, 285. Although at present there are only a few commercial applications of 
aptamers, they certainly have beneficial properties for application as therapeutics 
[e.g., FDA-approved Pegaptanib (Macugen) 82]. In addition, aptamers have potential in 
the fields of targeted drug-delivery systems, biological recognition tools in biosensors 
and imaging tools 245.
Aptamers that specifically bind predefined targets are generally selected in 
vitro by SELEX (systematic enrichment of ligands by exponential enrichment). The 
SELEX procedure consists of multiple selection rounds, starting with a large pool of 
synthetic oligonucleotides containing a variable region (1014–1015 variants) flanked 
by constant regions. Rounds of selection are initiated by exposure of RNA or ssDNA 
oligonucleotides to an immobilized target molecule. Subsequently, non-binding 
oligonucleotide molecules are washed away, after which bound molecules are 
recovered, amplified by PCR or RT-PCR and made single-stranded again. Several 
selection procedures have been successfully applied over the years, including affinity 
chromatography 305, capillary electrophoresis 177 and enrichment through the use 
of target-coated magnetic beads 268. After successful selection, the minimal binding 
sequence should be obtained, in order to increase specificity and to reduce synthesis 
costs. Approaches to identification and characterization of the minimal binding 
sequence can be straightforward, but only when a conserved nucleotide motif and 
folding pattern is enriched.
A relevant feature of an aptamer is its affinity for its target. The dissociation constant 
(KD in M) is often measured by approaches that do not provide insight into the actual 
kinetics of binding. However, the kinetic parameters can reveal valuable information: 
the association rate constant (ka in M
-1 s-1) is a measure of how rapidly a complex is 
formed, whereas the dissociation rate constant (kd in s
-1) is a measure of how rapidly 
a complex falls apart. The dissociation constant can easily be calculated from the 
ratio of the dissociation and association rate constants (KD = kd / ka); this illustrates 
how different kinetics can result in similar affinities. Knowledge of underlying kinetic 
parameters is therefore relevant for better understanding of the molecular basis 
of complex formation and stability. One of the methods used to determine kinetic 
parameters (ka and kd) is surface plasmon resonance (SPR), an advanced method for 
following binding interactions in real time 49.
Streptavidin, a 60 kDa homo-tetrameric protein originally isolated from 
Streptomyces avidinii, is used extensively in molecular biology, because the 
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interaction between streptavidin and its natural ligand biotin is one of the strongest 
non-covalent molecular interactions known (KD ~10
-14 M). In the absence of biotin, 
a loop close to the binding pocket is open; however, upon biotin binding the loop 
moves to cover the pocket. This conformational change explains the exceptionally 
high affinity –the result of a very low kd value– for biotin 
148. In two recent studies, 
streptavidin has been used as target for aptamer selection. Remarkably, the predicted 
secondary structures of the enriched binding motifs were quite similar, although only 
a few nucleotides appeared to be conserved 14, 268. From equilibrium analyses and 
competition experiments, dissociation constants ranging from 40 to 85 nM were 
reported, although no data on the kinetics are available. In addition, biotin was shown 
to compete with streptavidin-binding aptamers, suggesting that the aptamers bind in 
or near the biotin-binding pocket 14. Nevertheless, the stoichiometry and the location 
of binding are not known.
Here we set out to test whether or not multiple independent selection experiments 
would result in similar aptamers, in terms of sequence and structure as well as kinetic 
properties. In addition, we wanted to obtain a thorough understanding of the kinetics 
underlying aptamer selection, ideally resulting in aptamers with improved binding 
affinities. Streptavidin was chosen as target because streptavidin-binding aptamers 
have already been described, because detailed knowledge on its structure is available, 
and because its stability makes it relatively easy to perform SPR experiments. Seven 
rounds of selection resulted in streptavidin-binding oligonucleotides with a conserved 
secondary structure. Five different aptamer families could be distinguished, and SPR 
analysis showed that, despite their similarity, they differ greatly in their affinities (35–
375 nM) and their kinetic behavior. In addition, the stoichiometries of the complexes 
were determined by native mass spectrometry, and small angle X-ray scattering 
(SAXS) data were used to generate a structural model of the aptamers.
Results
Streptavidin-binding aptamers
Through the use of the experimental approaches described later in this chapter 
we aimed to obtain ssDNA aptamers that would bind to streptavidin. After seven 
rounds of selection, the enriched pool of aptamers was cloned. In total, 91 clones 
were sequenced and used for subsequent analysis. Assembly of individual sequences 
yielded 12 clusters that each contained two to 13 fully identical sequences, whereas 19 
sequences occurred only once, resulting in a total of 31 unique sequences (Figure S3.1 
in the Supplementary information).
Structural predictions of all unique sequences (clusters and singlets) were made 
using mfold (a selection is depicted in Figure S3.2). In 26 out of the 31 sequences 
a similar structure of a stem-bulge-stem-loop was predicted (Figure 3.1); in the 
remaining five sequences (two clusters representing 16 clones, and three singlets) no 
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Figure 3.1:  Secondary 
structure of the predicted 
stem-bulge-stem-loop 
sequences. Nucleotides in 
capitals are conserved in 
the majority of sequences, 
nucleotides in lower case 
italics are conserved within 
a family (or families), and 
nucleotides between 
parentheses are absent in 
some families. n represents 
one of four nucleotides, 
and s represents C or G.n
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Figure 3.2: Alignment of stem-bulge-stem-loop sequences. Nucleotides conserved in 
the majority of sequences and those conserved in families are highlighted. Ctg is a contig 
based on the number of sequences indicated in parentheses. Percentages indicate the 
occurrence of a certain family within the clone library.
Stem1a Bulge Stem2a Loop Stem2b Stem1b  
  
Ctg_03(5) ------GAA---CGCGT---GTG---TT--GCT---CAC----TTC      
A03 ATTGTTCCA---CGCGT---GTG---TT--GCT---CAC----TGGCACAAT
A12 ------CCA---CGC----GTAA---TT--GGG---TTAC---TGG      
D07 --CTTTTCA---CGC----ATGA---TT--GGG---TCAT---TGAAAAG  
G11 ----GTCGA---CGC----GTTG---TT--GGG---CAAC---TCGAC    
                                                    
Ctg_02(12) -----GGTA--TCGCT---ACCT---GA-CGCA---AGGT---TACC     
Ctg_05(13) -----CGAA---CGC-----ATC--TGA-CGCAG--GAT----TTCG     
Ctg_06(4) ------CAA--TTGCC---AACC---GA-CGCA---GGTT---TTG      
Ctg_07(11) ---ATTCAA--TTGCC---ACGT---GA-CGCA---ACGT---TTGAAT   
Ctg_09(4) ---AAGGTG--CCGCT---ATTC---GA-CGCA---GAAT---CAGCTT   
Ctg_11(2) ------CAA---TGC----CCCT---GT-CGCA---AGGG---TTG      
A07 ----CATCA--TCGCC---ACCC---GA-CGCA---GGGT---TGATG    
F05 ----CGATT---CGC----GTAC---GT-CGCA---GTAC---AATCG    
                                                    
Ctg_10(2) ------CTA---CGC----GAGT---GC-CGCA---ACTC---TAG      
Ctg_12(10) ---AGATCA---CGC-----GAC---GC-TGCA---GTC----TGATCT   
A05 ATTGTAACA---CGC----GTGC---GG-CGCA---GCAC---TGTACAAT 
C04 ---GTACGG--TCGCC--CCCAT---GC-CGCA---ATGGG--CCGTAC   
D01 -TTACGATT---CGC----GTAC---GC-TGCA---GTAC---AATCGTAA 
E02 -----ACGA--CCGCT---ATAC---GC-CGCA---GTAT---TCGT     
F04 TATTACTAA---TGC----CCAC---GG-CGCA---GTGG---TTAGTAAG 
                                                    
Ctg_01(2) --ACATTAA---CGC-----CCG---TATTGCT---CGG----TTAATGT  
G04 -----AGAA---CGC-----CCG---TATTGCT---CGG----TTCT     
G05 ----GTGAA---CGC-----GGG---TGTTGCT---CCC----TTCAC    
G07 ------CCG---CGC-----TCG---TATTGCT---CGA----CGG      
                                                    
Ctg_04(5) ----AAAAG-GACGC-----ACC---GATCGCA---GGT-TA-CTTTT    
Ctg_08(2) ---TTTCCA---CGC-----ACC---GATCGCA---GGT----TGGAAA   
B05 -CAATTGAA---CGC-----tCC---GATTGCA---GGA----TTCAGTTG 
E04 ------TTA---CGC-----ACC---GATCGCA---GGT----TAA      
E07 -----TGTA---CGC-----ACC---GATCGCA---GGT----TACA     
G09 -----ACCA---CGC-----ATC---GATCGCA---GAT----TGGT     
H07 -----AGTT---CGC-----ACC---GATCGCA---GGT----AACT     
10%
53%
19%
6%
12%
StrepApt1
StrepApt2
StrepApt3
StrepApt4
StrepApt5
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such structure was predicted. After manual sequence inspection, however, regions 
that could form stem-bulge-stem-loop structures were found in these five sequences 
as well. Submission of these sequence fragments to mfold confirmed this prediction. 
As expected, the locations of the structure motifs are not fixed within the DNA 
sequences; on some occasions the primers, flanking the random regions, seem to be 
involved in the structures (Figure S3.1).
In order to gain insight into the conservation of nucleotide sequences and 
structures, the sequences predicted to form the stem-bulge-stem-loop structures 
were manually aligned according to their positions within the predicted structures 
(Figure 3.2). Despite the overall structural similarity some small variations could be 
observed: loop sizes vary between five and seven nucleotides, the bulges contain 
either three or five nucleotides, and stem 2 has three base pairs when the loops 
contain seven nucleotides and four base pairs in cases of smaller loop sizes. In 
particular, the nucleotides in the bulges (CGC) and loops (CGCA) are well conserved, 
whereas the actual compositions of the stems do not seem to be important as long 
as proper Watson-Crick base pairing is maintained.
From the alignment and the small differences between sequences it was possible 
to distinguish five aptamer families that occur at different frequencies in the library 
of selected clones. A shortened aptamer representing each family –StrepApt1 to 
StrepApt5– was designed for subsequent experiments while maintaining the specific 
features of each family (Figure 3.3).
Aptamer binding kinetics
Shortened aptamers –StrepApt1 to StrepApt5‒ as well as St-2-1 described by 
Bing et al. 14, were used for the determination of aptamer binding kinetics by SPR. A 
titration-kinetics approach was used: in one run increasing aptamer concentrations 
Figure 3.3: Shortened aptamers representing aptamer families. Nucleotides in bold are those conserved 
in the majority of sequences. Nucleotides in italics are not based on specific features in the alignment, but 
instead are added to assure stable conformations.
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Figure 3.4: SPR data of streptavidin-aptamer interactions. A) Titration kinetics of shortened aptamers, 
different shapes indicate a different kinetic behavior (see table 3.1 for details). B) mutated variants StrepApt5.1 
and 5.2 show reduced binding affinity, while StrepApt5.3 does not show any binding at all. C) Addition of 
biotin, indicated by an arrow, results in a more rapid aptamer dissociation. Subsequent aptamer injections do 
not result in binding, suggesting that the binding sites are blocked. Double referenced are shown in black; fits 
according to a simple 1:1 binding model are depicted in gray (A and B).
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were sequentially injected over a streptavidin-coated surface. Double referenced data 
were used for fitting according to a simple 1:1 binding interaction model designed for 
fitting titration kinetics data 126. Experimental data and corresponding fits are shown 
in Figure 3.4A, whereas rate constants (ka, kd) and dissociation constants (KD) derived 
from fitted data are presented in Table 3.1.
Although the differences in sequences and predicted structures are small, the 
binding kinetics of the five streptavidin aptamer types varied dramatically. In direct 
relation to the differences in their kinetics, the dissociation constants (KD) range from 
35 to 375 nM (Table 3.1). The dissociation constant found for St-2-1 (79±2 nM) agrees 
well with data reported earlier (40±18 nM) 14. It should be noted that association 
and dissociation rates for this aptamer were not reported in that study because of 
limitations of the analytical approach used. From the association rates (ka) of the 
five shortened aptamers designed in this study it was possible to distinguish two 
groups: those that form complexes rapidly (StrepApt2 and StrepApt3; Table 3.1) and 
those that form complexes slowly (StrepApt1, StrepApt4 and StrepApt5). From the 
dissociation rates (kd) it was possible to distinguish two other groups: those that 
dissociate rapidly (StrepApt1, StrepAtp2 and StrepApt3) and those that dissociate 
slowly (StrepApt4 and StrepApt5).
StrepApt4 and StrepApt5 (low values of ka and kd) represent only minor fractions of 
sequences in the clone library, which is dominated by StrepApt2, representing 53% of 
all sequences. Despite being the most abundant sequence, StrepApt2 does not have 
the highest affinity (77 nM). Rather, the highest-affinity aptamer (StrepApt5, 35 nM) 
represents only 12% of the sequences in the clone library. It is interesting to note 
here that the affinity and kinetic behavior of St-2-1 are similar to those of StrepApt2 
(Table 3.1).
Table 3.1: Relative occurrence of short the clone library. Together with kinetic 
parameters of aptamer-streptavidin binding as determined by SPR analysis. Highest 
association rates and slowest dissociation rates are highlighted in bold.
Occurrence in 
clone library (%) KD (nM) ka (×10
4 M-1 s-1) kd (×10
-3 s-1)
StrepApt1 10 375±50 1.37±0.05 5.1±0.7
StrepApt2 53 77±3 3.98±0.09 3.07±0.09
StrepApt3 19 105±4 4.8±0.8 5.0±0.8
StrepApt4 6 181±7 0.73±0.07 1.32±0.08
StrepApt5 12 35±1 1.04±0.03 0.36±0.01
St-2-1 - 79±2 3.2±0.3 2.5±0.2
Influence of mutations and biotin binding
Two conserved regions, sharing a common CGC motif, were found in the majority 
of the shortened aptamers (Figure 3.3). In order to determine the importance of 
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the conserved guanines for streptavidin binding, they were replaced by thymines 
in StrepApt5, our best binder. Replacement of one guanine resulted in a strongly 
reduced affinity in the micromolar range (~2 µM; Figure 3.4B). Although we performed 
only one injection series for these mutants the data were still fitted for the purpose 
of obtaining a rough estimate of the KD value. Replacement of both guanines by 
thymines completely abolished binding, indicating that these residues are essential 
for binding in all aptamer families.
SPR was furthermore used for competition experiments. Biotin is the natural 
ligand bound by streptavidin, with an exceptionally high affinity (KD ~10
-14 M) 148. 
In order to assess the impact of biotin on aptamer binding, the streptavidin-coated 
chip was first loaded with StrepApt5, the aptamer with the highest affinity, followed 
by normal dissociation (Figure 3.4C). After regeneration the chip was reloaded with 
aptamer, directly followed by injection of biotin (by use of the coinject command). 
The faster dissociation and increased baseline, even after regeneration, revealed that 
biotin out-competes StrepApt5. In addition, subsequent aptamer injections did not 
result in any binding.
Stoichiometries of the complexes
The binding stoichiometries of 
the various streptavidin-aptamer 
complexes were determined by 
native mass spectrometry. Native 
mass spectrometry is a powerful 
method for study of non-covalent 
complexes, the exact mass analysis 
often being sufficient to determine 
the stoichiometry of a complex 
unambiguously. Streptavidin was 
found to bind a maximum of two 
aptamer units simultaneously, 
regardless of the aptamer used 
(Figure 3.5). In addition to identifying 
binding stoichiometries, native mass 
spectrometry can also be applied 
to monitor the binding strengths of 
aptamers to streptavidin. The relative 
abundances of free streptavidin, of 
streptavidin bound to one aptamer 
and of streptavidin bound to two aptamers confirmed that aptamer 5 has the highest 
affinity for streptavidin (Figure 3.5B and Table S3.1).
Figure 3.5:  Native mass spectrometry data. A) 
Spectra of the lowest-affinity binder and of the 
highest-affinity binder. B) Relative abundances of free 
streptavidin, streptavidin bound to one aptamer and 
streptavidin bound to two aptamers. Diamonds show 
data corresponding to free streptavidin, squares data 
corresponding to streptavidin+1 aptamer, and triangles 
data corresponding to streptavidin+2 aptamers.
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Structural model of StrepApt2 and the complex
Modelling of the 3D structure of StrepApt2 was performed with use of the MC-Fold 
and MC-Sym pipeline to provide insight into the structural basis of aptamer binding 
to the streptavidin tetramer. In total, 57 3D 
structures were predicted for StrepApt2, 
from its sequence and the 2D structure 
predicted by mfold. In order to identify 
the best prediction, SAXS data for the 
aptamer were compared with theoretical 
scattering of the 57 predicted models. The 
structure (Figure 3.6) with the lowest Chi2 
value (5.32, Figure S3.3) was considered 
the best match with the experimental 
scattering. This structure indicates that the 
conserved nucleotides in the loop (CGCA) 
and bulge (CGC) are solvent-exposed and 
are therefore the most likely candidates to 
interact with streptavidin.
Discussion
DNA aptamers that bind to streptavidin, with affinities in the low to middle nanomolar 
range (35–375 nM), were enriched in seven sequential rounds of selection. Sequence 
analysis of 91 clones revealed 31 unique sequences at different relative abundances. 
Structural predictions, based on mfold, and sequence analysis show that all 
sequences contain stem-bulge-stem-loop structures. Interestingly, similar structures 
for streptavidin-binding aptamers had been reported earlier, although the aptamer 
sequences vary slightly, and nucleotides in the bulge (CGC) and loop (CGCA) regions 
seem to be conserved throughout various independent selection experiments 14. 
Variation in loop composition and size (five to seven nucleotides), bulge size (either 
three or five nucleotides) and stem 2 length (three or four base pairs) further allowed 
five aptamer families to be distinguished. The compositions of the stems do not 
seem to be important as long as proper Watson-Crick base pairing is maintained. The 
length of stem 1, however, is important for stability of the aptamer, as has been shown 
previously by Bing and co-authors 14. Shortened aptamers –StrepApt1 to StrepApt5– 
for each of the five types, based on the alignment, were designed, with the specific 
features of each family maintained. Single mutations of the conserved guanines in 
the loops and bulges resulted in reduced binding of the aptamers, whereas in the 
double mutant binding was abolished, indicating that these conserved guanines play 
an essential role in streptavidin binding.
We further determined the kinetic properties of the shortened aptamers StrepApt1 
 
Figure 3.6: Predicted 3D model of StrepApt2. 
Prediction 28 of the MC-Fold and MC-Sym pipeline 
that best matches experimental scatter. Stems 
are in gray, bulge and loop in light gray. The two 
guanines that are essential for binding are depicted 
in black (and are indicated by arrows).
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to StrepApt5 by use of SPR titration kinetics. The obtained results showed widely 
different dissociation constants (35–375 nM), but no obvious relation between 
affinity and abundance in the clone library was observed. The number of clones is 
limited and might not represent the complete range of aptamers present after seven 
selection rounds, but results of independent studies showed enrichment of similar 
aptamers. Kinetic parameters of representative aptamers indicate that the rapid 
binders (StrepAtp2 and StrepApt3, loop size 6 nt) dominate the clone library, together 
representing 72% of all sequences. In contrast, the slowly dissociating aptamers 
(StrepApt4 and StrepApt5, loop size 7 nt) are a minority, together representing 18% 
of the clone library. The kinetic parameters determined in this study show that slow 
dissociation seems to be related to a loop size of seven nucleotides, whereas rapid 
association seems to be associated with a loop size of six nucleotides. It is interesting 
to note here that the aptamer with the highest affinity was not the most abundant in 
our clone library. Because of its structural similarity we also included St-2-1, selected 
by Bing and co-authors 14, in our SPR analysis. The kinetic parameters of St-2-1, as 
well as its predicted folding motif, were most similar to those of StrepApt2. Two 
independent selection experiments hence resulted in similar binders, with rapid 
association rates; it is therefore tempting to speculate that the selection procedure is 
somewhat biased towards selection of rapid binders, rather than high-affinity binders. 
This is also observed in the extensive work by Win et al. 306 on codeine-binding RNA 
aptamers. These authors found several sequences to be present more than once in 
their clone library, whereas the five best binders, those with the lowest KD values, 
occurred only once.
Consistently with the study of Bing et al., we also observed competition between 
aptamer (StrepApt5) and biotin. Nevertheless, our data clearly showed aptamer 
binding to be completely suppressed when streptavidin is saturated with biotin, 
whereas Bing et al. still observed some binding in the presence of biotin 14. Both 
studies, however, unequivocally suggest that the aptamer binds in, or close to, the 
biotin-binding pocket.
To gain insight in the stoichiometry of the streptavidin-aptamer complex we 
performed native mass spectrometry, which indicated that streptavidin can bind a 
maximum of two aptamer moieties simultaneously, regardless of the aptamer used 
and its affinity. This leaves the question, however, of whether one aptamer binds two 
biotin pockets at once, or if access to a single biotin pocket is blocked by a bound 
aptamer. In order to gain insight in the location of binding, and to provide an answer 
to the question of whether or not one aptamer binds two biotin pockets, structural 
predictions (57) of StrepApt2 were generated by use of the MC-Fold and MC-Sym 
pipeline. The conserved nucleotides in the loop and bulge are solvent exposed and 
are therefore the most likely candidates to interact with the loops that cover the two 
biotin pockets once biotin is bound (Figure S3.4). On the basis of this model it can be 
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hypothesized that one aptamer occupies two biotin pockets. This is supported by the 
presence of two conserved regions and by the fact that two simultaneous mutations, 
one in each of these conserved regions, are required to yield a non-binding aptamer. 
Our approach of obtaining a 3D model for an aptamer, supported by SAXS data, 
might also be helpful as a new strategy to afford insight into the binding sites of 
other aptamers.
Conclusions
All streptavidin-binding aptamers selected in this work have similar structures 
and conserved nucleotides, but still vary slightly at sequence level. Although the 
differences in sequence are small, the differences in binding kinetics are substantial. 
One streptavidin tetramer can accommodate up to two aptamers, and we propose 
that one aptamer occupies two biotin-binding pockets. It is interesting to note that 
the aptamer with the highest affinity is not the most abundant. Instead, selection 
appears to be driven by the binding kinetics. This could be the result of the presence 
of a limited number of binding sites that are quickly saturated by rapid binders 
when selection progresses through subsequent rounds. This finding indicates that 
it might be better either to increase the number of target binding sites (by using 
more beads, or less DNA) or to limit the number of selection rounds. Moreover, these 
findings indicate that one should focus on post-selection characterization of potential 
aptamers, by using complementary approaches introduced here, for example, in 
order to find the aptamer with the highest affinity.
Materials and methods
Oligonucleotides
Unmodified primers AP10 (ataccagcttattcaatt) 268 and AP30 (ctaactgattacgattgt) 
(R. Stoltenburg, personal communication), the random pool (ataccagcttattcaatt-n64-
acaatcgtaatcagttag, PAGE purified), primer AP60, equivalent to AP10 but containing 
5’-fluorescein, and shortened aptamers (for sequences see Table 3.2) were obtained 
from Biolegio (Nijmegen, the Netherlands). Primer TER-AP30, equal to AP30 but 
containing 5’-poly-dA20-hexa(ethylene glycol), was ordered from IBA (Göttingen, 
Germany).
SELEX procedure (FluMag-SELEX)
The selection procedure was as described previously 268. Briefly, before each selection 
round ssDNA was heated to 95°C for 8 min, cooled on ice for 10 min and left at room 
temperature for at least 10 min. In the first round, 26 pmol of the random pool was 
added to streptavidin-coated beads (Dynabeads M-280, Invitrogen), and in subsequent 
rounds 250 µl of the ssDNA preparation (see below) was added. Approximately 1×108 
beads were washed with selection buffer [NaCl (100 mM), MgCl2 (2 mM), KCl (5 mM), 
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CaCl2 (1 mM), Tris-HCl (pH 7.6, 
20 mM)], and after addition of 
the ssDNA to the beads they 
were incubated at 25°C with mild 
shaking for 30 min. Unbound 
oligonucleotides were removed 
by washing three times with 
selection buffer. Subsequently, 
bound oligonucleotides were 
eluted by addition of selection 
buffer and incubation at 95°C for 
5 min with mild shaking.
Eluted oligonucleotides were 
PCR-amplified in 15 parallel 
PCR reactions, each mixture 
containing MgCl2 (1.9 mM), 
dNTPs (0.2 mM each), primer (AP60 and TER-AP30, 1 µM of each), 1×buffer B2, and 
HOT FIREPol (Solis BioDyne, 4 units) in a total volume of 100 µl. The PCR program 
was as follows: 15 min at 95°C, 30 cycles of 30 s at 95°C, 30 s at 52°C, 1 min at 72°C, 
followed by 7 min at 72°C after the last cycle. Electrophoresis on a 12% polyacrylamide 
(PAA) gel was used to confirm successful amplification of a DNA fragment of the 
correct size.
From the second selection round onwards, fluorescence in the starting sample, 
the non-bound DNA fraction, the wash fractions and the eluted DNA was measured 
in 96-well microtiter plates (Greiner bio-one) with a SpectraMax M2 instrument 
(Molecular Devices).
ssDNA preparation 
Unpurified PCR products were pooled and concentrated by ethanol precipitation and 
resuspended in TE buffer [Tris (10 mM), EDTA (1 mM), pH 7.4, 100 µl]. Strands were 
separated by electrophoresis of the concentrated sample on a denaturing PAA gel, 
containing PAA (8%) and urea (7 M) in TBE buffer [Tris (10 mM), borate (90 mM), EDTA 
(2 mM)]. Fluorescein-labelled DNA was visualized with a Safe imager (Invitrogen) 
and excised from the gel. The DNA was eluted from the gel slice by mashing and 
subsequent incubation in 600 µl EDTA (2 mM) and sodium acetate (pH 7.8, 300 mM) at 
80°C with mild shaking for 2 h. After ethanol precipitation the DNA was resuspended 
in selection buffer (300 µl).
Cloning, sequencing and structure analysis 
The DNA eluted in SELEX round 7 was amplified, under the conditions described 
Table 3.2: Sequences of shortened and mutated aptamers 
used in this study. Uppercase letters indicate nucleotides that 
are conserved in the majority of sequences within a given family. 
G→T mutations in StrepApt5.1, StrepApt5.2 and StrepApt5.3 are 
given in bold letters and underlined. All sequences are shown in 
the 5’-to-3’ direction. The sequence of St-2-1 was taken from 14. 
Sequence
StrepApt1 gggaACGCgttaTTGGGtaacTtccc 
StrepApt2 gggaatCGCcaccCGACGCAgggtTtccc 
StrepApt3 gggaACGCataCGCCGCAGtatTtccc 
StrepApt4 gggaACGCccgTATTGCTcggTtccc 
StrepApt5 gggaACGCaccGATCGCAggtTtccc 
StrepApt5.1 gggaACtCaccGATCGCAggtTtccc 
StrepApt5.2 gggaACGCaccGATCtCAggtTtccc 
StrepApt5.3 gggaACtCaccGATCtCAggtTtccc
St-2-1 attgaccgctgtgtgacgcaacactcaat
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above, by using unmodified primers AP10 and AP30 and ligated into pGEM-T 
(Promega). Escherichia coli XL1-Blue cells (Stratagene) were transformed with the 
vector constructs, 96 colonies were subsequently randomly picked, and inserts 
were sequenced (GATC, Konstanz, Germany). The DNA folding form of mfold 324 was 
used for secondary structure prediction with use of the default settings except for 
temperature (25°C) and ionic conditions [Na+ (100 mM), Mg2+ (2 mM)].
Native mass spectrometry 
High-resolution mass spectra of streptavidin complexes with StrepApt1 to StrepApt5 
and St-2-1 were recorded with an LCT instrument (Waters, Manchester, UK) in positive 
ion mode. Samples were loaded into gold-plated borosilicate capillaries made in-
house [with a Sutter P-97 puller (Sutter Instruments Co., Novato, CA, USA) and an 
Edwards Scancoat six sputter-coater (Edwards Laboratories, Milpitas, CA, USA)] for 
analysis with an LCT 1 mass spectrometer (Waters Corp., Milford, MA, USA), adjusted 
for optimal performance in high-mass detection 278. A capillary voltage of 1300 V was 
used, with a sampling cone voltage of 90 V. The source backing pressure was elevated 
in order to promote collisional cooling to approximately 6 mbar. All samples were 
sprayed from ammonium acetate (pH 7.6, 125 mM). Calibration of the instrument 
was carried out with a cesium iodide solution (25 mg ml-1). Processing of the acquired 
spectra was performed with MassLynx 4.1 software (Waters Corp., Milford, MA, USA). 
Minimal smoothing was used, after which the spectra were centered. The mass of the 
species was calculated with use of each charge state in a series. The corresponding 
intensities of each charge state were assigned by MassLynx and summed. This 
approach allows the relative quantification of all species in a sample.
Surface plasmon resonance 
In a Biacore 3000 system (BIACORE, Uppsala, Sweden), streptavidin (recombinant 
produced in E. coli, SIGMA), dissolved in sodium acetate (pH 4.0, 10 mM, GE 
Healthcare), was immobilized on a CM5 chip at 25°C (to approximately 2000 RU). 
The “aim-for-immobilized-level” wizard was used, together with reagents provided 
in the amine coupling kit (GE Healthcare). A reference channel was prepared by 
activating and subsequent blocking of the surface by the same procedure. The 
shortened aptamers StrepApt1 to StrepApt5.3 and St-2-1 were dissolved in selection 
buffer at concentrations of 100 µM and subsequently diluted in selection buffer to 
concentrations of 2.50, 0.83, 0.28, 0.09 and 0.03 µM. Titration kinetics were performed 
by sequential injections of each concentration (60 µl, starting with the lowest 
concentration) at 30 µl min-1, followed by 60 s dissociation. The fifth injection was 
followed by 20 min dissociation and subsequent regeneration with glycine (pH 3.0, 
10 mM, 10 µl) at 10 µl min-1. Titration kinetics reduce assay times as well as the 
number of chip regenerations required. Prior to aptamer injections a series of blank 
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injections, with only selection buffer, was run to allow for double referencing of the 
data. Selection buffer was used as running buffer. Each aptamer was injected three 
times and double referenced data were used for fitting according to a 1:1 binding 
model as described by Karlsson et al. 126. The concentration series of StrepApt5.1 to 
StrepApt5.3, which are mutated variants of StrepApt5, were injected only once.
Small-angle X-ray scattering and 3D modelling 
StrepApt2 was dissolved in selection buffer to concentrations of 4.2, 2.9 and 1.5 µg µl-1. 
SAXS data were collected at the SIBYLS beamline at 10°C, by procedures described 
previously 111. Briefly, the three sample concentrations and a buffer blank were 
measured in order (buffer, low, middle, and high concentration, and again buffer) at 
exposures of 0.5, 1.0 and 6.0 s. Scattering curves were merged with use of PRIMUS 142 
in the ATSAS program suite 141. The MC-Fold and MC-Sym pipeline was used to 
obtain predictions of the 3D structure of StrepApt2 215. Theoretical scattering of these 
predictions was calculated and compared with experimentally observed scattering of 
StrepApt2 with use of the FoXS web-server 252.
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Supplementary information
Table S3.1: Numbers used to create figure 3.5B. Affinity constants (KD) 
and relative abundances of free streptavidin, streptavidin+1 aptamer and 
streptavidin+2 aptamers, as measured by native mass spectrometry. At lower 
affinities more free streptavidin is present, whereas more Streptavidin+2 aptamers 
is present at high affinities.
KD (nM)
Free 
Streptavidin
Streptavidin 
+1 aptamer
Streptavidin 
+2 aptamers
StrepApt1 375 33 42 25
StrepApt2 77 2 11 87
StrepApt3 105 16 28 56
StrepApt4 181 11 39 50
StrepApt5 35 1 13 86
St-2-1 79 2 17 81
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Figure S3.1:  Sequences of all 31 unique aptamers. Primer sequences are included. Occurrence of contig 
sequences in the clone library is indicated in parentheses. Location of conserved secondary structure is 
highlighted bold and underlined. Aptamers given in italics were initially not predicted when providing the full 
length sequence.
                    Primer       |---------------------- Random region --------------------------|    Primer 
                          
Contig_01_(2)  ATACCAGCTTATTCAATT CCGCGCGAACACATTAACGCCCGTATTGCTCGGTTAATGTAGGGGTCTGCCTGAACTCCCCGGT ACAATCGTAATCAGTTAG 
Contig_03_(5) ATACCAGCTTATTCAATT GCCACACATCAATTTGTTGTGAGGTTGGTACCGTTATTGTTGAACGCGTGTGTTGCTCACTTCC ACAATCGTAATCAGTTAG 
Contig_04_(5) ATACCAGCTTATTCAATT CCAACCCCTCCAAAAGGACGCACCGATCGCAGGTTACTTTTTGAGGCTGTCCGAACCTCGTGCT ACAATCGTAATCAGTTAG 
Contig_05_(13) ATACCAGCTTATTCAATT CACGGACAGTAGTGTTGGGGTCGAACGCATCTGACGCAGGATTTCGTACCACCGTCCGCACTGT ACAATCGTAATCAGTTAG 
Contig_07_(11) ATACCAGCTTATTCAATT GCCACGTGACGCAACGTTTGAATAGGTATGTCGGCTGTCAGAATTTCATGCGAATATTGGTTGT ACAATCGTAATCAGTTAG 
Contig_08_(2) ATACCAGCTTATTCAATT CAGCAGCATTAGAGTTTTCCACGCACCGATCGCAGGTTGGAAATCTTCTGCGTTAGTTTTCCCC ACAATCGTAATCAGTTAG 
Contig_09_(4) ATACCAGCTTATTCAATT ACAAAAGGTGCCGCTATTCGACGCAGAATCAGCTTCTTGTTAATAATTTGACCTTATGCCCCGT ACAATCGTAATCAGTTAG 
Contig_10_(2) ATACCAGCTTATTCAATT GCATGCCCCGATATATCTACGCGAGTGCCGCAACTCTAGTATATCGATGACTGCACTACGTGGT ACAATCGTAATCAGTTAG 
Contig_11_(2) ATACCAGCTTATTCAATT ACGGACCATGTATTTGTGATGAGGATGTCTCTGTTATTGTCAATGCCCCTGTCGCAAGGGTTGT ACAATCGTAATCAGTTAG 
Contig_12_(10) ATACCAGCTTATTCAATT CCCCGACACTAGATCACGCGACGCTGCAGTCTGATCTTGTTCGCGTAATGGACCGGCCGTTGT  ACAATCGTAATCAGTTAG 
A03-T7[1] ATACCAGCTTATTCAATT CGTCAGGGTAATAGCTTGTACGCTGCAGTACTGTATTGTTCCACGCGTGTGTTGCTCACTGGC  ACAATCGTAATCAGTTAG 
A05-T7[2] ATACCAGCTTATTCAATT CCAGGCCGCTTCCTTTTGCTTGCACTGTGAACGGTATTGTAACACGCGTGCGGCGCAGCACTGT ACAATCGTAATCAGTTAG 
A07-T7[3] ATACCAGCTTATTCAATT ACATGCGGCTCATCATCGCCACCCGACGCAGGGTTGATGAACGCAGATCTGCGAACGTTCCCGT ACAATCGTAATCAGTTAG 
A12-T7[4] ATACCAGCTTATTCAATT CCGGCAGGTTCGGGAAGTCCACGCGTAATTGGGTTACTGGTCTTGCCTTTTGCCGGGACACTCT ACAATCGTAATCAGTTAG 
B05-T7[5] ATACCAGCTTATTCAATT GAACGCtCCgATTGCAGGATTCAGTTGATACGGTTATGATTTAAAAATTTAGCCGACCCTCTGC ACAATCGTAATCAGTTAG 
C04-T7[6] ATACCAGCTTATTCAATT GCCCATCaaTGGTATATGATGCGCTTCCCCGGGGTACGGTCGCCCCCATGCCGCAATGGGCCGT ACAATCGTAATCAGTTAG 
D01-T7[7] ATACCAGCTTATTCAATT GCACGACATACGATTTGAATTACGATCATTGGCTTATTGTTTTACGATTCGCGTACGCTGCAGT ACAATCGTAATCAGTTAG 
D07-T7[8] ATACCAGCTTATTCAATT CACCGCGGGTTATGCTTTTCACGCATGATTGGGTCATTGAAAAGGGTGAGGGGTGCTCAACGGT ACAATCGTAATCAGTTAG 
E02-T7[9] ATACCAGCTTATTCAATT CCAAAGTCTTCACGAAAGGACGACCGCTATACGCCGCAGTATTCGTTTTCCTGTGATATCCTGT ACAATCGTAATCAGTTAG 
E04-T7[10] ATACCAGCTTATTCAATT ACGCACCGATCGCAGGTTAAGTGAATAGTTCCGTTGTCACTCATGCTTCATGTTGctCCCCCGT ACAATCGTAATCAGTTAG 
F04-T7[12] ATACCAGCTTATTCAATT CCGCGATGATTATTACTAATGCCCACGGCGCAGTGGTTAGTAAGCGTATGCAATcGACGGCGGT ACAATCGTAATCAGTTAG 
G04-T7[14] ATACCAGCTTATTCAATT CGGCAACACTACTGTTGAATTGACTTCCCTCGATTATTAGAACGCCCGTATTGCTCGGTTCTGG ACAATCGTAATCAGTTAG 
G05-T7[15] ATACCAGCTTATTCAATT CCCAAACCAATGTTTTTGGCAGCCCTGTGAACGCGGGTGTTGCTCCCTTCACGTTATGCCATGT ACAATCGTAATCAGTTAG 
G07-T7[16] ATACCAGCTTATTCAATT CCCGGTCCTGAGTTGTCCATAACTTGACATCGGTTATTGTTCCGCGCTCGTATTGCTCGACGGT ACAATCGTAATCAGTTAG 
G09-T7[17] ATACCAGCTTATTCAATT ACCACATGTAAACGGTTACCACGCATCGATCGCAGATTGGTTGCCGTTTGCCCTACTGCCCCGT ACAATCGTAATCAGTTAG 
G11-T7[18] ATACCAGCTTATTCAATT CCAGCCCGGCATATTTTACTTGGCTCAGTCGACGCGTTGTTGGGCAACTCGACCTCCGTACGCT ACAATCGTAATCAGTTAG 
 
 
Contig_02_(12) ATACCAGCTTATTCAATT CGACGACATGCGGTATCGCTACCTGACGCAAGGTTACCCTAGGCGATTAATATTTCCACGTTGT ACAATCGTAATCAGTTAG 
Contig_06_(4) ATACCAGCTTATTCAATT GCCAACCGACGCAGGTTTTGGGAAGCCCCACCATCATTTTAACTCCCGTATGTTAATCCACGCT ACAATCGTAATCAGTTAG 
F05-T7[13] ATACCAGCTTATTCAATT GCACACCAGCCACTTTTCCTGCGCATGTTTGACTTATCGGATCCGATTCGCGTACGTCGCAGT  ACAATCGTAATCAGTTAG 
H07-T7[19] ATACCAGCTTATTCAATT ACGACCCGGCCAGAGTTAGTTCGCACCGATCGCAGGTAACTTACGATTCGTGTtgaGtcGCGGT ACAATCGTAATCAGTTAG 
E07-T7[11] ATACCAGCTTATTCAATT ACGGACCatTGGGTTAGTGTACGCACCGATCGCAGGTTATCAGGACCCATGGGCGGTTTTCTAT ACAATCGTAATCAGTTAG 
Figure S3.2: A selection of mfold predictions. Conserved binding domains are boxed.
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Figure S3.3: Comparison of theoretical scattering 
and actual scatter. Theoretical scatter of prediction 28, 
compared with actual scattering as determined by SAXS 
analysis. This prediction is considered the best match with 
experimental scattering.
Figure S3.4: Impression of how the aptamer could bind to streptavidin. Conserved guanines 
(black arrow) probably interact with the loops that move over the biotin binding pocket (black, *). The 
aptamer model was ‘fitted’ manually and only serves to illustrate that the aptamer could physically fit in 
the space between the two loops. (PDB code: 1N9Y).
*
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*
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Abstract
Aptamers are oligonucleotide ligands, either RNA or ssDNA, selected for high-affinity 
binding to molecular targets, such as small organic molecules, proteins or whole 
microorganisms. While reports of new aptamers are numerous, characterization of 
their specific interaction is often restricted to the affinity of binding (KD). Over the 
years, crystal structures of aptamer-protein complexes have only scarcely become 
available. Here we describe some relevant technical issues about the process of 
crystallizing aptamer-protein complexes and highlight some biochemical details on 
the molecular basis of selected aptamer-protein interactions. In addition, alternative 
experimental and computational approaches are discussed to study aptamer-protein 
interactions.
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Introduction
Aptamers are single-stranded DNA (ssDNA) or RNA oligonucleotides selected to 
bind specifically to a predefined target. Since their initial development two decades 
ago 58, 285 the field of aptamer research has matured. During these years, numerous 
aptamers, recognizing a wide range of targets, have become available, such as, for 
example, those binding small organic molecules 176, 212, 308, peptides and proteins 257, 268, 
or even whole microorganisms 27, 153.
The systematic evolution of ligands by exponential enrichment (SELEX) is the most 
common method by which aptamers are enriched from large pools of randomized 
DNA or RNA (1014–1015 variants), in an iterative process by applying several subsequent 
selection rounds. Selection is initiated by exposing the oligonucleotides to a target 
that is either coupled to a matrix (e.g., magnetic beads or column material) or already 
present on a surface (e.g., cell surface). Subsequently, non-binding oligonucleotide 
molecules are washed away, and the bound molecules are recovered, amplified by 
PCR or RT-PCR, and made single-stranded again. Several variations of the SELEX 
procedure have been successfully applied over the years 167.
In many cases, the minimal sequence required for efficient target binding is smaller 
than the length of the oligonucleotides that comprise the pool. In order to increase 
specificity and to reduce synthesis costs of the selected aptamers, the minimal binding 
sequence should be identified. Approaches to identify the minimal binding sequence 
can be straightforward when a conserved nucleotide motif or secondary structure 
is enriched 14, 247; otherwise, identifying the minimal binding sequence can be more 
laborious 128, 160, 304.
Aptamer-target interactions depend on the nature of the target and on the 
nucleotide sequence and 3D structure of the aptamer. Aptamers occur in a wide variety 
of structural shapes, such as hairpins, bulges, pseudoknots and G-quadruplexes 167. 
Due to these various structural shapes, aptamers can bind their targets by hydrogen 
bonds, hydrophobic interactions, van der Waals interactions, aromatic stacking or, in 
most cases, a combination thereof 89.
Crystal structures of aptamer-target complexes provide very detailed information 
on the interactions; they are therefore crucial for a thorough understanding of the 
aptamer-target binding mode. However, obtaining crystal structures of aptamer-
target complexes has proven difficult, and only a few co-crystal structures have 
become available over the years (Table 4.1). Besides X-ray crystallography, also other 
techniques, such as nuclear magnetic resonance (NMR), surface plasmon resonance 
(SPR), analysis using a quartz crystal microbalance (QCM) 91, isothermal titration 
calorimetry (ITC), Dynamic light scattering (DLS), circular dichroism (CD) 220 and small-
angle X-ray scattering (SAXS) 226, 247, have been used to study aptamer-target binding. 
Knowledge on the target-binding mode of newly described aptamers, however, is 
generally restricted to the affinity of binding. 
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In this chapter, relevant technical issues and difficulties in the process of crystallizing 
aptamer-protein complexes are described. In addition, we will highlight some 
successful examples. Besides X-ray crystallography, several alternative approaches to 
investigate the molecular basis of aptamer-target interactions will be briefly discussed 
as well.
Table 4.1: Structures of aptamer-target complexes in the PDB database.
Target DNA/RNA PDB entry code Ref.
Aptamer-protein complexes
von Willebrand Factor Domain A1 DNA 3HXO 3HXQ 108
Alpha-thrombin (human) DNA 1HUT 210
Alpha-thrombin (human) DNA 1HAO 1HAP 211
Alpha-thrombin (human) RNA 3DD2 158
Alpha-thrombin (human) DNA 3QLP 144
NF-κB(p50)2 RNA 1OOA 107
NF-κB P50-RelB DNA 2V2T 182
YmaH (Hfq) RNA 3HSB 3AHU 263
a human IgG RNA 3AGV 200
Enterobacterio phage MS2 coat 
protein complex RNA 6MSF
40
Enterobacterio phage MS2 RNA 5MSF 7MSF 243
Enterobacterio phage MS2 RNA 1U1Y 103
Aptamer-small molecule complexes
Malachite green RNA 1F1T 7
Vitamin B12 RNA 1ET4 1DDY 276
Streptomycin RNA 1NTB 1NTA 283
Biotin RNA 1F27 199
Structure determination
Currently, the three-dimensional structures of many proteins, nucleic acids 
(e.g., riboswitches) and other biological molecules have been determined. The only 
methods that can provide atomic resolution structures are NMR spectroscopy, 
electron microscopy (electron crystallography) of two-dimensional (2D) crystals, and 
X-ray crystallography. Each of these methods has its advantages and limitations. In 
particular, NMR methods for determining high-resolution structures are largely limited 
to relatively small molecules (<30–40 kDa), due to complexity of the data 262, 315. By 
comparison, X-ray crystallography can solve structures of arbitrarily large molecules, 
but it requires crystals that provide suitable quality diffraction data. Screening for 
conditions that yield well diffracting crystals is still a trial and error method and 
often requires a significant amount of effort 34. The chance of obtaining well-ordered 
2D crystals for electron crystallography is higher, when compared to obtaining 3D 
crystals required for X-ray crystallography; however, structure determination and 
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data processing from 2D crystals is still labor intensive and time consuming 227.
While providing very detailed information, crystal structures of aptamer-protein 
complexes have only scarcely become available. Here, we would like to describe some 
relevant technical issues in the process of crystallizing aptamer-protein complexes 
and highlight those parameters that make crystallization especially challenging.
Nucleic acid parameters
Several features of DNA or RNA play important roles in the process of co-crystallization. 
Apart from purity, the length and the ends (blunt or sticky) are also factors that must 
be explored when crystallizing nucleic acid-protein complexes.
Perhaps one of the most significant variables is the length of the nucleic acid. A 
general rule in protein-nucleic acid crystallization is to identify a sequence of minimal 
length that binds tightly to the protein 93, 96. On the one hand, oligonucleotides that 
are too short will destabilize the complex, as it might limit the number of potential 
interactions between nucleic acid and protein, but on the other hand it may improve 
crystal quality, as it will reduce flanking regions that could disturb crystal contacts. 
Consequently, determining the minimal binding sequence of an aptamer should be 
considered essential. Although this is not always straightforward and can be time 
consuming, removing nucleotides that are unnecessary for target binding will prevent 
them from potentially disturbing crystal contacts.
In addition to blunt-ended nucleic acids, single- or double-base overhangs (sticky 
ends) are commonly explored when crystallizing complexes containing DNA or RNA 93. 
It is often observed in crystals that sticky ends form crystal contacts by base-paring with 
complementary sticky ends, forming 
a pseudo-continuous double helix. In 
order to allow the best end-to-end 
packing, the overhanging bases of one 
strand should be complementary to 
the overhanging bases of the opposite 
strand 96. Nevertheless, this may not be 
easily applicable to aptamers, because 
sticky ends could disrupt the tertiary 
structure, and hence abolish binding, 
of the aptamer. It has been observed, 
however, that the 5′ extensions from 
two molecules of the vitamin B12 RNA 
aptamer form a crystal contact by 
creating a six-base-pair duplex with 
two stacked adenosine-adenosine 
pairs 276 (Figure 4.1).
Figure 4.1: Crystal contacts between two vitamin 
B12 aptamers. The six-base-pair duplex between two 
vitamin B12 aptamers consists of two stacked adenosine-
adenosine pairs (PDB code: 1ET4) 107. Aptamers shown 
in dark and light gray, vitamin B12 in black.
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It may also be critical to have highly purified DNA or RNA to obtain well-ordered 
crystals of a protein-nucleic acid complex 96. The most common methods for purifying 
synthesized oligonucleotides for use in crystallization experiments are anion exchange 
chromatography and purification from polyacrylamide gels (PAGE). Because results 
of purification can vary slightly, it is sometimes desirable to further treat the purified 
oligonucleotide, for instance by dialyzing against an appropriate buffer.
RNA synthesis is relatively expensive; if no modified nucleotides are required, 
it could be cheaper and perhaps more convenient to transcribe the RNA from a 
DNA template. When more stable RNAs are required, one could order chemically 
synthesized RNA aptamers, in which all or specific uridines and cytidines are 2′-fluoro-
modified. In some cases, these modified nucleotides have been used during both 
aptamer selection and crystallization 158, 273.
Protein parameters
A general requirement for crystallization experiments is that the protein needs to be 
homogeneous, i.e., highly pure (>98%) and in a low polydispersity state 64. DLS is a 
commonly used technique to measure the polydispersity of a protein sample. Other 
parameters that should be established before setting up crystallization screens are 
the stability of the protein in different buffers, and whether the protein is correctly 
folded (CD spectroscopy) and active (activity measurements).
Protein: aptamer ratio
It is good practice to try several protein:aptamer molar ratios. In crystallization 
experiments, protein and DNA are usually mixed at 1:1.2 to 1:1.5 molar ratios with 
DNA in excess 64, 96. The principle behind this ratio is that the concentrations of protein 
and DNA are frequently rough estimations and DNA could possibly not saturate all 
binding sites on the protein. Our advice is, therefore, to use similar ratios when setting 
up crystallization experiments of protein-aptamer complexes.
Crystallization screens
Screens for obtaining crystals should include a wide variety of crystallization conditions. 
Nowadays, many commercial screens are available from companies such as Hampton 
Research, Emerald BioSystems, Molecular Dimensions, Jena Bioscience and Qiagen; 
these also include screens specific for crystallizing nucleic acids and nucleic acid 
complexes. The commercial screens are undoubtedly the easiest way to initiate the 
first crystallization trials. For more elaborate information on protein crystallization, 
see 34, 64, 173. For more elaborate information on RNA and sample preparation for 
crystallization of RNA and RNA-protein complexes in particular, see 53, 68, 129.
In general, for nucleic acid crystallization, it is favorable to use polyethylene 
glycol (PEG) or 2-methyl-2,4-pentanediol (MPD) as precipitants, rather than high salt, 
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because high salt may disrupt charged interactions between protein and nucleic acid. 
It is not possible to predict which screen will result in crystal formation, because many 
factors influence crystallization; variables include pH, ionic strength, temperature, 
protein concentration, the presence of various salts, ligands or additives, the type 
of precipitant and the crystallization method (hanging drop, sitting drop, dialysis, 
etc.) 34, 173. 
Examples from literature
Over the years, only a limited number of crystal structures of aptamer-protein 
complexes have become available (Table 4.1), but they have provided a wealth of 
information. Here two aptamer-protein complexes are described that have been 
successfully crystallized.
Thrombin-aptamer complex
Thrombin is a trypsin-like serine protease with an important role in hemostasis, by 
converting soluble fibrinogen into insoluble fibrin strands. Shortly after the initial 
development of SELEX, thrombin-binding DNA aptamers were described 18, providing 
the first example of DNA binding to a protein normally not involved in DNA binding. 
The year after thrombin binding aptamers had first been described, a crystal structure 
of the thrombin-aptamer complex became available. It was obtained using a reservoir 
solution of 25–30% (v/v) PEG 8000, 375 mM NaCl, 0.5 mM NaN3 and 50 mM sodium 
phosphate at pH 7.3, which was also used for the crystallization of a thrombin-hirugen 
complex 210, 261. The crystal used for data collection grew in 2 months and diffracted 
to about 2.9 Å, it belongs to orthorhombic space group P212121. In the same year, an 
NMR solution structure 162, 297 became available for the thrombin-aptamer complex as 
Figure 4.2: Thrombin binding aptamer. A) Double G-quadruplex shown in gray, loops in 
black; B) Thrombin aptamer bound to exosite 1 (dark gray) of thrombin (PDB code: 1HUT) 7.
A                                                             B
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well. The crystal structure and NMR solution structure revealed that the core of the 
thrombin-binding aptamers is formed by two stacked G-quadruplexes (Figure 4.2A), 
although the crystal and NMR solution structure show different topologies of the 
G-quadruplex 134. It was also shown that the aptamer binds to exosite I of thrombin 
(Figure 4.2B). Recently, another crystal structure of a thrombin-aptamer complex has 
been published (crystallized at 20°C using 20% (w/v) PEG 20,000, 200 mM ammonium 
sulphate, 3% (v/v) n-propanol, 100 M sodium acetate at pH 5.8). It contains a modified 
thrombin binding aptamer that binds thrombin with higher affinity 144. 
Anti-IgG Fc RNA aptamer
Recently, the 2.15 Å resolution crystal structure of the anti-Fc RNA aptamer in complex 
with the Fc fragment of a human IgG1 antibody (hFc1) was elucidated 200. In most cases, 
RNA aptamers bind to their target proteins predominantly via electrostatic interactions 
between the negatively-charged phosphate backbones and positively-charged surface 
residues of proteins. To this end, the interaction between this aptamer and hFc1 is 
an exception, as it mainly consists of van der Waals contacts and hydrogen bonds, 
rather than electrostatic forces. The structure also revealed other interesting features. 
The RNA structure in the complex diverges greatly from its predicted secondary 
structure; it changes its conformation to one that structurally fits to hFc1 (Figure 4.3). 
The aptamer-hFc1 interaction is 
stabilized by a calcium ion and, 
therefore, binding and release of 
the aptamer can be controlled 
by either chelation or addition 
of calcium.
Crystals of the RNA aptamer 
in complex with hFc1 were grown 
by sitting-drop vapor diffusion 
using a reservoir solution 
containing 0.1 M Tris-HCl 
buffer (pH 8.0), 20% (w/v) 
PEG 1000 and 0.2 M calcium 
acetate. 273. The RNA aptamer 
was chemically synthesized 
containing 2′-fluoropyrimidines 
and purified by PAGE. NMR 
analysis showed that the 
interaction between the Fc fragment and the aptamer has a 1:2 (Fc fragment:aptamer) 
stoichiometry 180. Consequently, the aptamer was mixed with the Fc fragment in a 
molar ratio of 1:2.2 (Fc fragment:aptamer) for crystallization. The crystals belong to 
Figure 4.3: IgG binding aptamers. Two RNA aptamers 
bound to the Fc domain of human IgG. Residues binding the 
aptamer are shown in black, calcium ions (gray spheres) are 
indicated by arrows (PDB code: 3AGV) 315.
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the space group P21212 and diffracted to 2.15 Å. Interestingly, crystal quality was 
improved by applying a solution stirring technique 187.
Crystallization of a streptavidin-aptamer complex
In chapter 3, we described the kinetic and stoichiometric characterization of 
streptavidin-binding aptamers 247. In order to gain more insight into the molecular 
basis of the streptavidin-aptamer interaction, crystallization screens of the complex 
were conducted. Here, as an example, we will briefly describe our crystallization trials 
and the results obtained.
For our initial crystallization experiments, we used the commercially available 
crystallization screens JCSG+ Suite (Qiagen) and Crystal Screen & Crystal Screen 2 
(Hampton Research, CA, USA). Streptavidin and aptamer (Figure S4.1) were mixed in 
a ratio of 1 streptavidin tetramer to 5 aptamers. For further experimental details, see 
the Supplementary text. Crystals of sufficient quality for data collection (Figure 4.4) 
were obtained from a high salt condition (2.0 M 
ammonium sulphate and 5% (v/v) 2-propanol), 
not containing PEG or MPD. Analysis of the 
1.9 Å resolution structure showed the presence 
of extra electron density in the biotin-binding 
pocket, but this density was too small to have 
originated from an aptamer (Figures S4.2 
and S4.3, for refinement statistics see Table S4.1).
In a second series of crystallization 
experiments, we used the Natrix & Natrix 2 
screens (Hampton Research, CA, USA), which 
contain conditions more dedicated towards 
crystallization of nucleic acids and protein-
nucleic acid complexes. Streptavidin and 
aptamer were mixed in a ratio of 1 tetramer to 2.2 
aptamers on the basis of mass-spectrometry 247. 
Although recently the use of chromophoric 
ligands was proposed to visually screen co-crystals of putative protein-nucleic acid 
complexes 121, we choose to conduct the crystallization screens in triplicate, using 
(i) streptavidin-aptamer complex, (ii) only streptavidin and (iii) only aptamer. In 
four conditions, crystals were obtained for both the streptavidin-aptamer complex 
and streptavidin alone. Crystals of the complex differed largely in size and shape 
from those of streptavidin only (Table S4.2), whereas no crystals grew in the same 
conditions containing only aptamer (pictures not shown). This indicates that the 
aptamer has a major effect on the crystallization process. Unfortunately, none of the 
crystals from the streptavidin-aptamer mix were suitable for data collection; they 
Figure 4.4: Crystal used for data 
collection. The crystal was obtained 
by vapor diffusion against a reservoir 
solution consisting of 2.0 M ammonium 
sulphate and 5% (v/v) 2-propanol (Crystal 
screen 2 condition 5).
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were either micro-crystalline needles (1D) or plates (2D), and therefore it remains to 
be established whether they contain aptamer or not.
Alternative methods of investigating aptamer target interactions
Besides X-ray crystallography, alternative techniques exist to investigate the molecular 
basis of aptamer-target interactions. When used individually, these methods do 
perhaps not provide as much detailed information as a crystal structure, and they are 
probably not as visually appealing. However, using a combination of complementary 
techniques may still provide very detailed information on the interaction. Together, 
these techniques could be considered an alternative to X-ray crystallography, for 
instance, when crystallization trials fail to produce well diffracting crystals, or when no 
adequate equipment or expertise is available to conduct crystallization trials. Moreover, 
some of these techniques may provide information on the dynamics of complex 
formation, whereas crystallography gives a time- and position-averaged image. Since 
bioinformatics and experimental approaches are generally complementary, both will 
be discussed.
Computational approaches
The sequence of an oligonucleotide, and the intramolecular base-pairing that this 
sequence enables, largely defines the 3D-structure of the oligonucleotide. Base-
paired regions in the 3D-structure of the oligonucleotide are thought to act as 
stabilizers, allowing loops and bulges to position themselves in ways suitable for target 
interaction 78. The nucleotide composition of distinct aptamers that bind the same 
target can vary strongly, particularly in the base-paired regions; however, the overall 
structure could remain largely similar 14, 247, 306. In other words, structural elements 
shared between oligonucleotides might therefore not be easily visible from primary 
sequence alignments. In addition, defining the boundaries of the minimal sequence 
required for target binding is not straightforward. For these reasons, identifying a 
recurring structure, within a number of sequenced oligonucleotides of an enriched 
pool, can be challenging if only sequence alignments are used.
Secondary structure predictions of clones in enriched pools may reveal recurring 
structural features, at any position and with deviating primary structures of 
oligonucleotides. These predictions could also be useful tools for identifying the 
minimal binding sequence. Most popular secondary structure prediction programs, 
including mfold 324, may be of limited value as they can only predict relatively 
simple hairpin structures. For the analysis of more complex aptamer structures, 
dedicated programs should be used, e.g., for the prediction of pseudoknots 240 and 
G-quadruplexes 135.
Besides secondary structure prediction, software has been developed to predict 
tertiary structures, varying from ab initio modelling to approaches requiring detailed 
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information on base pairing and other interactions 147. Such software has not frequently 
been used in aptamer research, partly because these programs often do not provide a 
single prediction, but rather give numerous possibilities that each have to be scored 
for their relevance. For example, the MC-Fold and MC-Sym pipeline 215 that we have 
previously used for the generation of a 3D-model of a streptavidin binding aptamer, 
provided 57 widely different structural models 247. Eventually a prediction was 
selected by comparing theoretical scatter of the predicted models with experimental 
SAXS data of the aptamer. A manual fit of the aptamer model onto a streptavidin 
crystal structure (Figure S3.4) showed that the aptamer could physically occupy two 
biotin-binding sites, and that it probably interacts with the loops that normally cover 
the biotin-binding pocket. This would explain the stoichiometry (2 aptamers per 1 
streptavidin tetramer) and the presence of two distinct regions in the aptamer that 
are both essential for binding 247. Although this modeling approach requires much 
more effort than standard secondary structure predictions, it can provide valuable 
information on the aptamer binding site and on the parts of the aptamer and the 
target protein that are involved in the interaction.
Experimental approaches
As mentioned above, one of the requirements for the initiation of crystallization 
experiments with aptamer-protein complexes is establishing the minimal binding 
sequence of the aptamer. As described, this can be relatively easy if a recurring 
sequence or structural motif is found, but binding should still be confirmed.
Alternatively, a full length aptamer may be shortened from either the 5′ or 3′ end 
to various lengths, by either enzymatic trimming 254 or alkaline hydrolysis 152 , 304. The 
resulting pool of fragments of randomly distributed lengths is incubated with the 
target, bound and unbound fragments are recovered as separate fractions, and run 
on a gel (e.g., polyacrylamide) to separate all individual fragments. From the patterns 
that emerge on the gel and the full-length sequence, the minimal binding sequence 
can be deduced. An alternative approach to determine the minimal sequence required 
for binding is the use of fragments of defined lengths obtained by PCR 160 or as 
synthetic constructs 128, and screening them for their binding capacity, e.g., by SPR. 
To get a better understanding of the aptamer-target interaction, nucleotides that are 
predicted to be important, for instance based on sequence or secondary and tertiary 
structure modelling, could be mutated to other nucleotides and their effect on target 
binding determined.
Secondary structure predictions are particularly helpful to identify the smallest 
DNA or RNA molecule still capable of binding the target, and may also reveal the 
nucleotides that are involved in target binding. On the other hand, it is also useful 
to obtain information on which regions or amino acids of the target are actually 
interacting with the aptamer. To this end, alanine scanning, replacing specific amino 
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acids in a protein with alanine, has been successfully used to show that two arginine 
residues in the protease domain of non-structural protein 3 from the Hepatitis C 
virus are essential for aptamer binding 113. Although successful, this method is very 
laborious. Hydrogen/deuterium exchange in combination with mass spectrometry 
(HXMS) 313 could provide an alternative method to map sites on the protein that 
interact with the aptamer. Other examples of the investigation of ligand specificity 
are the binding of biotin to an RNA aptamer. Several small molecules, similar to 
biotin, or fragments thereof, were tested for their ability to bind the RNA aptamer. 
The results suggest that binding is not enabled by a single functionality, but rather 
that several interactions of different parts of biotin are required simultaneously 304. 
Results of another study, in which the binding capacity of various compounds to 
an ethanolamine-binding aptamer was investigated, showed that the aptamer has 
a preference for only one functionality in the target molecule: either an ethyl- or 
methylamine group 225.
Other advanced analytical techniques are available for investigating aptamer-
target interactions. ITC is a method used to determine thermodynamic parameters 
of interactions; the dissociation constant can, however, also be deduced from ITC 
data. SPR and QCM can be used to measure the association and dissociation rates 
that underlie the dissociation constant of an aptamer-target interaction. SAXS can be 
applied to obtain information on the size and shape of macromolecular structures; 
like SAXS, DLS (also referred to as Quasi-elastic light scattering) can also be used for 
the determination of particle sizes and shapes, but it also provides information on the 
diffusion coefficients in solution. CD is particularly useful in determining secondary 
structures of proteins and aptamer-protein complexes. Combining these dedicated 
analytical techniques can provide useful insights into the aptamer target interaction. 
A recent example for which a combination of these techniques was used (ITC, DLS, 
NMR and SAXS) is the transformation of a cocaine binding aptamer to one that 
became specific for deoxycholic acid, by only replacing a single base pair 226.
Conclusions and future outlook
Co-crystal structures of aptamer-protein complexes have provided detailed 
information about the interaction between the nucleic acid aptamer and the protein, 
and can distinguish between electrostatic interactions 144 and hydrogen-bonding 
interactions 200. Crystal structures are therefore crucial for a thorough understanding 
of the molecular basis of the interaction. Nevertheless, obtaining crystal structures of 
nucleic acid-protein complexes is challenging, because a large number of parameters 
can be varied and numerous conditions need to be screened. In the specific case 
of aptamer-protein complexes, screening becomes even more challenging, because 
care should be taken that the 3D-structure of the aptamer remains intact during 
crystallization experiments. Consequently, the nucleic acid parameters (e.g., length, 
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presence or absence of sticky ends) are not easily varied because they could disrupt 
the 3D-structure of the aptamer, which should be avoided.
Despite the technical advances and the use of high-throughput crystallization 
methods, it will remain a major challenge to obtain aptamer-protein crystals. 
Improvements in NMR techniques will allow larger complexes to be analyzed at 
lower cost in the near future, providing an appealing alternative for crystallography. 
However, this requires improvements in data analysis routines, because data analysis 
becomes more complicated with increasing molecule size 146.
Alternative experimental approaches, such as alanine scanning, ITC, DLS, and 
SAXS are perhaps not as visually appealing as atomic resolution structures, but in 
combination with computational approaches, they may provide very useful information 
about the molecular basis of the interaction. In addition, some of these techniques 
can provide information on the dynamics of complex formation, whereas atomic 
resolution structures provide a time- and position-averaged image. One promising 
technique for obtaining high-resolution information on aptamer-protein interactions 
is cryo-electron microscopy (cryo-EM). Currently, cryo-EM is often used to study the 
structure of macromolecular assemblies, but its lower limit (~0.1 MDa) 208 is still too 
high for most of the aptamer-protein interactions described today. As technology 
advances, the lower limit might go down, and cryo-EM could become an attractive 
alternative for X-ray crystallography. Despite the many alternative methods to study 
aptamer-protein interactions, screening numerous crystallization conditions will 
remain, and for the time being, is the only way to obtain atomic resolution structures 
of aptamer-protein complexes.
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Supplementary information
Material and methods
Crystallization
Crystallization experiments were performed using the sitting-drop vapor diffusion 
method with the conditions provided by the JCSG+ Suite (Qiagen), the Crystal screen, 
Crystal screen 2, and the Natrix and Natrix 2 crystallization screens (all from Hampton 
Research, CA, USA).
For the crystallization experiments using the JCSG+ Suite, Crystal screen and Crystal 
screen 2 conditions, pure lyophilized streptavidin (Mr = 16.62 kDa; Leinco Technologies 
Inc., St. Louis, Mo, USA) was reconstituted in Milli-Q water to a concentration of 
23.5 mg ml-1 (NanoDrop1000 spectrophotometer, Thermo Scientific, Wilmington, DE, 
USA), using a molar extinction coefficient at 280 nm of 41.940. The aptamer StrepApt5 
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(gggaACGCaccGATCGCAggtTtccc, Sigma; Mr = 7.96 kDa) was dissolved in Milli-Q 
water to a concentration of 1 mM. Streptavidin and StrepApt5 were mixed in a ratio 
of 1 tetramer: 5 aptamers, yielding a final protein concentration of 10 mg ml-1. Drops 
consisting of equal volumes of reservoir solution (1 μl) and Streptavidin-StrepApt5 
complex were equilibrated over 400 μl reservoirs (JCSG+) or 450 μl reservoirs (Crystal 
screen and Crystal screen 2) at 20°C.
For crystallization experiments using the Natrix and Natrix 2 crystallization screens, 
pure lyophilized streptavidin was reconstituted in Milli-Q water to a concentration 
of 25.5 mg ml-1. StrepApt5 was dissolved in binding buffer (100 mM NaCl, 2 mM 
MgCl2, 5 mM KCl, 1 mM CaCl2 and 20 mM Tris-HCl, pH 7.6) to a concentration of 
1 mM. Streptavidin and StrepApt5 were mixed in a ratio of 1 tetramer: 2.2 aptamers, 
yielding a final protein concentration of 10 mg ml-1. The mixture was left at room 
temperature to allow complex formation. In addition, samples with only streptavidin 
or StrepApt5 were prepared by diluting them in the same way as the Streptavidin-
StrepApt5 sample. Drops consisting of equal volumes of reservoir solution (2 μl) and 
either Streptavidin-StrepApt5 complex, Streptavidin, or StrepApt5 were equilibrated 
over 450 μl reservoirs (JCSG+) at 20°C.
X-ray data collection and analysis
A crystal obtained using a reservoir solution consisting of 2.0 M ammonium sulphate 
and 5% v/v 2-propanol (Crystal screen 2 condition 5) was used for data collection 
(Figure 4.3). For cryoprotection, the crystal was soaked in reservoir solution containing 
25% (w/v) glycerol. The crystal was mounted in a cryoloop and flash frozen in a stream 
of nitrogen gas at 110 K. Diffraction data was collected in house at 110 K using a 
Microstar rotating anode (Cu) X-ray source (Bruker AXS GmbH) in combination with 
Helios optics (Incoatec GmbH) and a MAR345dtb detector (Marresearch GmbH). In 
total, 220 data images were collected with an oscillation angle of 1°. The data was 
processed using the iMosflm program 6 and programs from the CCP4 Suite 307. For 
data collection statistics see Table S4.1. 
The structure of the crystallized protein was solved by molecular replacement 
using the program Phaser v.1.3 171 with the native streptavidin structure (PDB code: 
3RY1; 151) as the search model from which water and solvent molecules had been 
removed. After rigid-body refinement of the obtained solution, the R factor was 
0.396. Further refinement was done with the program REFMAC5 188, setting aside 
5% of the reflections to monitor refinement progress with the Rfree factor, but was 
stopped when it was clear that no aptamer was bound to the protein. Table S4.1 lists 
the refinement statistics.
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Table S4.1: X-ray data collection and refinement statistics.
X-ray source In house Microstar rotating anode X-ray source (Bruker AXS GmbH)
Wavelength (Å) 1.5418 Å
Space group C2
Molecules/A.U 4
Solvent content 36% (based on 64 kDa/tetramer)
Unit-cell parameters
a, b, c (Å) 83.9 47.6 104.7
α, β, γ (º) 90 100 90
Resolution (Å) 1.86 (1.96–1.86) *
Rmerge 0.101 (0.638)
Rp.i.m 0.056 (0.338)
Total No. of observations 138644 (18185)
Total No. of unique reflections 32195 (4221)
Mean I/σ(I) 7.7 (1.8)
Completeness (%) 93.8 (85.3)
Multiplicity 4.3 (4.3)
Refinement
R-factor 22.1
Rfree 27.1
RMSD from target geometry
Bond lengths (Å) 0.014
Bond angles (°) 1.58
Total number of atoms 3684
Number of amino acids 475 (A: 16–136, B: 15–132, C: 15–133, D: 16–132)
Number of water molecules 154
Ramachandran analysis (%) 36
Core 88.8
Allowed 10.3
Generously Allowed 1.0
Disallowed 0.0
* Between brackets: Statistics for the highest resolution shell.
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Table S4.2: Overview of crystals of streptavidin only and streptavidin-StrepApt5 complex in the same 
conditions.
Condition Composition Streptavidin only Streptavidin-StrepApt5 complex
Natrix 1 25
0.08 M Magnesium 
acetate 
tetrahydrate, 
0.05 M Sodium 
cacodylate 
trihydrate pH 
6.5, 30% w/v 
Polyethylene glycol 
4,000
Natrix 1 27
0.2 M Ammonium 
acetate, 0.01 M 
Magnesium acetate 
tetrahydrate, 
0.05 M Sodium 
cacodylate 
trihydrate pH 
6.5, 30% w/v 
Polyethylene glycol 
8,000
Natrix 1 45
0.025 M 
Magnesium 
sulphate hydrate, 
0.05 M TRIS 
hydrochloride 
pH 8.5, 1.8 M 
Ammonium 
sulphate
Natrix 1 48
0.2 M Ammonium 
chloride, 0.01 M 
Calcium chloride 
dihydrate, 0.05 M 
TRIS hydrochloride 
pH 8.5, 30% w/v 
Polyethylene glycol 
4,000
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Figure S4.1: Sequence and secondary structure of StrepApt5.
GGGAACGCACCGATCGCAGGTTTCCC
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G
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Figure S4.2: Analysis of electron density observed in the streptavidin structure obtained in this 
study. A) Electron density observed in the biotin-binding pocket of one of the subunits; density is present 
in all biotin-binding pockets; B) The observed density is too small to have originated from an aptamer, but it 
neither corresponds to a full biotin molecule (shown in sticks). We suspect it is a biotin analogue, used by the 
manufacturer to purify the protein. Unfortunately the resolution is not sufficient to identify the exact nature of 
this molecule; C) Symmetry-related mates of the central streptavidin show that there is no physical space for a 
large DNA molecule. Biotins are shown as spheres: 4 biotin molecules per streptavidin tetramer.
Figure S4.3: Streptavidin structural overlay. The structural model obtained from the collected data 
(unsuccessful attempt to obtain a streptavidin-aptamer structure) is shown in black. A biotin containing 
streptavidin structure (PDB code: 3MG5) 8 is shown in gray (biotins are hidden in this figure).
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Abstract
Aptamers are oligonucleotide ligands that are selected for high-affinity binding to 
molecular targets, varying from small molecules to whole cells. However, no predictions 
can be made as to which target molecule will successfully yield aptamers, and no 
predictions can be made on which sequence will bind a pre-defined target. Therefore, 
selection of aptamers still remains largely a trial-and-error approach. The protein 
used in this study, SpaC, is a subunit of pili present on the Gram-positive bacterium 
Lactobacillus rhamnosus GG, widely marketed as a probiotic. SpaC contains a binding 
domain for human mucus, which we consider an advantageous feature for selection. 
In addition, it is an extracellular protein and presumably stable. Here we describe the 
overproduction and purification of the SpaC protein in Escherichia coli, the aptamer 
selection procedure and the subsequent characterization of enriched DNA sequences. 
A total of 49 unique aptamers were obtained in nine selection rounds; 17 of those 
were found to reoccur multiple times in a clone library of 85 sequences. Binding of 
10 re-occurring sequences was assessed using Surface Plasmon Resonance and the 
results indicated that they specifically bind to SpaC.
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Introduction
Aptamers are single stranded DNA (ssDNA) or RNA oligonucleotides, capable of 
recognizing and binding pre-defined targets with great selectivity and affinity 131, 168; in 
that respect they are similar to antibodies, which are currently the most predominant 
affinity tool used nowadays 245. Aptamers are selected in vitro, during a process 
named systematic evolution of ligands by exponential enrichment (SELEX 269). A 
large pool of randomized DNA or RNA is incubated with a target molecule that is 
attached to a matrix (e.g. magnetic beads, or column material). After target exposure, 
any unbound oligonucleotides are washed away, bound molecules are recovered 
and amplified by PCR or RT-PCR; the resulting enriched pool serves as starting 
material for a new round of selection. Although numerous successful experiments 
have been described in literature 269, the selection of aptamers still remains largely 
a trial-and-error approach; partly because successful aptamer selection depends on 
properties of the target itself. Aptamers often interact via a combination of aromatic 
stacking, hydrogen bonding, target encapsulation, and electrostatic interactions 89; in 
addition proteins are recognized via shape complementarity 89, 246. Target molecules 
that enable such interactions would probably be more suitable for aptamer selection 
experiments, but it is not quite clear, which properties are decisive.  In addition, it 
is not possible to predict which particular sequence will bind the target of interest. 
Some attempts have been made to increase the chance of successful enrichment, 
using partially randomized nucleic acid pools 120, 138, or pools designed to adopt a 
certain conformation 48, 202.
After several selection rounds the enriched pool of nucleic acid fragments is 
usually cloned and sequenced, in order to identify the enriched sequences. Moreover, 
this allows for further characterization, usually in terms of secondary structure and 
binding affinity. Aptamers can adopt a wide variety of structural shapes, such as 
hairpins, bulges, pseudoknots and G-quadruplexes 167. Therefore, it can be challenging 
to accurately predict secondary structures 246. The dissociation constant (KD in M) of an 
aptamer for the interaction with its target is often measured by equilibrium methods 
(see e.g. in 14). These methods cannot provide information on the rates of complex 
formation (ka in M
-1 s-1) and dissociation (kd in s
-1), although a lot of useful information 
is concealed within these parameters. Besides measuring the dissociation constant, 
it can also be calculated from the ratio between the dissociation and association 
rates (KD = kd / ka). This also illustrates how different kinetics can result in a similar 
dissociation constant. To this end, surface plasmon resonance (SPR) is an advanced 
technique that allows measuring of the association and dissociation rates, and to 
subsequently calculate the dissociation constant. 
Lactobacillus spp. are Gram-positive bacteria used in a wide range of food 
fermentations but also include groups that are marketed as probiotics 51. One of the 
best known representatives of the latter category is Lactobacillus rhamnosus GG, which 
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is marketed worldwide 251. Comparative and functional genomics studies revealed 
L. rhamnosus GG to produce pili, which are extracellular proteinaceous polymers that 
had previously only been reported in pathogenic bacteria 124. The L. rhamnosus GG 
pili consist of repeating units of the 25 kDa SpaA that are decorated with 92 kDa 
SpaC 228, 294. The pilin subunits are linked by intermolecular isopeptide bonds 88, 123. 
Detailed analysis showed that SpaC is most often located at the pilus tip and contains 
a human mucus binding domain that enables L. rhamnosus GG to persist for longer 
times in the human intestinal tract. In addition, a part of the N-terminal SpaC protein 
sequence is similar to the type A domain of the von Willebrand factor (vWFA). The 
presence of such mucus-binding pili posed a new mechanism on how probiotic 
bacteria can interact with host tissue 124. 
Although no predictions can be made on which target molecule will successfully 
yield aptamers, SpaC seemed a suitable candidate for an experimental approach 
to generate aptamers. SpaC contains a human-mucus binding domain that is 
already designed to bind another compound: human mucus. In addition, SpaC is 
an extracellular protein and stable due to the presence of intramolecular isopeptide 
bonds 124, which is advantageous during selection. Here we describe the production 
of recombinant SpaC protein, the aptamer selection procedure and the subsequent 
characterization of enriched sequences.  
Results and Discussion
Full length SpaC protein is produced
SpaC has a theoretical mass of 91780 Da, but the protein that was produced in E. coli 
BL21(DE3) pSJS1244 cells was found to run with the same mobility as the 75 kDa 
marker protein (Figure 5.1). Previously, however, no such aberrant running behavior 
has been reported 294. The SpaC protein was purified using the C-terminal Strep Tag II, 
indicating that the C-terminal region should be intact. In addition, sequence analysis 
FT        W1      W2       W3       E1        E2        E3        E4        E5        M
75 kDa
100 kDa
Figure 5.1: Purification of SpaC from cell free extract. Fractions are run 
on an 8% SDS-PAGE gel. The dark band in E1 shows purified SpaC. FT, Flow 
through; W, wash fractions; E, elution fractions; M, marker.
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of the cloned gene revealed no abnormalities. Especially the N-terminal protein 
sequence (similar to vWFA) is of interest during selections; to exclude the possibility 
that this piece, or any other piece, of the protein is missing, the purified SpaC protein 
(a different batch than shown figure 5.1) was subjected to mass spectrometry analysis. 
This resulted in a molecular weight of 91594 Da, and although it is not an exact 
match, it confirms that full-length protein is indeed produced. Further analysis of 
the protein sequence revealed a theoretical pI of 4.85, causing the protein to be 
negatively charged at neutral pH; this could explain why the full-length protein runs 
with the same mobility as the 75 kDa marker protein. An alternative explanation might 
be that the presence of intramolecular isopeptide bonds in SpaC gives rise to altered 
formations causing aberrant migration 294; formation of such bonds can indeed be 
catalyzed by the protein itself 106.
Guanine-rich oligonucleotides are enriched
Through the use of the experimental approaches described later in this chapter, we 
aimed to obtain ssDNA aptamers that would bind to the pili subunit protein SpaC. 
After nine selection rounds, 1% of the 
input DNA was recovered (Figure 5.2), 
and the enriched pool was cloned and 
inserts were sequenced. Assembly of 85 
sequences resulted in 32 sequences that 
only occurred once; the 53 remaining 
sequences could be divided among 
17 clusters, consisting of two to seven 
sequences (Figure 5.3), amounting to a 
total 49 unique sequences in the pool 
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Figure 5.2: Normalized fluorescence of elution 
fractions of subsequent selection rounds. More 
than 1% of the input DNA is recovered for the first 
time in elution 1 of round #9. 
Figure 5.3: Sequences of the region between the two primer sites of the sequence 
clusters.  The number of sequences that form a particular cluster is indicated in parentheses. 
Cluster 1A and 1B differ by only one nucleotide at position 14.
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Clstr_1A(6) GGGAGGGCGGGGGAAGCGTTGGTATGGGGGATGGAGGTGGCCCGTTGGGCTTGCTCGTTGACGC
Clstr_1B(7) GGGAGGGCGGGGGGAGCGTTGGTATGGGGGATGGAGGTGGCCCGTTGGGCTTGCTCGTTGACGC
Clstr_2(4) CGGAGCCGTTTGGTGGAGGAGGGGGTGTTTTTGGGTGGGCTGGGTCTCTCCGAATGTTCACTGC
Clstr_3(4) GGGAGGcGTGATGGGTATCGGTGGGGTATGGGTTGGGGGTGGGTTTTTAACGTTGATTTGTGCT
Clstr_4(4) GGGGGGGTGGGGGTTAAGCTTGGTATGGGGGATGGTGGACACGTCGTTTTCCTGGGTGGCTTGC
Clstr_5(3) GgCGGGGGGTGGGCGGGGTCTGCCTCGGGGGACATGTGGGTGGGCTTGGTCTATTTAGTATTCG
Clstr_6(2) GGGCGCAGGAGGGGGTGCGTTGGTATGGGGGTGGTGGGCGTCATCCGGTGGCCTTGCCGTTTCG
Clstr_7(3) GGCGGGGGGGGGAAGCGCGTGTATTGGGGTGGGAGGTATGTGATCTTCCTGGTTGTGTATTTCC
Clstr_8(3) GGGGTGGGGACTTGTGGGTGCGCGAGCCTGTGTAACTGGTGTTCGTTCGGGGTGGGGGGCTTGG
Clstr_9(2) GGGGTGTTGCGGGTGTAGGGGGTGGGCTGCGGGGTGGGTTTTTTCGCATTTGTTGTGTTGTTGG
Clstr_10(2) ACCGTGTGTGCCCTGGGTGGGTAGGAGGGGGTGGGTGGAGGGCTGGTGCATCCGGGGCTGCTGT
Clstr_11(2) GGTGGTGGGTGGCCGAGGTCGGTATTGGGTGGTGGGCGGGGGTATTTTGCGCGTTTCCTGTCGT
Clstr_12(2) GGGGTGAtGGGTGGATGCGTAAGTTAGCGGGAGGGCGGGGGAATTGCTGTGTCGTGTCTGATGT
Clstr_13(2) GGGGGGGCGGGGGAAGCGTAGGGTATGGGGGCATGGGCGGACTTTCCCCGCTGCCTGGATTGCC
Clstr_14(2) CGGTCGGGatGGGGTGCGAAGCTGGGACGGGTGGGGGGCTTGGCGGACATGTGGGGTTCCTGTG
Clstr_15(2) GCGGACCTGTGAGTTAGGGGAGGGGACTTGCGGGTGGCTTGGGATTCTTTGCCTGGGTGGGGT 
Clstr_16(3) GGGGGGGAGGGGGGAATTAGCTGGTTCGGGGGTGGTTGGAGGCAGTATTGTTGGTTTGCATGG 
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of 85 clones analyzed 
by sequencing. The 
difference between 
the most predominant 
sequences, cluster 1A 
(six sequences) and 1B 
(seven sequences), is 
only one nucleotide; 
1A contains an 
adenine at position 14, 
whereas 1B contains a 
guanine. Although this 
is probably caused by a point-mutation during PCR, it could also be an exceptional 
example of convergent evolution. 
All sequences appear to have a high guanine content in the 64 nt randomized 
region, varying from 44–55% in the clusters (Figure 5.4). This suggests that a 
G-quadruplex might be formed, further strengthened by the predictions made by 
QGRS mapper, a tool designed among others for predicting the presence of these 
structures in oligonucleotides 135. In a G-quadruplex, four guanines pair through 
Hoogsteen pairing, forming a planar structure 194. Target recognition and binding 
could be through the loops connecting the guanines, or by electrostatic interactions 
of the nucleic acid backbone. The best studied example of a G-quadruplex forming 
aptamer is the thrombin-binding one 144. The presence of a G-quadruplex precluded 
the use of secondary structure predictions, such as those made by mfold, and hence 
structural predictions were omitted at this stage 246, 324.
Aptamers bind specifically to SpaC
The observations that multiple sequences occur more than once in the clone library, 
and that they all share a guanine rich region, might hint to successful enrichment. 
In previous work, SELEX experiments that showed clear signs of enrichment but that 
failed to deliver a proper aptamer, showed no re-occurring sequences in the clone 
library nor did they share any particular feature (unpublished results). 
No obvious sequence or secondary structure seemed to be conserved, as was the 
case with streptavidin binding aptamers (Chapter 3) 247. Therefore ten oligonucleotides 
of selected clusters, 1A, 1B, 2–8, and 15 (excluding the primer regions) were 
synthesized and tested for binding in SPR experiments. Such long oligonucleotides 
have their drawbacks, however, once binding is confirmed efforts can be made to 
find out which portion of the oligonucleotide sequence is essential for binding 246. 
The binding capacity was tested on two different surfaces, one containing covalently 
coupled SpaC and the other containing captured SpaC. Covalent coupling yields a 
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Figure 5.4: Nucleotide distribution in the sequence clusters, in the 
region between the two primer sites. Guanine content varies between 
44–55%. 
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more stable surface, but requires harsh conditions that might damage the protein. 
In contrast, capture approaches work at physiological conditions but are generally 
less stable (Chapter 2). In addition, the Avi-tag allows for site specific biotinylation, 
resulting in a more homogeneous surface after capture. 
It was our initial aim to first screen for binding in a qualitative way, and to 
subsequently characterize binding of a smaller subset of oligonucleotides in more 
detail. To this end all oligonucleotides were injected at a high concentration. In 
a second run a regeneration step was included, by injecting 1 M NaCl for 1 min. 
Unfortunately these SPR measurements revealed ambiguous results (Figure 5.5). 
There was an increase in response units, both for the covalently coupled SpaC as well 
as captured SpaC, which indicates binding. Furthermore, the responses to captured 
SpaC were much higher than to covalently coupled SpaC. The shape of the binding 
curve, however, provided reason to be cautious about the data. The association phase 
is generally not expected to follow linear behavior (although mass transport limitation 
could yield linear responses) and should certainly not drop below zero. During the 
dissociation phase complexes generally fall apart, showing a decrease in response 
units; this did not seem to happen in this case. 
We observed some non-specific binding when the dissociation phase was followed 
by a buffer injection (Figure 5.6). Interestingly, the non-specific interaction appeared 
to be absent when the dissociation phase was followed by an injection of 1 M NaCl. 
A possible explanation for this observation could be that residual NaCl had not yet 
been fully washed away at the time a new oligonucleotide was injected. Both with 
and without injections of 1 M NaCl, the responses immediately dropped back to the 
baseline after the sample injection as is to be expected from a reference surface. 
In contrast, the responses did not drop back to the baseline on the SpaC coated 
surfaces, suggesting that the interaction is specific for SpaC.  
Conclusion
In this work we have described our attempt to select aptamers specific for SpaC, 
a 92 kDa mucus-binding protein decorating the pili present on Lactobacillus 
rhamnosus GG. The enrichment procedure and sequence analysis indicated 
that aptamers were successfully enriched. In addition, the binding of several 
selected aptamers seemed to be specific for SpaC protein. However, we could not 
unambiguously demonstrate this by using SPR. Various options are open to further 
explore this interaction. When more SPR experiments are considered it might be 
useful to explore the effect of higher salt concentrations in the running buffer. 
Although this deviates from the original selection conditions, the regeneration with 
1M NaCl provides a clue that this might be useful. Another option would be to 
characterize this interaction using an alternative technique, for instance by using 
Microscale Thermophoresis 119, 302.  
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Figure 5.5: Double referenced SPR data of oligonucleotide injections (5 µM). A) Oligonucleotide binding 
to covalently bound SpaC (4912RU). B) Oligonucleotide binding to captured SpaC (4886 RU). Black curves were 
obtained without injection of 1M NaCl, gray curves were obtained with injection of 1M NaCl.
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Figure 5.6: Unreferenced SPR data of oligonucleotide injections (5 µM). A) Reference surface. B) 
Covalently bound SpaC (4912RU). C) Streptavidin reference surface. D) Captured SpaC (4886 RU). Black curves 
were obtained without injection of 1M NaCl, gray curves were obtained with injection of 1M NaCl. Gray curves 
stay flat during sample injection over the reference surfaces (A and C), whereas black curves display non-specific 
binding on the reference surfaces. Both gray and black curves go back to baseline on the reference surfaces, 
whereas they do not on the SpaC coated surfaces (B and D), indicating that binding is specific.
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Materials and methods
Cloning of spaC coding sequence 
The coding sequence of spaC (LGG_00444), excluding the C-terminal cell wall sorting 
signal and N-terminal signal peptide, was PCR amplified from a plasmid containing 
a synthetic codon-optimized spaCBA gene cluster (F. Douillard and W.M. de Vos, 
unpublished data). The coding sequence was amplified in three parallel 50 µl PCRs, 
containing each 50 ng template DNA, 0.2 mM of each dNTP, 0.2 mM of primers BG3764 
(ttcTCATGActgataacattcgcccaacc) and BG3765 (ttcGCGGCCGCcggcaaaattgcaagtgg), 
1×Buffer HF and 1 Unit Phusion II (Finnzymes). The PCR program was as follows: 30 s 
at 98°C, 30 cycles of 10 s at 98°C, 20 s at 65°C, 45 s at 72°C, followed by 5 min at 
72°C after the last cycle. Purified PCR product was subsequently digested with BspHI 
and NotI (sites marked in capitals) restriction enzymes, while the destination vectors, 
pWUR533 and pET24d-AviHisC, were digested with NcoI and NotI. Both fragments 
were ligated together, and E. coli strain XL1-blue was transformed with the resulting 
plasmids (pWUR533_SpaC and pET24-SpaC-AviHis) for plasmid propagation. The 
destination vector pWUR533 is a derivative of pET52-1b, but it contains a C-terminal 
HRV 3C protease site instead of a thrombin protease site, and a Strep Tag II instead 
of a His tag; pET24d-AviHisC contains a C-terminal Avi tag for in vivo biotinylation 10, 
and His tag for purification.  
Production of recombinant SpaC
E. coli BL21(DE3) pSJS1244  was transformed with the pWUR533_Spac plasmid, 
encoding SpaC conjugated to StreptagII, for protein production. Fresh LB medium, 
containing ampicillin (final concentration: 100 µg ml-1) and spectinomycin (final 
concentration: 50 µg ml-1), was inoculated with 1% overnight culture. After three 
hours of incubation at 37°C, protein production was induced by adding isopropyl-β-
D-thiogalactopyranoside (IPTG), to a final concentration of 1 mM. Three hours later, 
cells were harvested by centrifugation. 
E. coli BL21-AI was transformed with pET24-SpaC-AviHis, encoding SpaC 
conjugated to the Avi-His tag, for protein production. This strain contains the pBirA 
plasmid coding for BirA biotin ligase; the vector carries chloramphenicol resistance 10, 31. 
Fresh LB medium, containing kanamycin (final concentration: 50 µg ml-1) and 
chloramphenicol (final concentration: 10 µg ml-1), was inoculated with 1% overnight 
culture. Protein production and biotinylation was induced, three hours later, by adding 
isopropyl-β-D-thiogalactopyranoside (IPTG) (final concentration: 1 mM), L-arabinose 
(final concentration: 0.02%) and biotin (final concentration 50 µM). A 5 mM biotin 
stock solution was prepared in 10 mM tricin buffer pH 8.3. Three hours later, cells 
were harvested by centrifugation. Cell pellets were either processed immediately 
after harvesting, or stored at -20°C until further processing. 
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Purification of recombinant SpaC
Cell pellets were either resuspended in lysis buffer (150 mM NaCl and 10 mM HEPES 
pH 7.4) and subsequently lysed using a French press, or resuspended and lysed in 
B-PER (Thermo Fisher Scientific, Netherlands). Clarified cell free extract (CFE) was 
passed through a 0.45 µm filter before incubation with purification resin. 
SpaC conjugated to Strep Tag II was purified using Strep-Tactin® Sepharose (IBA, 
Göttingen, Germany), which was equilibrated with lysis buffer prior to use. After 
incubation, the column material was washed three times with four column volumes 
lysis buffer. Bound protein was eluted in fractions of two column volumes using 
elution buffer (150 mM NaCl, 10 mM HEPES pH 7.4 and 4 mM desthiobiotin). 
SpaC conjugated to the Avi-His tag was purified using HIS-Select® Nickel affinity 
gel (Sigma-aldrich), which was equilibrated with water and wash buffer (50 mM sodium 
phosphate buffer, pH 8.0, with 0.3 M sodium chloride and 5 mM imidazole). After 
incubation, the column material was washed three times with four column volumes 
of wash buffer. Bound protein was eluted in fractions of two column volumes using 
elution buffer (50 mM sodium phosphate buffer, pH 8.0, with 0.3 M sodium chloride 
and 250 mM imidazole). 
SpaC bead preparation
In order to exclude the possibility of enriching aptamers binding the Strep Tag II, 
it was removed prior to immobilizing the protein on magnetic beads. Four units of 
HRV 3C protease (EMD Millipore, Billerica MA, USA) were added to 1.9 mg of SpaC 
protein and left overnight at 4°C. The tag and protease were subsequently removed 
using a Vivaspin 20 centrifugal concentrator (Sartorius, Gottingen, Germany), with a 
50 kDa molecular weight cut-off. SpaC protein was coupled to M-280 Tosylactivated 
Dynabeads (Invitrogen) according to the procedures described in the manual. Briefly, 
20 mg beads were washed with buffer B (0.1M Na-phosphate buffer pH 7.4), then 
0.8 mg SpaC in 450 µl lysis buffer and 300 µl buffer C (3M ammonium sulphate in 
buffer B) were added to the beads. After 24hr incubation at RT, under constant upside-
down rotation, supernatant was removed and beads were blocked using 1 ml buffer E 
(PBS pH 7.4 with 0.5% (w/v) BSA). After 1 hr beads were washed two times using buffer 
F (PBS pH 7.4 with 0.1% (w/v) BSA), and stored at 4°C in buffer F. Successful coupling 
was assessed by measuring the protein concentration before and after coupling using 
a Nanodrop 1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA).
Oligonucleotides for SELEX
Unmodified primers AP10 (ataccagcttattcaatt) and AP30 (ctaactgattacgattgt) 247, 
primer AP60, equal to AP10 but containing 5’-Fluorescein, were obtained from 
Biolegio (Nijmegen, the Netherlands). Primer TER-AP30, equal to AP30 but containing 
5’-poly-dA20Hexaethylenglycol, was ordered from IBA (Göttingen, Germany). The 
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random pool (ataccagcttattcaatt-n64-acaatcgtaatcagttag), purified using a reverse-
phase cartridge, was obtained from Eurogentec (Seraing, Belgium).
SELEX procedure (FluMag-SELEX)
The SELEX procedure was performed essentially as described in chapter 3 247. Briefly, 
before each selection round ssDNA was heated to 95°C for 8 min, cooled on ice for 
10 min and left at RT for at least 10 min. In the first round 26 pmol of the random 
pool was added to SpaC coated beads, and in subsequent rounds 250 μl of the 
ssDNA preparation 247 was added. Approximately 1×108 SpaC beads were washed 
with selection buffer (100 mM NaCl, 2 mM MgCl2, 5 mM KCl, 1 mM CaCl2 and 20 mM 
Tris-HCl, pH7.6), and after addition of the ssDNA to the beads they were incubated 
at 25°C with mild shaking for 30 min. Unbound oligonucleotides were removed by 
washing three times with selection buffer. Subsequently, bound oligonucleotides 
were eluted by adding selection buffer and incubation at 80°C for 5 min with mild 
shaking. In SELEX round 8 the selection buffer was supplemented with 0.05% BSA. In 
SELEX round 9 approximately 1.4×108 beads were used, and the selection buffer was 
supplemented with 0.1% BSA. 
Eluted oligonucleotides were PCR-amplified in 15 parallel PCR reactions, each 
containing, 25 µl template (elution fraction), 1.9 mM MgCl2, 0.2 mM dNTPs each, 
1 μM of each primer (AP60 and TER-AP30), 1×Buffer B2, and 4 Units HOT FIREPol 
(Solis BioDyne) in a total volume of 100 μl. The PCR program was as follows: 15 min 
at 95°C, 30 cycles of 30 s at 95°C, 30 s at 52°C, 1 min at 72°C, followed by 7 min at 
72°C after the last cycle. Electrophoresis on a 12% polyacrylamide (PAA) gel was used 
to confirm successful amplification of a DNA fragment of the correct size. 
From the second selection round onwards fluorescence in the starting sample, 
the non-bound DNA fraction, the wash fractions, and the eluted DNA was measured 
in 96-well microtiter plates (Greiner bio-one) using a SpectraMax M2 (Molecular 
Devices). 
Cloning and sequencing of enriched fractions
DNA eluted in SELEX round 9 was amplified, according to conditions described above, 
using unmodified primers AP10 and AP30 and ligated into pGEM®-T (Promega). 
Escherichia coli XL1-Blue cells (Stratagene) were transformed with the vector 
constructs, subsequently 96 colonies were randomly picked and vector inserts were 
sequenced using the T7 forward primer (GATC, Konstanz, Germany). 
Surface Plasmon Resonance
SPR experiments were performed on a Biacore 3000 system (BIACORE, 
Uppsala, Sweden), at a constant temperature of 25°C. Sensor chips (CM5), 
0.1 M N-hydroxysuccinimide (NHS), 0.4 M 1-ethyl-3-(3-dimethylaminopropyl) 
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carbodiimide hydrochloride (EDC), 1 M ethanolamine hydrochloride (pH 8.5) 
and 10 mM sodium acetate pH 4.0, were from GE Healthcare (Uppsala, Sweden). 
Streptavidin was obtained from Leinco Technologies Inc (St. Louis, MO, USA). A flow 
of 5 µl min-1 was used during all coupling and capture steps.
On one CM5 chip, biotinylated SpaC was covalently bound in fc 2, to a density of 
4912 Response Units (RU), and captured on a streptavidin surface in fc 4, to a density 
of 4886 RU. The surface in fc 2 was activated by injecting 35 µl of a 1:1 mixture (v/v) of 
EDC and NHS. Then 100 µl SpaC, approximately 50 µg ml-1 in 10 mM sodium acetate 
pH 4.0, was injected. Finally, the surface was blocked by an injection of 35 µl 1 M 
ethanolamine hydrochloride. A reference surface was created in fc 1 by activating 
and blocking the surface. A streptavidin surface was created in fc 3 and 4 using the 
same approach, by injecting 150 µl streptavidin, diluted to approximately 50 µg ml-1 
in 10 mM sodium acetate pH 4.0, after activation of the surface. Subsequently, SpaC 
was captured in fc 4, and fc 3 was left empty, to serve as reference surface. 
The 64 nucleotide region (in between the primers) of ten of the enriched 
oligonucleotides was synthesized (Biolegio, Nijmegen) and tested for binding, using 
selection buffer as running buffer. To this end, 30 µl of a 5 µM solution of each 
synthetic oligonucleotide was injected (using the kinject command) at a flow of 
30 µl min-1, followed by a dissociation phase of three min. In one set of experiments 
the dissociation phase was followed by a 15 µl buffer injection, in another set of 
experiments it was followed by a 15 µl injection of 1 M sodium chloride. Data was 
processed and analyzed using Scrubber (BioLogic Software, Campbell, Australia).
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Abstract
Despite the successes in aptamer selection towards specific and sensitive binding 
molecules, the dynamics of the in vitro selection process are not fully understood. 
Experimental conditions could be further optimized, instead of being based on practical 
considerations and convenience, as it is often the case. In addition, not necessarily 
the tightest binder is enriched but rather those with the most rapid association rate. 
Here we describe a multiplexed high throughput sequencing approach, in which 70 
samples were mixed, derived from eight distinct aptamer selection experiments, in 
order to get a more thorough understanding of the dynamics of aptamer selection. 
We also compared the effect of various elution methods. To our knowledge, this is 
the first time that so many samples of multiple selection experiments are combined 
in one study. Over 84 million paired-end reads were obtained, and a preliminary 
analysis of the data shows a decrease in α-diversity for successful aptamer selection 
experiments. Furthermore, the comparison between thermal and affinity elution 
methods (β-diversity) clearly shows that different oligonucleotides are enriched. A 
small-scale comparison of two clone libraries further suggests that the affinity elution 
method specifically enriches rapid binders. 
93
Assessing the dynamics of aptamer selection 
6
Introduction
Aptamers are single stranded DNA or RNA oligonucleotides selected to bind a 
predefined target. Since their initial development two decades ago 58, 285 the field of 
aptamer research has matured, and aptamers have become available for numerous 
targets.
Systematic evolution of ligands by exponential enrichment (SELEX) is the procedure 
by which aptamers are selected from a large pool (1014–1015 variants) of randomized 
nucleic acids. Over the years, various modified SELEX procedures have been described 
and successfully used 269. Generally a SELEX procedure consists of multiple subsequent 
selection rounds, and starts with exposing RNA or ssDNA oligonucleotides to a target 
molecule that has been immobilized on a surface matrix, e.g. column material 305 
or magnetic beads 268. Non-binding oligonucleotide molecules are washed away, 
after which bound molecules are recovered by either specific (affinity elution) or 
non-specific (e.g. heat elution) elution methods. Recovered oligonucleotides are 
amplified by PCR or RT-PCR and made single-stranded again in order to be used as 
starting material in a next round of selection. After successful enrichment is observed, 
the enriched pool is cloned and sequenced. Often, binding parameters of several 
individual sequences are assessed to identify the tightest binder.
Despite the successes in aptamer selection, the dynamics of the selection process 
are not fully understood and hence experimental conditions could perhaps be further 
optimized, to aid more rapid selection procedures and to yield tighter binders. 
Nowadays experimental conditions are often based on practical considerations, 
such as available expertise and experiences in the past. Convenience, such as the 
availability of a target-coated matrix plays a role as well; column materials with a large 
variety of targets are commercially available, whereas target coated magnetic beads 
are not widely available. Conditions like the amount of beads or column material, 
the amount of starting nucleic acid, the elution method and the number of selection 
rounds used during a SELEX experiment also influence the final outcome of a SELEX 
experiment. In addition, not necessarily the tightest binder is enriched but rather the 
binder with the most rapid association rate (chapter 3) 247. 
In recent years, unprecedented advances in sequencing technologies 178 have led 
to a variety of new sequencing applications 255. As might be expected, the SELEX 
procedure has been subjected to high throughput sequencing approaches as well. 
Such studies, however, primarily aimed to develop more rapid selection methods 38, 102, 
as opposed to studying the actual selection process. One study, also aiming for 
an improved selection method, provided somewhat more insight in the relative 
abundance levels of dominant sequences throughout several selection rounds 253. 
However, more informative methods are available for the analysis of the diversity and 
structure of e.g. microbial communities 159. Generally, diversity within a community 
is characterized by α-diversity, which gives an estimate of the number of species 
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present (species richness). Furthermore, relatedness between communities can be 
characterized using β-diversity parameters, which are often based on the number of 
species shared between communities 222. 
In the present study, we describe a multiplexed high throughput sequencing 
approach, aiming to study the diversity and composition of enriched oligonucleotide 
pools, using α and β-diversity estimates originally developed for ecological studies. In 
total, 70 samples of subsequent selection rounds of eight distinct SELEX experiments 
were pooled and sequenced. In four of these SELEX experiments, aptamers were 
selected for streptavidin and hemoglobin, using affinity elution and thermal elution. 
Samples of the four remaining SELEX experiments are not discussed here for IP-related 
reasons. Studying these samples provides more insights in the dynamics of aptamer 
selection, and allows us to compare the effect of different elution methods on the 
outcome of selection targeting a similar target. 
Results and discussion
Aptamer selection for streptavidin and hemoglobin
In total, six selection rounds were performed for streptavidin using affinity elution. 
For hemoglobin, six rounds were completed for the thermal elution selection, while 
four selection rounds were completed using 
affinity elution. For streptavidin, enrichment 
was first observed after four selection rounds 
and continued to increase in rounds five and 
six, when more than 30% of the input DNA was 
recovered (in Elution 1) based on normalized 
fluorescence of DNA in the elution fractions 
(Figure 6.1A). PCR reactions on DNA eluted 
in round four and five, however, yielded 
only very small amounts of DNA, resulting 
in decreased starting amounts of material in 
round five and six (data not shown). 
During the selection of hemoglobin 
aptamers, using non-specific thermal 
elution, enrichment was observed in round 
three, although it should be noted that, 
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Figure 6.1: Normalized fluorescence of elution 
fractions in subsequent selection rounds. A) 
Enrichment detected from round four onwards during 
streptavidin affinity elution, B) no recovery after negative 
selection (neg) during the hemoglobin thermal elution 
selections, C) During hemoglobin affinity elution there 
is no enrichment at all. Scales for both hemoglobin 
experiments are the same, for easy comparison. 
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unexpectedly, the highest recovery was found for elution 2 (Figure 6.1B). After a round 
of negative selection, by exposure to ‘empty’ streptavidin beads, however, no DNA was 
recovered anymore after round 3. In addition, no enrichment was observed for the 
hemoglobin selection when affinity elution was used (Figure 6.1C). This suggests that 
streptavidin binders were being enriched, instead of hemoglobin binders, when using 
thermal elution. Although both hemoglobin SELEX experiments did not result in an 
aptamer being enriched we have included the selection samples, to possibly identify 
aptamer sequences enriched throughout subsequent selection rounds. Enrichment 
of specific sequences can be accurately traced back in large sequence datasets 102. 
Diversity decreases in subsequent selection rounds
Through the use of a multiplexed high throughput sequencing approach, we aimed 
to gain a more fundamental insight in the dynamics of the SELEX procedure. A 
total of 70 samples, obtained during eight SELEX experiments, were mixed in one 
equimolar mixture and sequenced on a HiSeq2000. In total 84.511.225 pairs of 
reads were obtained. The overall quality of the sequence data was good and the 
complete random region was covered. Theoretically, each sample is expected to be 
represented by ~1.2×106 reads. From the actual read distribution (Table 6.1), however, 
it is apparent that samples with a pool length of 100 nt (samples number 1–27 and 63) 
contain more reads, averaging 1.8±0.7×106, than those with a 76 nt pool length 
(samples number 28–62 and 63–70), averaging 4.3±1.4×105. However, this poses 
no problem for subsequent analysis, because the reads are distributed quite evenly 
within samples of each SELEX experiment. 
Streptavidin-binding oligonucleotides were enriched in two different ways. In one 
SELEX experiment, described in chapter 3, binding oligonucleotides were recovered 
in a non-specific manner, by thermal elution. In this study, binding oligonucleotides 
were recovered in a specific manner, by affinity elution 247. Rarefaction analysis of 
selection samples of both streptavidin SELEX experiments revealed indeed that the 
α-diversity decreased as selection progresses, indicated by the lower asymptote of 
the rarefaction curves of later selection rounds (Figure 6.2 A and B). As a consequence 
of using a database for OTU picking, containing only those sequences represented 
by a minimum of 100 reads across the entire dataset, only a small number of the 
reads in the earlier selection rounds are incorporated in the analysis. This resulted in 
a limited number of points in the rarefaction curves, but nevertheless it is clear that 
these curves are heading towards a more diverse composition. Interestingly, there 
is a clear difference between both elution methods. Selection using thermal elution 
resulted in a more gradual decrease in α-diversity, whereas selection using affinity 
elution is characterized by a sudden decrease in α-diversity after round 4 (S3 to S4 in 
Figure 6.2B). Moreover, the affinity elution samples appeared to be less diverse than 
those obtained by thermal elution, although the latter might not yet have stabilized. 
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Rarefaction curves of both hemoglobin SELEX experiments (Figure 6.2 C and D) 
indicate that α-diversity does not significantly decrease in subsequent selection 
rounds; this observation was especially valid for thermal elution. Although the 
α-diversity was somewhat decreasing for the affinity elution experiment, only a 
small number of reads (max 5%) were re-occurring often enough to be included in 
the data analysis. The small number of reads included in the analysis and the high 
diversity indicated by rarefaction, which is likely to be an underestimation, might 
explain why these selection experiments did not show enrichment using fluorescence 
measurements. This does not exclude the possibility that aptamers are enriched for 
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Figure 6.2: Rarefaction analysis of aptamer selection samples. A) Diversity decreases in subsequent 
selection rounds B) At S4 diversity is stabilized. C and D) No obvious decrease in diversity is observed. E) Control 
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hemoglobin, however, more detailed analyses are required to address this 102. The 
two samples that were included as controls behaved as expected and showed a low 
diversity (Figure 6.2E), however, approximately 10–25% of the control reads were not 
included in the analysis. This suggests that either the template was not completely 
homogeneous or, more likely, that the error rate during sequencing is high. 
Rapid binders are enriched by affinity elution.
A more detailed comparison (Pearson Principle Coordinate Analysis) of both 
streptavidin selection experiments revealed that communities of the early selection 
rounds of both selection methods are more similar to each other than the enriched 
pools of later selection rounds (Figure 6.3). Forward and reverse sequencing reads 
were kept separate during this analysis. The forward reads for the samples of the first 
two rounds of selection (marked by S1* and S2*) were slightly dissimilar from the 
other early selection rounds (S1–S3), however, this could be due to the small number 
of reads that were included in the analysis. Furthermore, samples of later selection 
rounds of thermal and affinity elution samples, formed separate clusters respectively, 
indicating that different oligonucleotides were enriched by both elution methods. 
In order to gain a more detailed understanding of the differences caused by 
the different elution methods a small-scale comparison was initiated. To this end, 
the enriched pool of streptavidin binding oligonucleotides, recovered using affinity 
elution, was cloned after round four (Sample S5). Signs of enrichment were detected 
for the first time at the end of round four by fluorescence measurements, even though 
it should be noted that rarefaction analysis of Illumina sequences showed already 
a large drop in α-diversity at the start of round four (S4; Figure 6.2B). Moreover, 
the starting material of round four also clusters with the enriched fractions of later 
selection rounds, indeed suggesting that enrichment had already commenced. 
In total, 96 clones were sequenced, of which 84 were used for subsequent analysis. 
Assembly of individual sequences yielded eight clusters that each contained two to 
26 fully identical sequences, whereas six sequences occurred only once, resulting in a 
total of 14 unique sequences. Structural predictions of all unique sequences (clusters 
and singlets) were made using mfold 324, and in all sequences a similar structure of a 
stem-bulge-stem-loop was predicted, in line with previous findings 247.
The sequences predicted to form the stem-bulge-stem-loop structures were 
manually aligned according to their positions within the predicted structures 
(Figure 6.4). Despite the overall structural similarity some small variations could be 
observed: loop sizes vary between five and six nucleotides, and the bulges contain 
either three or five nucleotides. In particular, the nucleotides in the bulges (CGC) and 
loops (CGCA) are well conserved, whereas the actual compositions of the stems do 
not seem to be important as long as proper Watson-Crick base pairing is maintained. 
From the alignment and the small differences between sequences it was possible to 
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Figure 6.3: Pearson Principle Coordinate Analysis of Streptavidin selection rounds. Results of both 
forward reads (continuous lines) and reverse reads (dashed line) are shown, thermal elution samples are indicated 
as gray circles and affinity elution samples as black squares. Arrowheads indicate the direction of samples 
of subsequent selection rounds, toward the thermal elution cluster and affinity elution cluster, respectively. 
* Indicates forward reads that are slightly dissimilar. 
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distinguish three aptamer families that are similar to three of the five families that 
we described in chapter 3 247. Some sequences are even identical to those we found 
before, for instance AE_Ctg2 of this study. 
After four rounds of affinity elution, the number of unique sequences has dropped 
to 14, whereas thermal elution resulted in 31, after seven rounds of selection. Moreover, 
in the clone library of the thermal elution SELEX, five distinct families of streptavidin-
binding aptamers were identified (Figures 3.2 and 3.3). Each family has their own 
distinct kinetic behavior, and it was noted that the three aptamer families with a rapid 
rate of complex formation dominated the clone library. In the clone library of round 
four of the affinity elution SELEX, however, we could identify only 3 families, similar 
to those we described before. Interestingly, these three families all correspond to 
the three families that dominated the thermal elution SELEX. Hence, while affinity 
elution is expected to result in aptamers more specific to a pre-defined target, it also 
seems to specifically enrich for rapid binders. This is not completely unexpected, 
because during affinity elution two distinct binding stages can be distinguished. First, 
binding of oligonucleotides to the target coated matrix. Second, re-binding of bound 
oligonucleotides to uncoupled target present in the affinity elution buffer. It seemed 
likely that during both of these events rapid binders have an advantage, but this has 
not been so clearly demonstrated before. 
Figure 6.4: Alignment of stem-bulge-stem-loop sequences enriched by affinity elution. AE stands for 
affinity elution, Ctg is a cluster of identical sequences. The number of sequences in a particular cluster is indicated 
in parenthesis. Percentages indicate the occurrence of a certain family within the clone library.
Stem1a Bulge Stem2a Loop Stem2b Stem1b
 
 
 
Family 1
(StrepApt1)
AE_Ctg5(4) ---GAA----CGCGT---GTG----TT-GCT----CAC-----TTC
AE_Ctg8(14) ---CCA----CGCGT---GTG----TT-GCT----CAC-----TGG
AE_B05 --GATA----CGC-----GTAA---TT-GGG---TTAC----ATC 
23%
Family 2
(StrepApt2)
AE_Ctg1(26) -TTCAA---TTGCC----ACGT---GACGCA---ACGT----TTGAA
AE_Ctg2(17) --CGAA----CGC-----ATC---TGACGCAG---GAT----TTCG 
AE_Ctg3(3) -AGGTG---CCGCT----ATTC---GACGCA---GAAT----CAGCT
AE_Ctg4(9) ---CAA----TGC-----CCCT---GTCGCA---AGGG----TTG  
AE_A11 AACTAA----CGC-----CAAT---GTCGCA---ATTG----TTGTT
AE_B11 ---CAA---TTGCT----AACC---GACGCA---GGTT----TTG  
68%
Family 3
(StrepApt3)
AE_Ctg6(3) --GATT----CGC-----GTAC---GCTGCA---GTAC----AATC 
AE_Ctg7(2) -CGATT----CGC-----GTAC---GCTGCA---GTAC----AATCG
AE_A09 -CGATT----CGC-----GTAC---GCTGCA---GTAC----AATCG
AE_C06 -TTCAA---TTGCC----CGTC---GCCGCA---GACG----TTGAA
AE_G04 -AATTA----CGC-----AACC---GGCGCA---GGTT----TATTT
10%
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Conclusion
The multiplexed high throughput sequencing approach presented in this chapter 
has shown to be helpful in obtaining diversity indices of a large number of selection 
samples from eight distinct SELEX experiments. As is to be expected, diversity dropped 
during the course of selection, clearly demonstrated by the rarefaction analysis of 
the streptavidin SELEX experiments. In addition, community structure analysis of 
two elution methods, used for enriching streptavidin-binding oligonucleotides, 
showed that different oligonucleotides were enriched. Furthermore, the small scale 
comparison of two clone libraries, originating from these two distinct enrichment 
experiments, provided a clear indication that affinity elution methods specifically 
enrich for rapid binders. As a next step, representation of aptamer families throughout 
the selection process in the HiSeq2000 dataset should be explored in more detail, 
especially because we can relate a certain family type to kinetic behaviour for the 
streptavidin-binding aptamers. Possibly, newly developed high-throughput methods 
to identify sequence structures 94 could help us to zoom in on the point at which 
the slow binders take the defeat of the rapid binders, a turning point for the kind of 
properties that are beneficial for enrichment. 
Materials and methods
Hemoglobin bead preparation
Hemoglobin (Sigma, CAS: 9008-02-0) was biotinylated according to procedures and 
reagents provided in the EZ-Link Sulfo-NHS-LC-Biotinylation Kits (Thermo Fisher 
Scientific, Etten-Leur, The Netherlands). To 1.2 mg hemoglobin (in 2 ml PBS), 37 µl of a 
10 mM Sulfo-NHS-LC-Biotin was added and left rotating at RT for 1 hour. Uncoupled 
biotin was removed by using a Vivaspin 20 centrifugal filter with a 30 kDa cut-off 
(Sartorius), in three consecutive rounds of centrifugation (10–15 min, 4500 rpm 
at 4°C) and buffer addition. Coupling of biotin to hemoglobin was assessed using 
the HABA assay, provided with the biotinylation kit. Biotinylated hemoglobin was 
captured on streptavidin magnetic beads (Dynabeads® M-280, Invitrogen). Prior to 
capture, beads were washed three times with PBS. Beads were left to rotate at RT for 
1 hour after addition of biotinylated hemoglobin. 
SELEX samples
Samples from streptavidin thermal elution were derived from another SELEX 
experiment, described in chapter 3 247. Hemoglobin SELEX samples, both thermal 
and affinity elution, as well as streptavidin affinity elution samples were obtained 
for this work by methods exactly as described previously 247. For the affinity elution 
method, however, elution of bound oligonucleotides was done by using selection 
buffer containing 0.6 mg ml-1 hemoglobin or 0.6 mg ml-1 streptavidin, and subsequent 
incubation at room temperature for 15 min. A list of all samples is found in Table 6.1. 
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Samples 28–70, except for 63, were obtained from collaborators (Department of 
Environmental Biotechnology, Centre for Environmental Research Leipzig-Halle 
GmbH), and will not be discussed further in this chapter. 
Cloning, sequencing and structure analysis
DNA eluted in round four of streptavidin affinity elution selection was amplified, 
using unmodified primers AP10 and AP30, and ligated into pGEM®-T (Promega). 
Escherichia coli XL1-Blue cells (Stratagene) were transformed with the vector 
constructs, subsequently 96 colonies were randomly picked, and vector inserts were 
sequenced using the T7 forward primer (GATC Biotech, Konstanz, Germany). The DNA 
folding form of mfold 324 was used for secondary structure prediction with use of the 
default settings except for temperature (25°C) and ionic conditions: Na+ (100 mM) 
and Mg2+ (2 mM).
Barcodes for high throughput sequencing
Eight nucleotide error-correcting golay barcodes were selected in such a way that 
they were at a mutation distance 3. Of the resulting 727 barcodes, 70 barcodes were 
selected in such a way that the distribution of each nucleotide at each position is 
as close to 25% as possible in order to meet technical requirements of the Illumina 
HiSeq2000 protocols. Each barcode was assigned to one of 70 samples (see Table 6.1). 
The resulting 140 primers were obtained from Biolegio (Nijmegen). 
Equimolar mixture for high throughput sequencing
Samples 28–70 (except 63) were PCR amplified using unmodified AP10 and AP30 
or AP20 (65–70, agattgcacttactatct) primers in two PCR reactions of each 100 μl, 
containing 1 µl template, 1.9 mM MgCl2, 0.2 mM dNTPs each, 1 μM of each primer, 
1×Buffer B2, and four units HOT FIREPol (Solis BioDyne). The PCR program was as 
follows: 15 min at 95°C, 30 cycles of 30 s at 95°C, 30 s at 52°C, 1 min at 72°C, followed 
by 7 min at 72°C after the last cycle. Both reactions were pooled and subsequently 
purified using the GeneJET™ PCR Purification Kit (Fermentas), using the optional 
steps for molecules <500bp. 
Barcodes were added by PCR in three PCR reactions of each 100 μl, containing 
approximately 10 ng template, 1.9 mM MgCl2, 0.2 mM dNTPs each, 1 μM of each 
primer, 1×Buffer B2, and 4 Units HOT FIREPol (Solis BioDyne). The PCR program was 
as follows: 15 min at 95°C, 5 cycles of 30 s at 95°C, 30 s at 52°C, 1 min at 72°C, followed 
by 25 cycles of 30 s at 95°C, 30 s at 60°C, 1 min at 72°C followed by 7 min at 72°C 
after the last cycle. All three reactions were pooled and purified using the GeneJET™ 
PCR Purification Kit (Fermentas), using the optional steps for molecules <500bp. DNA 
was eluted in 50 µl MQ-water. 
DNA concentrations were measured on a Qubit fluorimeter (Invitrogen, Bleiswijk, 
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The Netherlands) using the Qubit® dsDNA BR Assay Kit (Invitrogen). Subsequently, 
equimolar amounts were pooled. To avoid pipetting of very small volumes, the 
calculations were done in such a way that 0.75 µl of the highest concentrated sample 
was added to the equimolar mixture. 
Multiplexed high throughput sequencing and data processing
The resulting equimolar mixture was concentrated in a speedvac prior to shipping 
to GATC Biotech (Konstanz, Germany) for sequencing. Tagged adapter sequences 
were added at GATC Biotech, in order to prepare the equimolar mix for paired end 
sequencing on a HiSeq 2000 (one lane). Sequences were sorted by tag, omitting 
those that contain one or more mismatches in the tag region from further analysis. 
Distribution of the reads is shown in Table 6.1. Tag-sorted data was further processed 
and analyzed using QIIME 28. Because de novo picking of Operational Taxonomic Units 
(OTU) is not feasible with such a large data set, a reference database was created and 
used for OTU picking. In the database only sequences were included that are present 
more than 100 times within the whole dataset. The resulting OTU table contains 7.923 
OTUs, representing a total of 49.863.130 sequence reads. This OTU table was used 
for subsequent diversity analysis (without assigning taxonomy or phylogenetic tree 
building). 
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Table 6.1: Sample information, sequence read distribution and read numbers used for analysis.
Sample Tag sequence
Pool 
(nt) Forward read Reverse read
Used in analysis % of reads used
For Rev For Rev
1
St
re
pt
av
id
in
Th
er
m
al
 e
lu
tio
n
St
ar
t r
nd
1 AACCAACG 100 874.261 920.984 4999 12232 0,57 1,33
2 2 AACCAGAA 100 1.037.658 1.124.556 5931 16226 0,57 1,44
3 3 AACCATGC 100 1.035.882 1.104.454 6207 15372 0,6 1,39
4 4 AACCGCCA 100 1.266.246 1.330.986 331132 369172 26,15 27,74
5 5 AACCGGTT 100 2.307.385 2.348.734 1721563 1880887 74,61 80,08
6 6 AACCTAGA 100 2.685.035 2.718.364 2187676 2312630 81,48 85,07
7 7 AACGAAGT 100 2.743.379 2.753.127 2247819 2390344 81,94 86,82
8 Elut 7 AACGACTA 100 3.136.441 3.154.407 2520478 2712633 80,36 86,94
9
St
re
pt
av
id
in
A
ffi
ni
ty
 e
lu
tio
n
St
ar
t r
nd
1 AAGAACCA 100 816.869 822.748 4162 10022 0,51 1,22
10 2 AAGAATGG 100 2.128.859 2.139.143 8376 19901 0,39 0,93
11 3 ACCAAGAT 100 937.413 857.049 9953 14150 1,06 1,65
12 4 ACCAGACC 100 1.788.445 1.715.084 1201850 1288774 67,2 75,14
13 5 ACGCTAAT 100 2.528.396 2.515.405 2067837 2195257 81,78 87,27
14 6 AGAACCGG 100 3.433.389 3.423.678 2633607 2892181 76,71 84,48
15 Elut 6 AGAACTCT 100 2.145.333 2.131.134 1771028 1852726 82,55 86,94
16
H
em
og
lo
bi
n
Th
er
m
al
 e
lu
tio
n
St
ar
t r
nd
1 AGAGGTCC 100 1.076.855 992.637 6745 12933 0,63 1,3
17 2 AGGTCGAA 100 1.267.505 1.178.806 6475 13403 0,51 1,14
18 3 ATTGCATT 100 1.060.307 883.472 6813 12627 0,64 1,43
19 4† CATAATTA 100 1.944.824 1.932.058 5080 16212 0,26 0,84
20 5 CATGATGC 100 1.708.233 1.656.882 5314 16034 0,31 0,97
21 6 CCAAGAGT 100 1.625.796 1.565.088 12049 23767 0,74 1,52
22 Elut 6 CCAGAGCG 100 1.339.154 1.306.730 21491 32484 1,6 2,49
23
H
em
og
lo
bi
n
A
ffi
ni
ty
 e
lu
tio
n
St
ar
t r
nd
1 CCAGCTGG 100 1.807.394 1.769.239 8223 19656 0,45 1,11
24 2 CCGGTTAG 100 1.840.722 1.787.755 6603 16894 0,36 0,94
25 3 CCTCCGGT 100 2.079.973 2.071.485 47893 63597 2,3 3,07
26 4 CCTCCTTG 100 1.408.784 1.390.268 65407 71192 4,64 5,12
27 Elut 4 CCTGCCAA 100 1.376.475 1.347.476 61450 67444 4,46 5,01
28
Sö
re
ns
 ta
rg
et
 1
Start 1 CGAAGCTG 76 347.246 326.677 1848 4660 0,53 1,43
29
En
d 
rn
d
3 CGTCCTCC 76 345.801 347.828 4770 9300 1,38 2,67
30 4 CGTCTGAG 76 378.425 381.974 18812 24940 4,97 6,53
31 5 CTAGTTGC 76 435.839 428.503 58493 72733 13,42 16,97
32 6 CTGCAATG 76 355.856 349.518 62596 75344 17,59 21,56
33 7 CTGCTGAA 76 561.194 550.698 133206 157601 23,74 28,62
34 8 CTGGATAA 76 525.082 503.704 162315 182925 30,91 36,32
35 9 CTTGGCCT 76 502.224 486.944 169806 192166 33,81 39,46
36 10 GAACCGTT 76 317.038 307.159 124549 135021 39,29 43,96
Table 6.1 continued on next page
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Sample Tag sequence
Pool 
(nt) Forward read Reverse read
Used in analysis % of reads used
For Rev For Rev
37
Sö
re
ns
 ta
rg
et
 2
En
d 
rn
d
2 GAACGCTG 76 299.104 285.497 1660 3731 0,55 1,31
38 3 GAATCATG 76 491.899 475.980 2599 6687 0,53 1,4
39 4 GATGGACC 76 222.241 208.059 2167 4851 0,98 2,33
40 5 GATTCCAG 76 405.535 422.321 15722 20899 3,88 4,95
41 6 GCATTGGT 76 424.129 432.667 76728 86515 18,09 20
42 7 GCCATGCC 76 304.279 290.145 83371 88677 27,4 30,56
43 8 GCTTGATG 76 486.752 488.432 277400 292706 56,99 59,93
44 9 GGCAGCCG 76 67.572 53.781 27143 20738 40,17 38,56
45 10 GGCTTGAA 76 329.567 338.577 202698 206295 61,5 60,93
46 11 GGTAACGC 76 164.090 147.767 97545 91297 59,45 61,78
47 12 GGTCGGCG 76 207.560 213.174 113768 123197 54,81 57,79
48 13 GGTTCAGC 76 361.445 361.865 240894 252782 66,65 69,86
49
Sö
re
ns
 ta
rg
et
 3
En
d 
rn
d
1 GTATCTGA 76 421.927 386.178 1887 4912 0,45 1,27
50 2 GTATTCTC 76 458.182 413.134 2899 6623 0,63 1,6
51 3 GTCATCTA 76 395.176 345.992 2439 5173 0,62 1,5
52 4 GTCTTGGC 76 450.350 416.149 2693 5143 0,6 1,24
53 5 GTTAAGTT 76 521.085 464.094 6535 9941 1,25 2,14
54 6 TAACGTCG 76 630.440 651.833 17881 27950 2,84 4,29
55 7 TCAGTTAA 76 718.189 758.279 29760 46263 4,14 6,1
56 8 TCGGTCAT 76 510.011 549.094 26848 40270 5,26 7,33
57 9 TCGTTCGA 76 518.197 545.801 43235 60089 8,34 11,01
58 10 TCTTATAT 76 590.943 667.692 50996 73218 8,63 10,97
59 11 TGCGGACT 76 460.134 458.023 62823 84224 13,65 18,39
60 12 TGGACCAT 76 606.732 627.486 110205 146180 18,16 23,3
61 13 TGGCGTTA 76 386.141 392.634 52738 70222 13,66 17,88
62 14 TGGTAATT 76 464.450 507.065 47980 65569 10,33 12,93
63 Control 1 ‡ TGGTTGAC 100 2.998.366 3.028.812 2255501 2722832 75,22 89,9
64 Control 2 § TTAGGATG 76 654.441 653.731 478699 582387 73,15 89,09
65
St
ol
te
nb
ur
g 
ta
rg
et
 1
En
d 
rn
d
8 TTATCGTC 76 482.902 496.709 282350 362336 58,47 72,95
66 9† TTCTGAAC 76 587.991 588.874 328907 412315 55,94 70,02
67 10† TTGAGACC 76 435.779 428.292 216286 271648 49,63 63,43
68 11҂ TTGATCCA 76 542.430 529.515 279369 336267 51,5 63,5
69 12҂ TTGGCAGA 76 484.700 482.071 246744 307636 50,91 63,82
70 13ϩ TTGGCTCC 76 380.577 375.618 184456 234635 48,47 62,47
Unassigned 15.878.191 16.401.130
Total used: 49863130
† = Negative selection step (StrepBeads)
‡ = acagatcgagggcagcgatagctgggctaataaggttagccccatcggtcctggacttgggact
§ = ggagccgaactgtctgagtagtgttgacattcttctacgt
҂ = Negative selection step (EA-TosylBeads) + subtraction Step (EA-TosylBeads) after elution EA = ethanolamine
ϩ = Negative selection step (EA-TosylBeads)
Table 6.1 continued
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Abstract
Proteins that recognize and bind specific sites in DNA are essential for regulation of 
numerous biological functions. Such proteins often require a negative supercoiled 
DNA topology in order to function correctly. In current research, short linear DNA 
is often used to study DNA-protein interactions. Although linear DNA can easily be 
modified, for capture on a surface, its relaxed topology does not accurately resemble 
the natural situation in which DNA is generally negatively supercoiled. Moreover, 
specific binding sequences are flanked by large stretches of non-target sequence in 
vivo. Here we present a straightforward method for capturing negatively supercoiled 
plasmid DNA on a streptavidin surface. It relies on the formation of a temporary 
parallel triplex, using a triple helix forming oligonucleotide containing Locked Nucleic 
Acid (LNA) nucleotides. All materials required for this method are commercially 
available. Lac repressor binding to its operator was used as model system. Although 
the dissociation constants for both the linear and plasmid-based operator are in 
the range of 4 nM, the association and dissociation rates of Lac repressor binding 
to the plasmid-based operator are ~18 times slower than on a linear fragment. 
This difference underscores the importance of using a physiologically relevant DNA 
topology for studying DNA-protein interactions.
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Introduction
Proteins that recognize and bind specific sites in DNA are essential for controlling a 
wide range of biological functions at the level of DNA replication 65, 66, regulation of 
gene expression 267, homologous recombination 97 and various other processes. In turn, 
proteins involved in such processes often require a negative supercoiled (nSC) DNA 
topology in order to function correctly 4. Recently, it was also shown that an nSC DNA 
topology is also required for the specific DNA binding of Cascade, a protein complex 
involved in the prokaryotic CRISPR-Cas immune system 300. Given the importance of 
DNA topology, it is not surprising that a lot of effort is made to maintain a correct 
DNA topology in vivo 13, 295. 
Proteins that bind specific sites in DNA also face the challenge of finding their 
specific binding site amongst megabases of non-target DNA. A combination of 1D 
diffusion (sliding) along the DNA and 3D diffusion (hopping) in the cytoplasm 85 can 
lead to more rapid targeting, according to the facilitated diffusion model 11, 12, 237. 
Intersegmental transfer can also play a role, however, this is only relevant for proteins 
containing two distinct DNA binding sites such as for instance the Lac repressor and 
Cre recombinase 84, 249.
DNA-protein interactions can be studied using a variety of techniques, amongst 
others single-molecule techniques such as total internal reflection fluorescent 
microscopy (TIRF) 277 and surface plasmon resonance (SPR) 164. Especially in SPR 
experiments, short linear target DNA is often used to study the kinetics of DNA-protein 
interactions. Short linear target DNA is convenient for SPR analysis, because the 3’ 
or 5’ ends are easily biotinylated, which allows for stable capturing on a streptavidin 
surface. However, such linear targets do not accurately mimic the natural situation, 
in which an nSC DNA topology prevails and where non-target DNA is much more 
abundant than specific binding sites. This might give rise to distortions in the data. 
In that respect, attaching nSC plasmid DNA, containing a specific binding site, 
would be more appropriate to use in SPR experiments. The lack of 3’ or 5’ ends, 
however, makes it not straightforward to attach plasmid DNA to a surface. In the 
present study, we aimed to create an irreversible topological link between an nSC 
plasmid and a biotinylated triplex-forming oligonucleotide (TFO), which results in 
a padlock-modified plasmid, or catenane, that can be captured on a surface. The 
production of padlock-modified plasmids has previously been described for sequence 
specific labelling double-stranded DNA 59, 72, 242, in order to form such a complex with 
a good yield, a stable triple helix must be formed. 
DNA triplex formation requires stretches of homo-purines (A, G) in one strand and 
homo-pyrimidines (C, T) on the opposite strand of the double stranded target DNA 56. 
Generally, two classes of triplexes can be distinguished, according to the orientation 
and composition of the third strand: pyrimidine-rich third strands bind parallel to the 
purine strand of the duplex and form T·AT and C+·GC triplets; alternatively, purine-rich 
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third strands bind antiparallel to the purine strand of the duplex and form G·GC, 
A·AT and T·AT triplets (in A·BC, BC indicates the natural base pair and A the third 
strand) 81. Parallel triplexes only form at low pH, because protonation of the third 
strand cytosine (C+) is required, whereas formation of anti-parallel triplexes is pH 
independent. Previous studies involving padlock-modified plasmids have mostly 
relied on the formation of very stable antiparallel triplexes, formed in the presence 
of a DNA intercalator that is not commercially available 242. However, incorporation of 
locked nucleic acids (LNAs) in the pyrimidine third strand of parallel triplexes improves 
triplex stability and can alleviate the requirement for a low pH to some extent 274. 
Here, we present a facile method for capturing of plasmid DNA on a streptavidin 
surface. A DNA triplex is formed by addition of an LNA-modified pyrimidine-rich 
biotinylated TFO, which is subsequently self-ligated in order to create a padlock-
modified plasmid, or catenane. The Lac repressor has been mutated to exist as a dimer 
(not a tetramer) that interacts with only one DNA binding site (operator). Plasmids 
with and without specific Lac repressor operator sequences are used as a model to 
demonstrate the relevance of this approach in SPR experiments. We observed different 
binding kinetics to the supercoiled plasmid-based operator compared with a short 
linear operator. This approach therefore represents a helpful tool to study protein-
DNA interactions using a DNA substrate with a physiologically relevant topology. 
Results
Strategy and design 
In the present study we aimed to develop a method for capturing plasmid DNA, 
which would allow the use of DNA with a physiologically relevant topology in SPR 
experiments, and in other experiments that require target immobilization. To allow 
the approach to be generally applicable, it should be straightforward and easily 
achievable with general molecular biological techniques and commercially available 
reagents. A general outline of the method is shown in Figure 7.1A. A newly designed 
target site for triple helix formation was inserted in our plasmid of interest. We have 
adopted a parallel triplex design (Figure 7.1B) for two main reasons. First, it does not 
require stabilizing molecules that are not commercially available 242; for stabilization 
of the triplex, and to alleviate the requirement for a very low pH for triplex formation, 
the triplex-forming part of the TFO contains alternating LNA Thymine and DNA 
Cytosine 274. Second, and inherently related to a parallel triplex, artifacts arising from 
the presence of a triplex are possibly avoided, at least at neutral pH, because parallel 
triplexes only form at low pH and are generally expected to dissociate at neutral pH. 
After addition of the closing probe, the TFO is circularized and a topological bond 
is introduced between the circular TFO and the plasmid. At this stage, the triple 
helical structure could be disrupted, as it is not required for plasmid capture anymore. 
In additional experiments, padlock-modified plasmids were digested with DraI. The 
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plasmids contain two DraI sites, one of which overlaps with the THS (Figure 7.1B). One 
of these sites is therefore not accessible if a triplex is formed, and hence the plasmid 
will only be linearized. The results suggest that in 40–50% of the analyzed padlock-
modified plasmids the triplex is not fully dissociated at neutral pH (Supplementary 
Methods and Figure S7.1), most likely due to the length of the triplex and because the 
TFO is heavily modified. The THS is located between the ampicillin resistance gene 
and the origin of replication; hence, is it located at great distance of the operator 
sequence, and therefore we expect the triplex not to intervene with Lac repressor 
binding. However, the triplex could be shortened, should the presence of the triplex 
intervene with the study of other binding events.
Binding affinity of Lac repressor
After padlock-modified plasmids were captured on a SA SPR chip, we performed 
subsequent measurements showing that Lac repressor specifically interacts with 
these immobilized plasmids. This confirms that the production and capture of 
padlock-modified plasmids was successful. Double referenced SPR data of Lac 
repressor binding to both padlock-modified plasmids was fitted with a simple 1:1 
binding model (Figure 7.2A), yielding an overall dissociation constant (KD) of 337 nM 
Figure 7.1: Padlock-modified plasmids. A) General procedure to prepare a padlock-modified plasmid, see 
materials and methods for details. The triplex (dashed lines) only exists at low pH and dissociates at neutral pH. 
B indicates a biotin dT, 5’P indicates a 5’ Phosphate. B) The Triple Helix Site (THS) that is inserted in the vector 
forms a parallel triplex together with TFO2.0 . Regular Watson-Crick base pairs are indicated by “-”, triplex bonds 
(Hoogsteen interactions) by “·”. The DraI site is highlighted by a box, “z” indicates LNA thymine, “x” indicates 
biotin dT. C) Two interactions take place on pPAD-ΔO3, a non-specific interaction with plasmid DNA (marked by 
ka1 and kd1), and a specific interaction with the operator sequence (marked by ka2 and kd2).
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for pPAD-ΔO1ΔO3 (not containing an operator) and 155 nM for pPAD-ΔO3 (containing 
operator 1) (Figure 7.2B). Fits shown in Figure 7.2A nicely follow the association and 
equilibrium phase, fits shown in Figure 7.2B are not matching the data as nicely, 
although this is to be expected (discussed later in the text). In addition, microscale 
thermophoresis (MST) measurements, using the same plasmids, yield dissociation 
constants in the same range as SPR measurements; 147 nM for pPAD-ΔO1ΔO3, and 
188 nM for pPAD-ΔO3 (Table 7.1, Figure S7.2A and B). 
Double referenced data of Lac repressor binding to linear O1 DNA was fitted 
with a 1:1 model that takes mass transport limitation into account 192 and resulted in 
 
Figure 7.2: SPR data and fits. Double referenced data of replicate injections (gray) and fits to it (black). A) 
1:1 fit to pPAD-ΔO1ΔO3, B) 1:1 fit to pPAD-ΔO3, C) 1:1 fit with mass transfer limitation to linear O1 DNA, D) 
Heterogeneous fit to pPAD-ΔO3, assuming fixed values for ka1 and kd1. Resulting values for the dissociation 
constants and kinetic rate constants are summarized in Table 7.1.
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Table 7.1: Kinetic parameters for the interaction of Lac repressor with the various DNA targets. Including 
those found by Bondeson et al. 19. Values in bold refer to interactions with operator DNA, Values in italics indicate 
those that were fixed during fitting with the heterogeneous model.
Target DNA SPR MST EMSA
Fit model ka1 (×105 M-1 s-1)
kd1 
(×10-2 s-1)
KD1 
(nM)
ka2
(×104 M-1 s-1)
kd2 
(×10-4 s-1)
KD2 
(nM)
KD 
(nM)
KD 
(nM)
Linear O1 DNA Mass transfer 12 0.48 3.9 4.5
pPAD-ΔO1ΔO3 1:1 1.55 5.2 337 147
pPAD-ΔO3 1:1 1.09 1.7 155 188
pPAD-ΔO3 Heterogen 1.55 5.2 337 6.8 2.7 4.0
Linear O1 DNA n.a. 18 0.034 0.2 4.2 
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a dissociation constant of 3.9 nM (Figure 7.2C), whereas a dissociation constant of 
4.5 nM was obtained using MST (Table 7.1, Figure S7.2C). The association rate constant 
(ka) as well as the dissociation constant (KD) are well in range with values determined 
earlier 19 (Table 7.1). Despite the high flow rate used during SPR measurements, 
mass transport effects are to be expected because of the high association rate of 
Lac repressor 85; together with the somewhat high ligand density, this feature could 
account for the deviation between fit and actual data. Affinity data, together with all 
association rate constants (ka) and dissociation rate constants (kd), are presented in 
Table 7.1. These values show that different methods yield similar affinities and that 
there are differences in the affinity of Lac repressor binding to both padlock-modified 
plasmids; this is to be expected because one of these plasmids contains a specific 
binding site.
Heterogeneous binding kinetics of Lac repressor
Kinetic parameters for the interaction of Lac repressor with the plasmid-based operator, 
were derived by fitting the binding curves of pPAD-ΔO3 with a model that assumes 
a heterogeneous ligand (plasmid), and that the analyte (A, Lac repressor) can bind 
independently to two ligand sites, specifically to the operator (C) and non-specifically 
to the rest of the plasmid (B) (Figure 7.1C): 
Equation 7.1A A + B
ka1
⇄
kd1
AB 
Equation 7.1B A + C
ka2
⇄
kd2
AC 
The kinetic parameters for the non-target interaction (ka1 = 1.55×10
5 M-1 s-1 
and kd1 = 0.052 s
-1) were derived from the interaction of Lac repressor with the 
pPAD-ΔO1ΔO3 plasmid and are considered to be similar for both plasmids. Hence 
these values were taken into account during fitting of the data, yielding a dissociation 
constant of 4.0 nM for the interaction of Lac repressor with the plasmid-based 
operator. Fits according to the heterogeneous model are shown in Figure 7.2D. This 
fit is much better than the fit with a 1:1 binding model as shown in Figure 7.2B. The 
association and dissociation rate constants for the specific interaction of Lac repressor 
with the plasmid based operator (ka2 = 6.81×10
4 M-1 s-1 and kd2 = 2.74×10
-4 s-1) are 
~18 times slower in comparison with those obtained for the interaction with linear 
O1 DNA, while the dissociation constants are equal (Table 7.1). 
Discussion
In this work, we present a straightforward approach to capture plasmid DNA on 
a streptavidin surface, and we demonstrate its usefulness by characterizing the 
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interaction between Lac repressor and plasmid DNA. Our strategy requires the 
insertion of a target site for triple helix formation in the plasmid of interest. Next to a 
pUC plasmid, this insertion can be performed in many other commercially available 
vectors, which also contain the targeted region (see Table 7.2). Further steps are also 
easy to implement, making our design a generally applicable method for plasmid 
capture. 
Short linear target DNA is often used to study DNA-protein interactions. However, 
this does not accurately reflect the natural configuration of DNA, because DNA 
topology as well as non-target DNA are important factors contributing to binding 
affinity. Moreover, DNA topology has a direct influence on the interaction between 
DNA and many DNA-binding proteins, as exemplified by the supercoiling-dependent 
DNA binding of Cascade 300. This is also demonstrated by the binding of DnaA to the 
origin of replication (oriC) on the Escherichia coli genome: this complex is more stable 
if oriC has an nSC topology 65, 66. In addition, it has been shown that promoters can 
be stimulated or inhibited by increased negative supercoiling 267, most likely related 
to the binding efficiency of the RNA polymerase complex. 
Here we have selected the E. coli Lac repressor as a model system, because this 
protein and the three operators it can bind are well studied 154, 184, 205. It has been 
shown that supercoiling has an effect on the dissociation of Lac repressor-operator 
complexes 57, 301 and on Lac repressor-mediated DNA looping 201; however, the proteins 
used in these studies were all naturally occurring tetramers. 
Specifically, the interaction of Lac repressor with O1 has been studied in great 
detail, and remarkably high association rates have been reported based on equilibrium 
methods, spanning the range between 1×108 –1×1010 M
-1 s-1 76, 238. It is, however, 
more relevant to compare our results to those obtained in a previous SPR analysis 
of this interaction 19, in which the following kinetic parameters were determined, a 
ka of 1.8×10
6 M-1 s-1, a kd of 3.4×10
-4 s-1 and a KD of 0.2 nM. In the latter study, the 
dissociation constant was also determined using an electrophoretic mobility shift 
assay: a KD of 4.2 nM. This number is well in range with the values we find, using SPR 
(3.9 nM and 4.0 nM) and MST (4.5 nM). The major difference between both studies 
is that Bondeson et al. 19 used a wild type (tetrameric) Lac repressor, which can bind 
two operators at the same time, whereas we used a mutated (dimeric) Lac repressor 
that can bind only one operator at the same time. In general, the presence of multiple 
binding sites is disadvantageous for SPR analysis; it could give rise to avidity effects 
and substantial rebinding, which results in a higher apparent affinity 189. This explains 
why our dissociation rate from the linear O1 DNA (4.8×10-3 s-1) is substantially higher, 
and hence results in a lower affinity (3.9 nM). 
The affinities for interaction with the captured plasmids are considerably lower 
when compared with the linear target DNA, but Lac repressor still binds with 
nanomolar affinity to the plasmids. Binding curves of both captured plasmids were 
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initially fitted to a 1:1 binding model. A comparison of these 1:1 fits already shows 
differences between both plasmids; association rates are in the same range, but 
the dissociation from the pPAD-ΔO3 plasmid appears to be three times slower. The 
higher affinity interaction with the pPAD-ΔO3 plasmid, is in line with the fact that a 
specific binding site (operator 1) is present on this plasmid. Affinity values obtained 
using MST are in the same nanomolar range. They do not follow the trend that the 
affinity for pPAD-ΔO3 is higher than for pPAD-ΔO1ΔO3. For MST to be accurate, it 
is essential that the DNA concentrations are precisely known, however, in the course 
of this project it has proven difficult to accurately measure concentrations of highly 
concentrated, and hence viscous, DNA preparations. We believe this to be the origin 
of the discrepancy between these values.
Although previously fitted with a 1:1 binding model, binding of Lac repressor to 
the pPAD-ΔO3 plasmid should actually be considered as a heterogeneous event. Lac 
repressor can independently bind to either non-target DNA or operator DNA. We 
fitted the pPAD-ΔO3 binding data with a model for heterogeneous binding, in order 
to obtain the kinetic parameters for the secondary, specific, interaction. To do so, we 
assumed the kinetic parameters for the non-target interaction to be similar for both 
plasmids and used these as known variables for ka1 and kd1. As such we found a KD2 of 
4.0 nM for the interaction between Lac repressor and its plasmid-based operator. 
This is remarkably close to the values we found using SPR (3.9 nM) and MST (4.5 nM) 
(Table 7.1). Interestingly, the actual kinetics are widely different for the interactions 
of Lac repressor with the plasmid operator and linear O1 DNA. Both the association 
and dissociation rates are ~18 times slower for binding to the plasmid operator, 
indicating that the presence of negative supercoiling and non-target DNA indeed has 
a considerable effect on the actual kinetics of binding. 
Conclusion
In the work presented here, we demonstrate the feasibility and usefulness of a newly 
developed plasmid capture approach, by applying it for the characterization of Lac 
repressor binding. To our knowledge, this is the first time that SPR has been used to 
determine the affinity and kinetic parameters of the interaction between a protein 
and its specific target sequence, which is located on a supercoiled plasmid. We believe 
this to be a versatile approach that could be useful in SPR, single molecule and other 
experiments, to expand the range of substrates for DNA-protein interactions beyond 
the use of short linear target DNA. In addition, the biotin in TFO2.0 could be replaced 
by other functionalities, such as fluorophores, and thus will enable studies requiring 
plasmid visualization. The use of padlock-modified plasmids provides a useful 
addition to the molecular biology toolbox, and may be used to uncover properties of 
supercoiling dependent proteins, that could not be studied before. 
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Materials and methods
Oligonucleotides
All oligonucleotides used in this study, except for TFO2.0, were obtained from Sigma 
and ordered without any special requirements. TFO2.0 was ordered from Eurogentec 
and PAGE-purified by the manufacturer. Details on all oligonucleotides and their 
sequences are given in Table 7.2. 
Cloning of Lac repressor coding sequence
The first 331 residues of the coding sequence of Lac repressor, hence excluding the 
C-terminal tetramerization domain (residues 340–357), were PCR amplified from a 
pCDF-1b plasmid. The coding sequence was amplified in 3×100 µl PCR, containing 
15 ng of template DNA, 0.2 mM of each dNTP, 0.2 mM of primers BG3874 and BG3917 
(containing a HRV3C site and an 8×His-tag), 1×Buffer HF and 3 Units Phusion II 
(Finnzymes). The PCR program was as follows: 30 s at 98°C, 5 cycles of 10 s at 98°C, 
20 s at 60°C, 60 s at 72°C, 25 cycles of 10 s at 98°C, 20 s at 70°C, 60 s at 72°C, followed 
by 5 min at 72°C after the last cycle. Purified PCR product and destination vector, 
pWUR533, were subsequently digested with NcoI and SacI restriction enzymes. Both 
fragments were ligated together and the resulting plasmid (pWUR533-LacI) was 
transformed to the Escherichia coli strain XL1-blue for plasmid propagation. 
Expression of recombinant Lac repressor
The pWUR533-LacI plasmid was transformed to E. coli BL21(DE3) pSJS1244 for protein 
expression. Fresh LB medium, containing ampicillin (final concentration: 100 µg ml-1) 
and spectinomycin (final concentration: 50 µg ml-1), was inoculated with 1% overnight 
Table 7.2: Oligo sequences used in this study. 
Purpose Modification
BG3534† THS insertion cttttctacggggtctgacgtttaaagagagagagagagaaacacgttaagggattttggtca
BG3535† THS insertion tgaccaaaatcccttaacgtgtttctctctctctctctttaaacgtcagaccccgtagaaaag
Targeted region cttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtca
BG3554 THS sequencing gctgaagccagttaccttcg
TFO2.0 Eurogentech 
(PAGE purified)
5’-phosphate 
X=Biotin dT, Z=LNA T
cctaggctcgaggxgcacttztzczczczczczczcztzttttcgatcgcagctggcatgc
BG3812 Closing probe  cgagcctagggcatgccagctg
BG3874 Cloning Lac repressor gatccatgggcaaaccagtaacgttatacgatgtcg
BG3917 Cloning Lac repressor HRV3C site and an 8x 
His-tag
ggtgagctcttagtggtggtgatggtgatgatggtgagcggagggtccctgaaagaggac
ttcaagcgccagggtggtttttc
BG3962 ΔO1ΔO3 aagccatggtcacacaggaaacagctatgac
BG3963 ΔO3 / ΔO1ΔO3 aagccatggcgctttccagtcgggaa
BG3964 ΔO3 aagccatggaatgtgagttagctcactcattagg
BG4162 Linear O1 S 5’-biotin tgtgtggaattgtgagcggataacaatttcacaca
BG4163 Linear O1 A tgtgtgaaattgttatccgctcacaattccacaca
† Underlined is the Triple Helix Site, the DraI site in Italics.
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culture. Protein expression was induced three hours later by adding isopropyl-β-D-
thiogalactopyranoside (IPTG), to a final concentration of 1 mM. After another three 
hours, cells were harvested by centrifugation. Cell pellets were either processed 
immediately, or stored at -20°C until further processing.
Purification of recombinant Lac repressor
Cell pellets were resuspended in 150 mM NaCl and 10 mM HEPES (pH 7.4) and 
subsequently lysed using a French press. Clarified cell free extract was passed through 
a 0.45 µm filter before incubation with HIS-Select® Nickel affinity gel (Sigma-Aldrich) 
which was equilibrated with water (3 ml) and 3 column volumes wash buffer [50 mM 
sodium phosphate buffer (pH 8.0) with 0.3 M sodium chloride and 5 mM imidazole]. 
After incubation, the column material was washed three times with four column 
volumes wash buffer. Bound protein was eluted in fractions of 2 column volumes 
using elution buffer [50 mM sodium phosphate buffer (pH 8.0) with 0.3 M sodium 
chloride and 250 mM imidazole]. Eluted protein was further purified on a Superdex 
200 column (GE Heathcare), using 150 mM NaCl and 10 mM HEPES (pH 7.4) as running 
buffer; peak fractions corresponding to the dimer protein were collected and used for 
SPR and MST measurements. 
Insertion of a Triple Helix Site in pUC19
A purine rich Triple Helix Site (THS, 19 bp), required for triple helix formation, was 
inserted between the ampicillin resistance gene and the origin of replication in a 
pUC19 vector. To do so, 25 ng plasmid was amplified in 50 µl using 0.2 mM dNTPs 
each, 125 ng of primers BG3534 and BG3535, 1×Buffer HF and 1 Unit Phusion II 
(Finnzymes). The PCR program was as follows: 90 s at 98°C, 18 cycles of 10 s at 98°C, 30 
s at 58°C, 80 s at 72°C, followed by 7 min at 72°C after the last cycle. After PCR, 10 units 
of DpnI (Fermentas) was added directly to the PCR reaction mixture, for degradation 
of template DNA, and left at 37°C for 2 h. The resulting plasmid (pUC19-THS) was 
transformed to chemical competent E. coli DH5α. Insertion of the THS was confirmed 
by restriction analysis (using DraI) and sequencing (GATC, Constance, Germany) using 
primer BG3554. 
Removal of lac operator sequences
The two lac operator sequences in pUC19-THS, operator 1 (aattgtgagcggataacaatt) 
and operator 3 (ggcagtgagcgcaacgcaatt), were removed to yield two plasmids. The 
pPAD-ΔO3 plasmid only contains operator 1, whereas pPAD-ΔO1ΔO3 contains no 
operator at all. The operator sequences were removed by PCR amplification of the 
whole plasmid, except for the operator region, using primers BG3963 and BG3964 
for ΔO3, and BG3962 and BG3963 for ΔO1ΔO3. Plasmid, 35 ng, was amplified in 
100 µl using 0.2 mM dNTPs each, 0.2 mM of each primer, 1×Buffer HF and 1 Unit 
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Phusion II (Finnzymes). The PCR program was as follows: 60 s at 98°C, 5 cycles of 10 s 
at 98°C, 10 s at 60°C, 1 min at 72°C, followed by 25 cycles of 10 s at 98°C, 10 s at 70°C, 
1 min at 72°C followed by 7 min at 72°C after the last cycle. Purified PCR product 
was digested with 10 units of DpnI and NcoI and left at 37°C for 2 h. Fragments 
were ligated and transformed to electro competent E. coli XL1-blue cells. Successful 
removal of the operator sequences was confirmed by sequencing (GATC, Constance, 
Germany) using the standard M13-F primer.
Padlock formation
For padlock formation, approximately 50 nM plasmid (use of more plasmid should 
be prevented, as this could result in lower yields because of molecular crowding) 
was mixed with 1 µM TFO2.0, acid buffer (20 mM MgCl2 and 20 mM ammonium 
acetate pH 5) was added to a total volume of 10 µl; low pH is needed to protonate 
cytosine on the third strand 72, 81, which is required in this approach. Plasmid and TFO 
were heated to 80°C and cooled down to 20°C at a rate of -1°C min-1 in a G-Storm 
GS1 thermocycler (start at 80°C for 30 s, then step-wise decrease to 20°C, in 350 
subsequent steps in which the temperature drops with 0.17°C and stays stable for 8 s). 
When at 20°C, 2 µM closing probe (BG3812) was added, followed by 1.5 µl 10×T4 
DNA ligase buffer (Fermentas), 1 µl of a 5 mM ATP solution and 5 Units (1 µl) of T4 
DNA ligase (Fermentas). The mixture was incubated overnight at room temperature. 
Padlock-modified plasmids were purified from a 0.8% agarose gel (Fermentas Kit) in 
order to remove excess TFO and closing probe, before capturing them on a Biacore 
SA chip. To yield enough padlock-modified plasmid for capture, padlock formation 
was routinely performed in three parallel reactions, only to be pooled during the gel 
purification procedure.
Surface Plasmon Resonance measurements
Experiments were performed in a Biacore 3000 system (BIACORE, Uppsala, Sweden) 
at a constant temperature of 25°C, using 10 mM HEPES at pH 7.4, and 150 mM NaCl 
as running buffer. Padlock-modified plasmids were captured on an SA chip at a flow 
of 5 µl min-1, pPAD-ΔO3 to a response of 140 RU, and pPAD-ΔO1ΔO3 to a response 
of 80 RU. An empty channel served as reference surface. For the padlock-modified 
plasmids, kinetic measurements were performed by injecting 20 µl Lac repressor at 
a flow of 10 µl min-1, using the kinject command, followed by a 5 min dissociation 
phase. In total, seven concentrations (2650, 883, 294, 98, 33, 11 and 4 nM) were 
injected twice. 
Linear Operator 1 (O1) DNA, prepared by hybridizing BG4162 and BG4163, was 
captured on another SA chip to 334 RU. Kinetic measurements were performed by 
injecting 90 µl Lac repressor at a flow of 90 µl min-1, using the kinject command, 
followed by a 5 min dissociation phase. An empty channel served as reference 
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surface. In total, six concentrations (577, 192, 64, 21, 7 and 2 nM) were injected twice. 
Data were processed using Scrubber (BioLogic Software, Campbell, Australia), and 
double referenced data were analyzed using BIAevaluation software provided with 
the Biacore. 
Microscale Thermophoresis (MST)
Plasmids for MST measurements were purified from 100 ml of overnight cultures, 
using a Jetstar 2.0 maxiprep kit (Genomed). The obtained pellet was re-suspended in 
50 µl milli-Q water; DNA concentrations were calculated from gel, by comparing peak 
intensities of linearized plasmid and the 3000 bp band of a marker (1 kb, Fermentas). 
Purified Lac repressor was labelled using a protein labelling kit, L003 Monolith™ 
(NanoTemper. München, Germany). MST measurements were performed in standard 
capillaries on a Monolith NT.115 machine, using 5% LASER power and 40% LED power. 
DNA concentrations were varied, while keeping the protein concentration constant 
at 25 nM. Protein was diluted to 50 nM in buffer (20 mM HEPES at pH 7.4, 300 mM 
NaCl,) and subsequently mixed in a 1:1 ratio with dilutions of DNA (in milli-Q). Data 
were analyzed using the software provided with the Monolith NT.115 (NanoTemper. 
München, Germany).
Acknowledgements
The authors wish to thank Intan Taufik (Groningen Biomolecular Sciences and 
Biotechnological Institute and Molecular Microbiology, Groningen) for help with MST 
measurements and Mitch Lewis (University of Pennsylvania) for helpful discussions on 
recombinant expression of Lac repressor. 
Funding
This work was supported by a grant from the Netherlands Organization for Scientific 
Research and the Netherlands Institute for Space Research (ALW-GO-PL/08-08) and 
by an NWO Vidi grant to SJJB (864.11.005).
118
Chapter 7
Supplementary information
Materials and methods
Removal of two DraI sites from pPAD-ΔO1ΔO3 and pPAD-ΔO3
Two DraI sites were removed to simplify restriction analysis. To do so, 25 ng plasmid 
was amplified in 50 µl using 0.2 mM dNTPs each, 125 ng of primers BG4394 
(cctagatccttttCaattaaaaatgaagttttCaatcaatctaaag, changed nucleotides are in 
capitals) and BG4395 (ctttagattgattGaaaacttcatttttaattGaaaaggatctagg), 1×Buffer HF 
and 1 Unit Phusion II (Finnzymes). The PCR program was as follows: 90 s at 98°C, 
16 cycles of 10 s at 98°C, 30 s at 58°C, 60 s at 72°C, followed by 7 min at 72°C after 
the last cycle. After PCR, 10 units of DpnI (Fermentas) was added directly to the PCR 
reaction mixture, for degradation of template DNA, and left at 37°C for 2 h. The 
resulting plasmids were transformed to chemical competent E. coli DH5α. Removal 
of both DraI sites was confirmed by restriction analysis (using DraI) and sequencing 
(GATC, Constance, Germany) using primer BG3554. 
Triplex restriction analysis
Padlocks for triplex restriction analysis were prepared as described in the main text, 
using five parallel reactions of each plasmid. After gel purification, padlocks were 
incubated with streptavidin coated magnetic beads (Invitrogen) for 45 min at RT under 
gentile rotation to prevent settling of the beads. Subsequently, beads were washed 
several times to remove unbound plasmid/padlock. Beads were used as template for 
restriction analysis, incubation was 45 min at 37°C for 45 min under gentile rotation 
to prevent settling of the beads. Enzymes were heat inactivated by incubation at 65°C 
for 20 min and run on gel (stained with SYBR-gold).
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     M             1              2               3              4              5              6              7
2000
1500
1000
750
M. Marker
1. Padlock pPAD-ΔO1ΔO3 + DraI
2. pPAD-ΔO1ΔO3 + DraI Expected: 1795 + 788 bp
3. pPAD-ΔO1ΔO3 + NcoI Expected: 2583 bp
4. Padlock pPAD-ΔO3 + DraI
5. Beads + pPAD-ΔO3 +DraI Expected: 1902 + 788 bp
6. pPAD-ΔO3 + DraI Expected: 1902 + 788 bp
7. pPAD-ΔO3 + NcoI Expected: 2690 bp
Figure S7.1: Triplex restriction analysis. Arrows indicate linearized vector, its presence 
shows that one DraI restriction site is not accessible, suggesting that a triplex is still present 
in 40–50% of the analyzed padlock plasmids. The two lower bands are products yielded 
after double digestion of the vector. 
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Figure S7.2: Microscale thermophoresis data. Curves fitted through the data points are shown as well. 
A) pPAD-ΔO1ΔO3, B) pPAD-ΔO3, C) Linear O1 DNA.
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Summary 
This thesis focuses on the selection and characterization of DNA aptamers and 
the various aspects related to their selection from large pools of randomized 
oligonucleotides. Aptamers are affinity tools that can specifically recognize and bind 
predefined target molecules; this ability, however, is not exclusively associated with 
aptamers. Antibodies are the most successful affinity tools used today, but alternative 
affinity tools such as aptamers, engineered binding proteins and molecular imprinted 
polymers are emerging as sound alternatives. A comparison of their properties is 
described in Chapter 1. The strength and specificity of the interaction between an 
affinity tool and its target molecule is an important feature. Generally, an affinity 
tool should have a high affinity for its target and should be highly specific in order 
to be useful for research or commercial purposes. One highly advanced method to 
characterize the interaction between an affinity tool and its target molecule makes 
use of a Surface Plasmon Resonance (SPR)-based biosensor. Although SPR is an 
optical phenomenon, in depth knowledge of the physics behind this phenomenon is 
not required to operate an SPR-based biosensor. Experiments should be performed 
in a correct way, and therefore it is important to understand how experimental 
parameters, such as flow rate, ligand density, surface preparation, and reagent quality 
either improve or adversely affect data quality. Experimental considerations, as well as 
methods for proper data analysis are discussed in Chapter 2. Data generated within 
the framework of the 2011 Global Label-free Interaction Benchmark study serves as 
a typical example. 
The ability of aptamers to bind a specific target originates from an intricate 
interplay between the oligonucleotide sequence and the three dimensional structure 
that this sequence allows to form. In Chapter 3 this is illustrated by the selection 
and characterization of streptavidin-binding aptamers. Five aptamer families were 
identified, sharing a similar secondary structure. Although slight variations at the 
actual sequence level are present, two guanines are completely conserved. Using 
site-specific mutagenesis it was demonstrated that these guanines are essential 
for streptavidin binding. Binding kinetics and the dissociation constant of each 
aptamer was determined by SPR and were all within the range of 35–375 nM. Two 
aptamers can bind one streptavidin tetramer at the same time, as was shown by 
native mass spectrometry analysis. In addition, the three dimensional structure of 
the most abundant aptamer was modelled and manually docked to the streptavidin 
structure, in order to gain more insight in the molecular basis of the interaction. To 
extend this knowledge even further, crystallization trails, aiming to obtain a co-crystal 
structure for the streptavidin-aptamer complex, were performed, and are described 
in Chapter 4. Unfortunately, these trials did only yield protein crystals, instead of 
the desired streptavidin-aptamer complex. Therefore, alternative experimental and 
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computational approaches were investigated that could be used to study aptamer-
protein interactions. Combining techniques as SPR, small-angle X-ray scattering 
(SAXS), isothermal titration calorimetry (ITC), and Dynamic light scattering (DLS) 
could be considered as an alternative to X-ray crystallography. In addition, some of 
these techniques may provide information on the dynamics of complex formation, 
whereas crystallography gives a time- and position-averaged image. 
Besides streptavidin, another protein, SpaC, was subjected to aptamer selection in 
this thesis. SpaC is a subunit of pili present on the probiotic Gram-positive bacterium 
Lactobacillus rhamnosus GG and contains a binding domain for human-mucus. 
Presence of this binding domain is considered an advantage, because it is already 
designed to interact with other molecules. Successful production and purification of 
recombinant SpaC protein is described in Chapter 5, as well as the characterization 
of DNA oligonucleotides enriched during subsequent selection rounds. Sequence 
analysis revealed that specific oligonucleotides are indeed enriched. Furthermore, 
results of pilot SPR experiments indicated that they bind specifically to SpaC, but 
more detailed experiments are required to unambiguously demonstrate this. 
The dynamics of aptamer enrichment are poorly understood. To address this 
issue and to gain a more fundamental insight in the aptamer selection process, a 
multiplexed high throughput sequencing effort was started, which is described in 
Chapter 6. In this approach samples of 70 selection rounds, derived from 8 distinct 
aptamer selection experiments, were barcoded, pooled together and sequenced; 
over 84 million paired-end reads were obtained and analyzed. Samples enriched to 
bind streptavidin show a decrease in α-diversity across subsequent selection rounds. 
Interestingly, large differences were found between the composition of fractions 
enriched by affinity elution and thermal elution. Moreover,  a small scale comparison 
of two clone libraries showed that affinity elution, which is expected to enrich more 
specific binders, also specifically enriches rapid binders. 
Supportive SPR experiments have made an important contribution throughout 
this thesis. The main focus in Chapter 7, however, is on a new application of SPR. 
The development of a capture approach for supercoiled plasmid DNA, using a triple 
helix forming oligonucleotide, is described. It could be demonstrated that plasmid 
DNA can indeed be captured and that SPR can subsequently be used to derive 
kinetic parameters of a specific interaction with a plasmid. In this particular case the 
interaction between Lac repressor and its plasmid-based operator was characterized, 
showing that the association and dissociation rates are ~18 times lower, but that the 
affinity is the same, when compared to binding to linear operator DNA. This difference 
underscores the importance of using a DNA substrate with a physiologically relevant 
topology for studying DNA-protein interactions.
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General discussion
Since the discovery of aptamers in 1990 58, 285 the field of aptamer research has 
progressed rapidly and has matured to a large and diverse field of research. In the 
course of the research project described in this thesis, ample developments have been 
accomplished in aptamer research. If the current project were to be re-initiated today, 
some of these developments could have influenced the strategy for aptamer selection 
that was adopted in this work. In the remainder of this chapter these developments 
are discussed, as well as how they could be used to enhance the success-rate of future 
aptamer selection endeavors. 
Target selection
Small organic compounds
A large number of aptamers are available that are capable of binding a wide variety 
of small organic compounds 269, 270; however, not every small organic molecule makes 
a good potential target for aptamer selection. Interactions between aptamers and 
small organic molecules occur via a combination of aromatic stacking, hydrogen 
bonding, electrostatic interactions and target encapsulation 89. Therefore, a large 
number of organic compounds that are targeted by aptamers have planar surfaces 
engaging in aromatic stacking interactions, or functional groups that allow hydrogen 
bonding, or most often a combination thereof. Examples of suitable aptamer targets 
include amino acids 60, 71, tetracycline antibiotics 197, 308, cofactors 150, hormones 136, 
nucleotides 110, 250, and pharmaceuticals 118. In addition, molecules containing amino-
modified sugar groups (e.g. aminoglycoside antibiotics) are also often targeted 
successfully 264, 298. Hence taking into account appropriate criteria for the selection of 
a target molecule that contains some of the aforementioned features, could increase 
the chances of successful aptamer enrichment. 
Other, more practical considerations are that the target molecule should be 
applicable for coupling to a matrix. A particular challenge here is confirming successful 
coupling of the target to the matrix; infrared spectroscopy has proven useful to this 
end 175. In addition, X-ray Photoelectron Spectroscopy (XPS) could for instance also 
be used to detect changes in the elemental composition of treated and untreated 
surfaces. Moreover, a target for aptamer selection should preferentially be water-
soluble. Although one aptamer is known that still binds its target in the presence of 
20% methanol 42, it was selected in an aqueous environment without methanol. 
Proteins
Similar to small organic molecules, DNA-protein interactions also occur by a 
combination of aromatic stacking, hydrogen bonding and electrostatic interactions; 
however, proteins are recognized via shape complementarity, rather than target 
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encapsulation. Some of the early protein-binding aptamers were selected to bind 
proteins that bind nucleic acids as part of their natural function, such as T4 DNA 
polymerase 285, HIV-1 Reverse transcriptase 286, and Taq DNA polymerase 43. Nowadays 
a variety of aptamers are available that bind proteins that are not associated with 
nucleic acid binding at all, but it is not possible to predict beforehand which proteins 
will successfully be bound by aptamers. A common feature shared between these 
proteins, however, seems to be that they all have a binding site, either for protein-
protein interactions, or for interactions with smaller molecules. Non-interacting 
(hydrophilic) protein surfaces might simply not provide enough support to facilitate 
aptamer binding. On the contrary, binding sites are designed to bind other structures, 
and hence might provide enough support to facilitate recognition by nucleic acid 
aptamers. This might explain why no obvious aptamer for hemoglobin could be 
enriched. Its oxygen binding pocked is most likely too small, and the protein surface 
might be too smooth to support binding of a nucleic acid aptamer. Presence of 
a binding site is on its own not a decisive factor for successful enrichment, as is 
supported by the ambiguous results of the enrichment of a specific aptamer for 
the mucus-binding protein SpaC described in this thesis (Chapter 5). Other factors, 
for instance protein stability, are important contributors to successful aptamer 
enrichment as well.
Nucleotide developments
Increased oligonucleotide stability
Throughout literature, both DNA and RNA aptamers are described, and the choice 
for either nucleic acid as a basis for aptamer development might seem arbitrary. 
This particular choice probably depends on practical considerations and partly on 
the final application. An obvious practical drawback of RNA is that it is prone to 
hydrolysis, by nucleophilic attack of the 2’-OH group on the near phosphorus atom, 
and enzymatic degradation. DNA lacks the 2’-OH and hence is inherently more stable. 
In addition, selection of RNA aptamers is more laborious as its processing requires 
additional enzymatic steps. On the other hand, RNA has a relatively flexible backbone 
in comparison with DNA, which enables it to adopt a wider range of three dimensional 
conformations. In that respect, RNA can potentially bind to a broader range of target 
molecules. Ideally, the stability of DNA is combined with the flexibility of RNA, and a 
solution for this is found in the use of modified nucleotides 168 (Figure 8.1). Various 
modifications result in increased stability, they comprise capping of the 5’ or 3’ ends, 
replacing the phosphate backbone by a phosphorothioate one, and modifications of 
the (deoxy)ribose sugar, such as locked nucleic acids; recently the use of alternative 
sugars has been reported, for instance to obtain arabinose nucleic acid (ANA) and 
anhydrohexitol nucleic acid (HNA) 219. The modifications that are most frequently 
used nowadays, however, are those in which the 2’-OH has been replaced, for 
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instance by a Fluor atom (2’-F) or an amino 
group (2’-NH2). Several of such modified 
nucleotides are commercially available (e.g. 
http://www.trilinkbiotech.com). Another 
factor attributing to their popularity is that 
several modified RNA polymerases are 
described that are capable of incorporating 
such 2’-modified nucleotides 35, 209. In other 
words, these 2’-OH modified nucleotides 
are compatible with the enzymatic steps 
of the selection procedure. At the start 
of this project, DNA was preferred above 
RNA for reasons of stability and ease of 
selection. However, if this project were to be 
re-initiated, an RNA library also containing 
2’-modified nucleotides could be a viable 
alternative to DNA libraries, given their 
increased availability, and providing a 
combination of stability and large structural 
diversity.
Increased variation of building blocks
Although aptamers with affinities in the picomolar range have been described 244, 
the majority of aptamers have affinities in the nanomolar, or even micromolar range. 
Antibodies, on the contrary, often have affinities in the low picomolar range. The 
foundation for this difference in affinity lies in the number and variation of the 
building blocks. DNA or RNA aptamers generally consist of only four building blocks 
with limited variation, whereas antibodies consist of twenty building blocks with a 
variety of amino acid side chains, allowing for much more variations and types of 
interactions to take place. Similar to aptamer-target interactions, antibody-antigen 
interactions occur through electrostatic interactions and hydrogen bonding. In 
addition, however, antibodies also interact through hydrophobic interactions with 
their antigen. Hydrophobic interactions are important, as their strength is proportional 
to the surface involved, and for some antibody-antigen interactions hydrophobic 
interactions account for most of the binding energy 116. The four natural bases are not 
able to form hydrophobic interactions, resulting in a physical drawback for aptamers. 
In fact, the limited number of aptamer building blocks and their similarity are the 
biggest limitation of aptamers. 
A variety of modified nucleotides have been described that increase the chemical 
diversity and properties of aptamer building blocks. Several modifications are 
Figure 8.1:  Frequent modifications on 
nucleosides. Modifications leading to increased 
stability are most often made on positions 
indicated by R1 and R2. The C5 position of uracil 
and thymine, R3, are often targeted to increase 
diversity of the building blocks (X), e.g. 115, 145, 149. 
Uridine 5’-phosphate is shown here, groups 
normally occurring are shown in bold. 
NH
O
O
R3
N
O
R1OH
HH
HH
OP-O
R2
O
R1 = OH, F, NH2, OCH3
R2 = O, S
R3 = H, X
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fully compatible with the enzymatic steps of the selection procedure and allow for 
(exponential) production by PCR from modified templates 168. Other modifications 
are not fully PCR-compatible but they can still be incorporated by primer extension 
methods, allowing (linear) production from unmodified templates. Some other 
modifications, however, can only be applied to aptamers after the selection procedure, 
for instance addition of a 3’ or 5’ functionality. Such modifications are referred to as 
post-selection modifications. Another interesting example, although not necessarily 
post-selection, is the attachment of a mixture of compounds, by dynamic combinatorial 
chemistry, to the 2’-NH2 group of amino-modified ribose rings 
25. The C5-position 
on thymine and uracil nucleobases (R3 in Figure 8.1) are the most suitable sites for 
modifications, because modifications at these sites are most often still accepted by 
polymerases 130. Hence it is not without reason that most modifications that increase 
the chemical variation of aptamer building blocks target this C5-position 115, 145, 149. 
Diversified oligonucleotides, however, do not necessarily yield higher affinity binders 
as exemplified by a modified thrombin aptamer that has a 4–10 fold weaker affinity 
as compared to the unmodified sequence 149. 
A more recent development concerns the modification of nucleotides that enable 
hydrophobic interactions between aptamer and target 290. Also in this case, uracil 
bases were modified at their C5-position, by the addition of various aromatic and 
aliphatic hydrophobic groups. Although the modifications were not fully compatible 
with PCR, primer extension could be used to produce sufficient material for aptamer 
selection. Indeed DNA aptamers containing modified nucleotides were selected 
(with KD values of 4 and 6 nM) to a protein target (tumor necrosis factor receptor 
superfamily member 9, TNFRSF9) for which enrichment of unmodified DNA aptamers 
remained unsuccessful in the past. Hydrophobic interactions are a key requirement 
for this interaction; recently the importance of hydrophobic interactions was also 
demonstrated for another target, by the description of a crystal structure of such a 
modified aptamer and platelet-derived growth factor B 47.
Altogether, modified nucleotides greatly increase the chemical variation of aptamer 
building blocks, which are now no longer constrained to the limited properties of 
natural nucleic acids. Although these developments broaden the range of potential 
targets, the limited availability and the required chemical knowledge on the synthesis 
of such modified nucleotides, poses a challenge for their widespread availability in 
the near future. 
Commercialization of aptamers 
Therapeutics
The most profound commercial application of aptamers today clearly demonstrates 
their large commercial potential. At the same time it also highlights a limitation 
that, amongst other reasons, prevents commercialization at a large scale. 
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Macugen (Pegaptanib) became the first FDA-approved aptamer therapeutic in 
2004 82, and remains the only one today. It is approved for the treatment of age-
related macular degeneration 196, because the RNA aptamer can bind all isoforms 
of vascular endothelial growth factor (VEGF), except for the smallest one (VEGF121), 
and prevents subsequent receptor-binding 244. Already two years later, an antibody 
fragment-based therapeutic (Lucentis, Genentech) was approved, also for treatment 
of age-related macular degeneration, and it quickly took over the market, because it 
binds all isoforms of VEGF, including the smallest. Therefore Macugen’s approval not 
only marks a milestone in aptamer research and commercialization, it also shows the 
supremacy of antibodies and antibody-based therapeutics. However, many aptamer-
based therapeutics are still in clinical trials, and hold the promise of a new generation 
of aptamer-based therapeutics in the near future 131, 275. 
Currently, Altermune Technologies LLC (Irvine, CA, USA) is developing a new and 
exciting application of aptamers that could result in new therapeutics and alternatives 
for antibiotics. In their approach, an aptamer that is specific for a particular non-
immunogenic target, e.g. a pathogen or a cancer cell, is fused to the α-gal epitope, 
to obtain the Altermune linker. The α-gal epitope is known to elicit a strong immune 
response, therefore the non-immunogenic target becomes highly immunogenic 
upon binding of the Altermune linker. As a result the target will be neutralized by 
the subsequent immune response 186. The principle of this chemical programming of 
immunity has already been shown to be effective with small organic molecules 174, 221. 
According to a recent global market analysis, the market of aptamer-based therapeutics 
is expected to grow from $13 million in 2012 to a value of $1.7 billion in 2017 114.
Diagnostics
Another area in which aptamers have potential applications is that of diagnostics. 
Over the years many aptamers have become available for a variety of targets. The 
use of aptamers in various assay-formats using various detection methods have been 
described in academic journals, but none of these were successfully commercialized. 
For any new technology to become successful, it must provide a clear advantage over 
any existing technology. Therefore, the widespread use of antibodies and their well-
established methods poses a major roadblock for successful introduction for aptamer-
based diagnostics. It was only recently that the first aptamer-based diagnostic test 
became commercially available 75, for the detection of Ochratoxin A in various food 
matrixes (NeoVentures Biotechnology Inc, London, Canada). Although the use of 
aptamers is not as strongly rooted in current research, this aptamer-based assay 
demonstrates that there is indeed a commercial potential for dedicated aptamer-
based diagnostics. 
Recently, SomaLogic (Boulder, CO, USA) introduced a new aptamer-based 
proteomics method 77. Their method can be used to simultaneously identify and 
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quantify 813 proteins. This method is a useful diagnostic tool that, among others, could 
be used to identify and validate potential drug targets. This breakthrough is enabled 
by the development of slow off-rate modified aptamers (SOMAmer). According to the 
same market analysis, the market for aptamer-based in vitro diagnostics is expected 
to grow from an expected value of $86 million in 2012 to $2 billion in 2017 114, 
exceeding that of aptamer-based therapeutics. 
Custom aptamer development
A convenient aspect of using antibodies for research applications is that antibodies 
for numerous targets are readily available. If an antibody for a specific target is 
not available, an array of polyclonal antibodies could quite easily be generated by 
immunizing a mouse or rabbit and subsequent (crude) antibody purification from 
blood plasma. Numerous companies offer services for the generation of such custom 
polyclonal antibodies. Aptamers, on the contrary, are not so readily available. Even 
if a target specific aptamer sequence is available, it should be confirmed that this 
sequence is indeed target specific and is not binding to the matrix used during 
selection. However, more and more companies are emerging that offer custom 
aptamer selection, probably using automated SELEX procedures, analogous to 
generation of custom polyclonal antibodies. Whether this coincides with the expiry 
of the original patents on aptamer technology is not completely clear, but it signals 
a new stage in the application and development of aptamers.
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Verreweg de bekendste functie van DNA is de opslag van genetische informatie, 
maar DNA is veelzijdig en geschikt voor veel meer functies. DNA bestaat uit vier 
bouwstenen (nucleotiden) en deze vier bouwstenen vormen voor de opslag van 
genetische informatie twee lange ketens. Samen vormen deze ketens de voor 
DNA typerende dubbele helix. De vier bouwstenen kunnen in elke willekeurige 
volgorde achter elkaar worden gezet, maar in levende organismen is deze volgorde 
heel specifiek vastgelegd (sequentie). Vergelijkbaar met morse code, waar punten 
en streepjes coderen voor letters, coderen blokjes van drie bouwstenen voor de 
letters (aminozuren) waaruit eiwitten zijn opgebouwd. Aan de hand van deze code 
kan DNA dus worden omgezet in eiwitten (via een RNA intermediair). Eiwitten zijn 
verantwoordelijk voor veel belangrijke processen in levende organismen. Een foutje 
(mutatie) in de volgorde van de DNA bouwstenen kan ervoor zorgen dat het eiwit 
zijn functie (deels) verliest. 
In de jaren ’90 is ontdekt dat korte stukjes DNA (of RNA), van 20 tot 60 bouwstenen 
in een enkele streng, selectief aan bepaalde moleculen kunnen binden; zelfs als deze 
moleculen van nature niet binden aan DNA (of RNA). Dit soort korte DNA (of RNA) 
stukjes worden aptameren genoemd. De targetmoleculen kunnen zowel relatief 
simpele moleculen zijn, zoals sommige geneesmiddelen (diclofenac), of complexere 
moleculen, zoals eiwitten (trombine). Dit proefschrift gaat voornamelijk over het 
selecteren en karakteriseren van zulke DNA aptameren. 
Net als al het DNA (en RNA) zijn ook aptameren opgebouwd uit vier verschillende 
bouwstenen (nucleotiden). De specifieke volgorde van bouwstenen in een aptameer 
codeert echter niet voor een eiwit, maar zorgt ervoor dat het korte stukje DNA (of RNA) 
een 3D-structuur vormt die het target kan binden. Van de vele miljarden mogelijke 
volgordes zijn er slechts enkele in staat om het target daadwerkelijk te binden, helaas 
is het niet mogelijk om vooraf te voorspellen welke volgorde van bouwstenen hiertoe 
in staat is. De uitdaging is dus om uit de vele miljarden mogelijke combinaties de 
juiste combinatie te vinden die het target het beste bindt.
Tegenwoordig zijn er methodes beschikbaar om miljarden korte DNA stukjes 
chemisch te produceren, elk met een willekeurige volgorde van de bouwstenen. De 
selectie van aptameren is te vergelijken met vissen in een vijver. Tijdens de selectie 
van een aptameer wordt het target (het aas) blootgesteld aan deze DNA stukjes 
(de vissen), met als gevolg dat de DNA stukjes die het target kunnen binden dit 
ook zullen doen. DNA stukjes die het target niet binden kunnen makkelijk worden 
weggewassen (deze zijn verder niet meer van belang). De gebonden DNA stukjes 
worden vervolgens teruggewonnen en vermenigvuldigd (zie Figuur 1). Doorgaans 
moeten deze stappen (blootstellen, wassen, terugwinnen en vermenigvuldigen) een 
aantal keer worden herhaald, om zo de meest geschikte aptameren te verrijken. Tijdens 
dit proces blijft de volgorde van de bouwstenen onbekend, deze kan pas in een later 
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stadium achterhaald worden (op enig 
moment heb je beet, zonder te weten 
hoe de vis er uit ziet; dit wordt pas 
duidelijk op het moment dat je de vis 
uit het water haalt). 
De eigenschap om specifiek 
een bepaald molecuul te binden is 
echter niet exclusief voorbehouden 
aan aptameren, er zijn verscheidene 
andere groepen moleculen die hier 
ook toe in staat zijn. In Hoofdstuk 1 
worden deze groepen (antilichamen, 
bindingseiwitten en MIPs) beschreven 
en hun eigenschappen met elkaar 
vergeleken. 
Een van de belangrijkste 
eigenschappen van aptameren is 
de sterkte en de specificiteit van de 
binding tussen het aptameer en het 
targetmolecuul. Over het algemeen 
geldt: hoe sterker en specifieker 
de binding hoe beter dat is. In 
Hoofdstuk 2 is een geavanceerde 
techniek beschreven (Surface Plasmon 
Resonance, ofwel SPR) die inzicht kan 
geven in hoe snel een aptameer-
target complex gevormd wordt en hoe snel het weer uit elkaar valt. Deze waarden 
vormen samen een maat voor hoe sterk de interactie is.  
De selectie en karakterisatie van aptameren die het eiwit streptavidine binden 
is beschreven in Hoofdstuk 3. Dit eiwit is een modelsysteem voor selectie van 
aptameren en is onder andere gekozen om de selectieprocedure van aptameren 
verder te ontwikkelen en te valideren. Uit de behaalde resultaten blijkt onder andere 
dat minimale verschillen in de volgorde van de bouwstenen grote invloed hebben op 
de sterkte van de aptameer-target interactie. Twee bouwstenen, elk op een specifieke 
plek, blijken zelfs essentieel; als ze vervangen worden door een andere bouwsteen is 
een interactie niet meer mogelijk. 
In Hoofdstuk 4 is de kristallisatie van een streptavidine-aptameer complex 
beschreven. Naast mooie plaatjes levert een kristalstructuur een schat aan 
gedetailleerde informatie op over de interactie. Helaas is het kristalliseren van eiwit-
DNA complexen erg lastig gebleken, het enige kristal van voldoende kwaliteit voor 
Binding
Random DNA 
(Vissen)
Geïmmobiliseerd target
(Aas)
Wassen
Terugwinnen
Vermenigvuldigen
Nieuwe 
ronde
Verdere 
karakterisatie
Ongebonden
Figuur 1: Selectie van DNA aptameren. Een 
grote hoeveelheid DNA fragmenten, met een 
willekeurige samenstelling, wordt blootgesteld aan 
een geïmmobiliseerd target. DNA moleculen die dit 
target kunnen binden zullen dit doen, het overige 
DNA wordt weggewassen en is niet meer van belang. 
Vervolgens wordt het gebonden DNA teruggewonnen 
en vermenigvuldigd. Deze stappen worden doorgaans 
een aantal keer herhaald om zo de beste binder te 
selecteren. In een latere fase worden de geselecteerde 
DNA moleculen verder gekarakteriseerd.
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verdere analyse bleek alleen uit eiwit te bestaan.
Naast de selectie van een aptameer dat streptavidine bindt is ook het SpaC 
eiwit gebruikt als target voor aptameer selectie. Dit eiwit is interessant omdat het 
de Lactobacillus rhamnosus GG bacterie, een probioticum, helpt om langer in de 
darmen te verblijven. De productie van dit eiwit, en de aptameer selectieprocedure 
zijn beschreven in Hoofdstuk 5. Een aantal korte DNA stukjes lijken specifiek aan dit 
eiwit te binden maar verdere experimenten zijn nodig om dat onomstotelijk vast te 
kunnen stellen.
Om beter inzicht te krijgen in de processen die leiden tot de verrijking van bepaalde 
DNA stukjes, is de volgorde van de bouwstenen van een groot aantal DNA stukjes 
bepaald (>84 miljoen). Uit een voorlopige analyse van deze data, beschreven in 
Hoofdstuk 6, blijkt dat de verrijking van aptameren zeer sterk beïnvloed wordt door 
de wijze waarop gebonden DNA stukjes worden teruggewonnen tijdens de selectie. 
Met deze kennis zou de selectieprocedure voor aptameren verder geoptimaliseerd 
kunnen worden. 
In Hoofdstuk 7 is een methode beschreven om een circulair DNA molecuul 
(plasmide) te vangen op een oppervlakte geschikt voor SPR metingen, zonder daarbij 
de natuurlijke ordening (topologie) van het DNA te verstoren. De natuurlijke ordening 
van DNA is van grote invloed op de bindingssterkte van eiwitten die onder andere 
betrokken zijn bij de vermenigvuldiging van DNA. Bij het bestuderen van dit soort 
eiwit-DNA interacties is het dus van belang de natuurlijke ordening van DNA zo 
accuraat mogelijk na te bootsen, de beschreven methode zou daarvoor zeer geschikt 
kunnen zijn. 
In Hoofdstuk 8 worden de belangrijkste bevindingen uit dit proefschrift 
samengevat. Tevens worden nieuwe ontwikkelingen op het gebied van aptameer 
bouwstenen en nieuwe kansrijke toepassingen van aptameren nader beschreven. 
147
Dankwoord
Dankwoord 
Het is gedaan. Het zit er op! Maar niet zonder dankwoord natuurlijk, want dit project 
zou nooit zo goed van de grond zijn gekomen zonder de bijdrage van velen en daar 
ben ik hen allen dankbaar voor. Ik kijk terug op een leuk uitdagend project, maar 
bovenal op een fijne tijd bij Microbiologie.
Slechts weinigen weten dat de aanzet voor dit project is terug te voeren tot 
Burger Bob’s en Ale Works in Bozeman Montana, waar ik destijds stage liep. In een 
intercontinentaal telefoongesprek, tijdens diezelfde stage, werd een promotieplaats 
binnen BacGen en MolEco beklonken. John, deze snelle en doelgerichte gang van 
zaken typeert je, evenals je tomeloze enthousiasme (die is benijdenswaardig). Hauke, 
ten tijde van dit bewuste telefoongesprek kenden we elkaar nauwelijks, toch durfde 
je het avontuur aan te gaan. Dank aan beide voor jullie vertrouwen, inspiratie en 
adviezen, ik heb er veel van opgestoken. Aptameren hebben de ruimte helaas niet 
gehaald, zoals dat ooit wel de bedoeling was, maar ik waardeer het dat jullie me 
de ruimte hebben gegeven het project anders in te vullen toen het originele plan 
gaandeweg niet haalbaar bleek. 
Binnen die ruimte was het mogelijk om aan SpaC te werken. Het kloneren van 
het gen en de productie van het eiwit gingen van een leien dakje, daarna waren de 
doorbraken jammer genoeg dunner gezaaid. Willem, ik vind het erg fijn dat ik aan dit 
project heb kunnen werken. Ik wil je bedanken voor je inspanningen om hoofdstuk 5 
naar een hoger niveau te tillen, maar ook voor je bezielende leiding van de vakgroep 
(en de efficiënte DB vergaderingen).  
Sebastian, wie kon in september 2003, aan het begin van onze studie, vermoeden 
dat we ooit bij dezelfde vakgroep promotieonderzoek zouden gaan doen? Door je 
snelle inzicht en rekenvaardigheid waren we vaak al klaar met de uitwerking van 
menig practicum nog voordat ik de vragen goed en wel begreep... Je kennis en 
hulpvaardigheid zijn ongeëvenaard, heel veel succes met het afronden van je eigen 
proefschrift! Mark L, in een vroeg stadium ben je bij dit project betrokken geraakt, 
ik denk dat we inmiddels wel van een productieve samenwerking mogen spreken. 
Dank voor je vele ideeën, suggesties, maar bovenal gezelligheid en goede (en minder 
goede) grappen. Ik vind het erg fijn en bijzonder dat jullie m’n paranimfen willen zijn! 
Involvement in this project was not restricted to people within microbiology, I am 
grateful to all collaborators for their valuable contributions. Regina und Beate, thanks 
for having me in Leipzig it really was a boost for the project! I am happy we could 
continue our collaboration with the high throughput sequencing; to be continued... 
Kevin and John T, despite the difficulties we managed to extract some nice publication 
figures from the SAXS experiments, it worked out well. Christophe, thanks for sharing 
your knowledge on DNA-triplexes already at an early stage of the project. Anke and 
Saurabh, I am glad that our collaboration resulted in some nice papers! Esther en Arjan, 
bedankt voor de Native MS metingen aan de streptavidine-aptameer complexen, 
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we hebben de resultaten een mooi plekje kunnen geven. Bauke en Johan, helaas 
bleek het kristal achteraf geen DNA te bevatten, maar de resultaten hebben toch 
hun weg naar de literatuur gevonden. Ook dank aan Maurice Franssen, zeker in de 
beginfase heb ik je bedolven onder organisch chemische vragen die je altijd geduldig 
beantwoordde. Graag wil ik hier ook de overige leden van de promotiecommissie 
bedanken voor al hun inspanningen.
Hoogtepunten en dieptepunten kunnen dicht bij elkaar liggen, maar in beide 
gevallen is het fijn ze te kunnen delen met collega’s, tijdens de lunch, koffie, of bij 
een andere gelegenheid, zoals de We-day, Veluweloop of het bierbrouwen. Een van 
de meest memorabele momenten was de AIO-reis langs de Amerikaanse oostkust: 
leerzaam, gezellig en voedzaam (...), die herinnering blijft. Herewith I would like to 
thank everyone who has spent time at Microbiology for contributing to the nice open 
atmosphere. Special thanks to Anja, Amos, Bart, Bas, Bram, Carel, Carolien, Chris, 
Clara, Daan, Detmer, Edze, Elleke, Faab, Farai, Farrakh, Gerben, Hans, Janneke, Jannie, 
Javi, John R, Marcel, Marco, Maria, Mark M, Matthijs, Milkha, Melvin, Naïm, Noora, 
Philippe, Raymond, Sjoerd, Sjon, Stan, Steven, Teunke, Tessa, Thomas, Tijn, Tom (vd B 
en vd W) and Wim, for your (un)conscious contributions to this thesis.
De boog kan niet altijd gespannen zijn en bij tijd en wijle is het dus goed om het 
onderzoek te laten voor wat het is. Ontspannen (en afzakken tot bedenkelijk niveau) 
lukt gegarandeerd met hulp van ‘Steunpunt Westland’; dames en heren Kantelaars 
dank daarvoor! ‘Lotgenotencontact’ met oud studiegenoten is hierbij overigens ook 
van groot belang geweest. Hier wil ik ook Elly en Susanne bedanken voor een stukje (...) 
ontspanning en interesse in mijn onderzoek. Vanzelfsprekend wil ik ook mijn ouders 
en zusje bedanken voor steun tijdens mijn studie, stage en promotieonderzoek. 
Ondanks dat mijn bezigheden altijd een beetje een mysterie voor jullie zijn gebleven 
(hopelijk kan m’n lekenpraatje daar wat verandering in brengen...).
Onderzoek is, net als hardlopen, veel leuker als je het niet alleen hoeft te doen. 
Lieve Marieke, je hebt me de afgelopen jaren enorm geholpen en het beste in me 
naar boven gehaald. Het is fijn om mooie resultaten en frustraties te kunnen delen 
met iemand die in hetzelfde schuitje zit. Dank voor al je liefde en ondersteuning. Het 
is erg fijn om bij je te zijn, laten we dat nog lang zo houden! 
Vincent
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